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1 Summary 
 
During splicing non-coding introns are excised from the transcribed pre-messenger RNA (pre-
mRNA), and the protein-coding exons are ligated to generate the mature mRNA. In cells, the pre-
mRNA splicing reaction is catalyzed by the spliceosome, a highly dynamic molecular machine 
composed of five small nuclear ribonucleoprotein particles (snRNPs) and additional non-snRNP 
factors (Wahl et al., 2009; Will and Luhrmann, 2011). At the earlier stages of spliceosome 
assembly, the U2 snRNP is recruited to the 3’ region of the intron for the U2 snRNA to base-pair 
with the branch-site (BS), in a complex and insufficiently understood process (Wahl et al., 2009). 
SF3B is the largest U2 subcomplex, and several of its seven subunits, including SF3B1, contact 
both the U2 snRNA and the intron near the BS, stabilizing the U2/BS base-pairing interaction. 
Recurrent somatic cancer mutations in SF3B1, and in several related splicing factors, reduce the 
accuracy of BS selection and, finally, lead to aberrant splicing (Dvinge et al., 2016). The 
compromised function of SF3B1 affects splicing of many different transcripts and thus translates 
to global changes in cancer cell transcriptome (Alsafadi et al., 2016; Darman et al., 2015). SF3B 
is also targeted by several small-molecule splicing modulators, regarded as promising 
chemotherapeutic agents (Bonnal et al., 2012; Effenberger et al., 2017). At the start of this project, 
it was unclear how SF3B is organized prior to its incorporation in the spliceosome, what structural 
features of human SF3B are perturbed in cancers, and how the antitumor compounds act on SF3B 
to modulate splicing.  
In the first part of this thesis work, we carried out a thorough structural analysis of the human 
SF3B complex (Cretu et al., 2016). Firstly, we have defined a structurally stable SF3B core 
complex (~254 kDa), composed of SF3B1’s C-terminal HEAT domain, SF3B3, SF3B5, and 
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PHF5A, and determined its structure by X-ray crystallography. The crystal structure of the SF3B 
core complex revealed that the 20 HEAT repeats of SF3B1 adopt a distinctive superhelical 
conformation and share extensive contacts with the other three core subunits (Cretu et al., 2016). 
SF3B3 exhibits a triple β-propeller fold and accommodates the three alpha helices of the SF3B5 
subunit in a deep, clam-shaped cleft (Cretu et al., 2016). Organized as a compact knot composed 
of three zinc finger motifs, PHF5A bridges the terminal repeats of SF3B1’s HEAT domain, 
contributing to the unique conformation of the superhelix. Using a set of orthogonal mass 
spectrometry approaches, we showed that SF3B1-PHF5A together with the more mobile 
SF3B6/p14 subunit form a multipartite RNA binding platform that, in spliceosomes, stabilizes the 
U2/BS helix and the downstream 3’ end of the intron (Fica and Nagai, 2017; Shi, 2017). 
Comparative analyses with recent cryo-EM structures of yeast spliceosomes (Fica and Nagai, 
2017) show that the cancer-related residues of SF3B1 map to a basic groove of the HEAT 
superhelix where, likely, the 3’ pyrimidine-rich region of the intron binds. Altogether, our analyses 
suggest how changes in SF3B1 structure and interactome may lead to a compromised BS selection, 
thus providing insights into the molecular mechanism of SF3B1-driven cancers.  
In the follow-up work (Cretu et al., 2018, unpublished data), we determined co-crystal structures 
of SF3B core variants in complex with different compounds that modulate splicing, including 
some approved for clinical trials. Our work shows that splicing modulators from the pladienolide 
and herboxidiene families target SF3B at the same site and bind to an hourglass-shaped tunnel 
formed by SF3B1’s H15-H17 repeats and PHF5A. Their molecular recognition is achieved in part 
by shape complementarity to the tunnel, enforced by the conjugated diene group – a moiety 
regarded as the common pharmacophore of SF3B modulators. Importantly, while SF3B1 exhibits 
a “closed” conformation in fully assembled spliceosomes, we observe a more “open” state in the 
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presence of splicing modulators. Structural comparisons indicate that the modulator binding site, 
available in the “open” conformation, is rearranged in the “close” state of SF3B1 to accommodate 
the invariant BS adenosine. Thus, our analyses suggest that splicing modulators interfere with a 
conformational rearrangement of SF3B1 and, in this respect, act as competitive BS antagonists. 
Overall, this work may serve as a conceptual framework for the structure-based design of next-
generation splicing modulators.          
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2 Introduction 
2.1 The central dogma of molecular biology 
The DNA macromolecule is central to life as we know it. In all cellular life forms, the genetic 
information, required to build entire molecules, organelles, and cells, is encoded as a sequence of 
nucleotides in the DNA (Watson et al., 2017). However, as a sophisticated computer program, the 
DNA is the raw source code defined by syntax and formalisms, composed of more autonomous 
subroutines (or “genes”), and separated by comments (or “noncoding regions”). To read and 
interpret the “code” a “compiler” is needed. In cells, various molecular machines cooperate to 
emulate the “compiler.” RNA polymerases “read” the DNA “code” and “transcribe” it into an 
RNA intermediate, so that other cellular machines, such as ribosomes could accurately translate 
(“execute”) it into proteins (Figure 2.1). Importantly, the end-result of “program’s” execution (i.e., 
proteins) cannot be used to generate the “source code” (DNA) or the intermediate “code” (RNA) 
(Watson et al., 2017). The unidirectional flow of genetic information from DNA, to RNA and 
proteins, has stood the test of time and is universally valid in all life forms, from Mycoplasma to 
yeast and humans (Figure 2.1).  
2.2 Split genes and pre-mRNA splicing 
In eukaryotes, different types of RNA polymerases “read” the different “subprograms” (i.e., genes) 
of the DNA “code”. RNA polymerase I transcribes ribosomal RNA genes (rRNA 5.8S, 18S, 28S) 
which account for ~80% of the total RNA species in cells (Vannini and Cramer, 2012; Warner, 
1999). RNA polymerase III synthesizes tRNAs, the U6 snRNA, and rRNA 5S (Khatter et al., 
2017). Importantly, RNA polymerase II (Pol II) “reads” all the protein-coding genes as well as the 
genes coding for all the other small nuclear RNAs (snRNAs), small nucleolar RNAs (snoRNAs), 
and microRNAs (miRNAs) (Hirose and Manley, 2000; Sainsbury et al., 2015). However, not all 
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sequences of a protein-coding gene will be equally translated into the amino acid sequence of a 
polypeptide chain; rather, most eukaryotic genes are split/mosaic. Typically, the pre-messenger 
RNA (pre-mRNA) molecule synthesized by Pol II consists of coding sequences, termed exons, 
interspersed by noncoding regions or introns (Figure 2.1). 
 
During pre-mRNA splicing, the noncoding introns are removed from the pre-mRNA, and each 
pair of exons are ligated to generate the mature messenger RNA (mRNA) (Will and Luhrmann, 
2011). The process is rather complicated and is catalyzed in cells by the spliceosome, a 
megadalton-size cellular machine composed of five uridine-rich small nuclear ribonucleoproteins 
(snRNPs) – so-called U1, U2, U4, U5, and U6 – and numerous associated non-snRNP factors 
Figure 2.1. The central dogma of molecular biology. 
The schematic depicts the unidirectional flow of genetic information from DNA, to RNA, to proteins. A 
typical eukaryotic gene is a mosaic of protein-coding sequences (exons) and non-coding regions (introns). 
The non-coding introns are removed from the pre-messenger RNA (pre-mRNA) by the spliceosome. At the 
same time, the newly transcribed pre-mRNA is polyadenylated and capped. The mature mRNA can then 
be translated into proteins by ribosomes in the cytoplasm.  
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(Wahl et al., 2009). In contrast to other molecular machines, such as RNA polymerases or 
ribosomes, the spliceosomes form de novo and in a stepwise manner onto each intron-exon pair of 
the pre-mRNA and do not exist as fully assembled complexes in the absence of their substrate 
(Will and Luhrmann, 2011). In a larger cellular context, spliceosome assembly can be coupled to 
Pol II transcription (termed co-transcriptional splicing) or may occur after pre-mRNA is fully 
transcribed, capped, and polyadenylated (post-transcriptional splicing) (Saldi et al., 2016).  
Introns account for a large part of the transcribed pre-mRNA and their length and number increase 
with the complexity of the organism (Irimia and Roy, 2014; Roy and Gilbert, 2006). For instance, 
an average human protein-coding gene has ~27 kb, and only ~5% of its entire sequence consists 
of coding exons (International Human Genome Sequencing, 2004; Venter et al., 2001). Thus, it is 
a particularly challenging task to accurately distinguish the shorter coding exons from the 
significantly larger introns in different sequence contexts (Wahl et al., 2009). Typically, intron-
exon junctions are defined in cis by relatively short consensus sequences, known as splice sites 
(SS) (Will and Luhrmann, 2011). While in yeast (Saccharomyces cerevisiae) these consensus 
motifs are well-conserved amongst different introns, in metazoans and plants the splice sequences 
are more degenerated (Wahl et al., 2009; Will and Luhrmann, 2011). 
The 5’ exon-intron border is defined by the 5’ splice site (5’SS); it has the 5’-GURAGU-3’ 
consensus sequence, where R represents any purine, in the majority of human introns (Will and 
Luhrmann, 2011) (Figure 2.2). In yeast, the 5’SS is extremely well-conserved and features the 5’-
GUAUGU-3’ sequence motif (Staley and Guthrie, 1998). The 5’SS region is complementary to 
the 5’ end of the U1 snRNA which precedes the first stem-loop (Staley and Guthrie, 1998). The 
intron-3’ exon border is specified by a conserved sequence motif, known as the 3’ splice site 
(3’SS). Largely, the 3’SS is defined by the 5’-YAG-3’ sequence, where Y represents any 
2 | Introduction 
 
7 
 
pyrimidine, in both yeast and human (Wahl et al., 2009; Will and Luhrmann, 2011). A uridine-
rich sequence motif usually precedes the 3'SS. This sequence is known in metazoans as the 
polypyrimidine tract (PPT) (Garcia-Blanco et al., 1989; Reed, 1989) (Figure 2.2). In higher 
eukaryotes, both the sequence composition and the length of the PPT are important for the accurate 
selection of the branch-site (BS) region (Bessonov et al., 2010; Norton, 1994; Roscigno et al., 
1993). The BS sequence element (Figure 2.2) is located ~10-60 nucleotides (nts) upstream of the 
3’SS (Black et al., 1985; Chabot et al., 1985; Taggart et al., 2017). Importantly, the BS interacts 
via base-pairing with the branch-site interacting region (BSiR) of the U2 snRNA (Query et al., 
1994; Wu and Manley, 1989; Zhuang and Weiner, 1989). As a result, the BS adenosine (BS-A), a 
site which is universally conserved across different species, is bulged out from the U2/BS duplex 
(Query et al., 1994; Wahl et al., 2009). The degeneracy of the BS in metazoans (i.e., 5’-YUNAY-
3’ consensus sequence, where N represents any nucleotide) (Figure 2.2) explains the more 
stringent requirement for additional cis sequences, such as the PPT and exonic enhancers (Corvelo 
et al., 2010; Gao et al., 2008; Taggart et al., 2017). Additional trans-acting factors are also required 
to ensure accurate BS recognition (Lee and Rio, 2015). In yeast, the BS is conserved and has the 
5’-UACUAAC-3’ consensus (Staley and Guthrie, 1998).  
A minority of human introns are excised from pre-mRNA by the minor spliceosome. The U12-
type introns, compared to the more common U2-type, are specified by alternative intron-exon 
borders: 5’-A/GU instead of 5’-GU, and AC/G-3’, instead of AG-3’ (Patel and Steitz, 2003) 
(Figure 2.2). Interestingly, the U12-type introns lack the PPT region and have a more conserved, 
yeast-like, BS sequence (5’-UCCUUAAC-3’) (Patel and Steitz, 2003). Most importantly, the U12-
type 5’SS base-pairs with the U11 snRNA, whereas the BS region interacts with the U12 snRNA, 
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both of which are part of the preassembled U11/U12 di-snRNP (Frilander and Steitz, 1999; Patel 
and Steitz, 2003).   
 
 
  
Figure 2.2. Introns are defined in cis by conserved splice sites. 
(A) The typical consensus splice sequences in yeast (S. cerevisiae). Importantly, the 5’SS (5’ splice site, 
light blue), the branch-site (BS, green), and the 3’SS (3’ splice site, orange) are, generally, well-conserved 
across different introns. The invariant branch-site adenosine is colored in green. The coding exons are 
represented as gray boxes. (B) The splice site sequences are more variable in human (H. sapiens) introns. 
In metazoans, in addition to the 5’SS, the 3’SS, and the BS, introns, typically, contain a polypyrimidine 
tract (PPT, dark purple), located upstream of the 3’SS. The U12-type introns have largely different 
consensus sequences and are spliced by the minor spliceosome. The sequence logo plots for the U2-type 
and U12-type introns depict the relative frequencies of each nucleobase at the corresponding splice site, 
and are adapted from (Scotti and Swanson, 2016). 
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2.3 The chemistry of pre-mRNA splicing  
Despite the overall complexity of the process, the general chemistry of the splicing reaction is 
rather simple. The excision of introns from pre-mRNA proceeds through two ordered SN2-type 
transesterification reactions which involve reactive groups from the cis-acting splice sequences 
(Will and Luhrmann, 2011) (Figure 2.3). These chemical reactions are isoenergetic and progress 
through a trigonal bipyramidal transition state stabilized by two catalytic metal ions (Fedor and 
Williamson, 2005).  
During the first transesterification reaction, called branching, the 2’-OH of the invariant BS 
adenosine acts as the nucleophile group and attacks the 5’SS to generate the cleaved 5’exon and 
an intron-3’exon lariat intermediate (Will and Luhrmann, 2011) (Figure 2.3). In the step 1 lariat 
intermediate, the BS-A is linked to the cleaved 5’SS via a 2’-5’ phosphodiester bond, thus resulting 
in an apparent three-way junction. In the second step of splicing, known as exon ligation, the 3’-
OH group of the excised 5’ exon performs a nucleophilic attack on the 3’SS (Will and Luhrmann, 
2011). As a result, the two consecutive exons are ligated, and the intron is liberated as a lariat 
intermediate (Figure 2.3).  
For the pre-mRNA splicing catalysis to occur, the chemically reactive groups from the 5’SS, the 
3’SS, and the BS have to be brought in proximity. However, eukaryotic introns lack inherent 
sequence conservation, except for the consensus SSs. (Will and Luhrmann, 2011). Thus, 
eukaryotic introns cannot adopt per se similar structures in isolation. In contrast, group II self-
splicing introns, from which, likely, eukaryotic introns derived, form complex structures in the 
absence of additional factors (Pyle, 2016; Zhao and Pyle, 2017). By the intrinsic folding of the 
group II intron, the reactive groups of the SSs, which are strikingly similar to the eukaryotic 
consensus sites, are precisely positioned within an RNA-only catalytic active center (Pyle, 2016). 
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Figure 2.3. The chemistry of pre-mRNA splicing. 
Introns are excised from pre-mRNA via two sequential transesterification reactions, 
known as branching and exon ligation, respectively. During branching, the 2’-OH 
group of the invariant branch-site (BS, green) adenosine performs a nucleophilic 
attach on the 5’ splice site (5’SS, light blue). During exon ligation, the 3’-OH group 
of the liberated 5’ exon attacks the 3’ splice site (3’SS, orange), releasing the intron 
as a lariat intermediate and joining the two exons. Exons are depicted as gray boxes.  
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In eukaryotes, it is the spliceosome that coordinates, in trans, the accurate recognition of the SSs 
and the “folding” of the intron within an intricate RNA-RNA network whereby the reactive groups 
are activated sequentially (Wahl et al., 2009). Importantly, the dynamic organization of the 
spliceosome complex results in a significant degree of flexibility, so that introns of different sizes 
and sequences can be equally well recognized and spliced. For instance, the efficient splicing of 
short introns (less than ~200 nts) can be achieved through a “cross-intron” assembly of the 
spliceosome (Fox-Walsh et al., 2005) – the typical assembly pathway in yeast. Conversely, long 
introns are specified across the exons which are significantly shorter in mammals (~120 nts) (Ast, 
2004; Berget, 1995; Deutsch and Long, 1999).    
2.4 snRNPs – the building blocks of the spliceosome 
The five uridine-rich U1, U2, U4/U6, and U5 snRNPs represent the core constituents of the U2-
type major spliceosome (Wahl et al., 2009). They are composed of an RNA moiety, the U snRNA, 
and a specific set of proteins (Figure 2.4). The U12-type spliceosome, which splices a minority of 
mammalian introns, assembles from a specific set of snRNPs: the U11 snRNP, the U12 snRNP, 
the U4atac snRNP, and the U6atac snRNP (Patel and Steitz, 2003). The U5 snRNP is present in 
both minor and major spliceosomes. The snRNA moiety of each snRNPs has a characteristic 
secondary structure, is posttranscriptionally modified and capped (Matera and Wang, 2014) 
(Figure 2.4). Although the overall structures are different, U1, U2, U4, and the U5 snRNA share 
a common uridine-rich site, the so-called Sm site, onto which the heteroheptameric Sm ring 
complex is loaded (Matera and Wang, 2014). The Sm protein ring assembles sequentially around 
the Sm site from SmB/B’, SmD1, SmD2, SmD3, SmE, SmF, and the SmG subunit (Kondo et al., 
2015; Li et al., 2016; Neuenkirchen et al., 2008). In contrast, the U6 snRNA lacks the typical Sm 
site. Instead, a specific uridine-rich sequence at the very 3’ end of the U6 snRNA serves as the 
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docking site for the Sm-like LSm complex (Didychuk et al., 2018). The heteromeric LSm ring 
forms from LSm2, LSm3, LSm4, LSm5, LSm6, LSm7, and LSm8 (Zhou et al., 2014). Importantly, 
the U4 and U6 snRNA base-pair to each other in the U4/U6 di-snRNP and the U4/U6.U5 tri-
snRNP (Didychuk et al., 2018; Wahl et al., 2009) (Figure 2.4). However, upon the activation of 
the spliceosome, this base-pairing interaction is disrupted to liberate the U6 intramolecular stem-
loop (ISL). 
 
Figure 2.4. Protein-RNA composition of human snRNPs from the major 
spliceosome. 
Each snRNP is composed of a snRNA moiety, the Sm or LSm ring complex, and a specific set of 
proteins. The secondary structure of each snRNA is schematically indicated. The protein 
nomenclature is as in (Fabrizio et al., 2009; Wahl et al., 2009).  
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In addition to the Sm or Lsm ring, each of the snRNPs has a characteristic set of proteins (Figure 
2.4). The U1 snRNP specific proteins U1-70K and U1-A play mainly architectural roles and 
interact with the stem-loop I and stem-loop II of the U1 snRNA, respectively (Kondo et al., 2015). 
Instead, U1-C is positioned at the 5’ end of the U1 snRNA and, likely, proofreads/tunes its 
interaction with the 5’SS (Kondo et al., 2015) (Figure 2.5). 
The human 17S U2 snRNP particle has a distinctive modular architecture (Figure 2.4; Figure 
2.5). The U2 snRNA moiety serves as an “extended scaffold” for the essential multimeric splicing 
factors SF3A, SF3B, U2-A’-U2-B’’, and the Sm ring (Kramer et al., 1999; Will et al., 2002; 
Plaschka et al., 2017). Additional splicing factors co-purify with these major U2 components (Will 
et al., 2002). These include two RNA helicases (DDX46/Prp5, DDX15/Prp43), U2AF1, U2AF2, 
PUF60, as well as several other proteins present in substoichiometric amounts (Will et al., 2002). 
The heteroheptameric SF3B complex is located mainly at the 5’ end of the U2 snRNA, close to 
the stem-loop IIa and stem-loop IIb (Dybkov et al., 2006; Plaschka et al., 2017). The conserved 
Sm ring and the U2-A’-U2-B’’ dimer form a second distinct module and reside at the 3’ extremity 
of the U2 snRNA (Bertram et al., 2017a; Kramer et al., 1999; Plaschka et al., 2017). The 
heteromeric SF3A complex (SF3A1/SF3a120, SF3A2/SF3a66, SF3A3/SF3a60) acts as a “protein 
bridge” between these two structural modules of the U2 snRNP (Kramer et al., 1999; Plaschka et 
al., 2017).  
Although the 13S U4/U6 di-snRNP and the 20S U5 snRNP can be isolated as stable complexes 
from the HeLa nuclear extract, these snRNPs are recruited to the spliceosome as a preassembled 
particle – the 25S U4/U6.U5 tri-snRNP (Wahl et al., 2009; Will and Luhrmann, 2011). Recent 
cryo-EM analyses of yeast (Nguyen et al., 2016; Wan et al., 2016b) and human (Agafonov et al., 
2016) tri-snRNP particles revealed the structural organization of this core building block of the 
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spliceosome (Figure 2.4; Figure 2.5). The overall structure of the yeast U4/U6.U5 tri-snRNP 
resembles a right-angled triangle with the U5 Sm, U4 Sm, and U6 LSm protein rings positioned at 
its three vertices (Nguyen et al., 2016; Wan et al., 2016b) (Figure 2.5). The U5 snRNA occupies 
the bottom-half of the tri-snRNP, the “foot” domain, and adopts a complex Y-shaped tertiary 
structure. The U5 stem I and stem II regions form a pseudo-continuous duplex, interrupted by the 
variable stem region (Nguyen et al., 2016; Wan et al., 2016b). The downstream stem III region of 
U5 is oriented at ~90o versus stem IV and continues with the Sm site which threads through the 
donut-shaped U5 Sm ring (Nguyen et al., 2016; Wan et al., 2016b). The U4/U6 di-snRNP is located 
in the upper-half of the tri-snRNP and forms the “head” and the “arm” domains, where the U4 
snRNA and the U6 snRNA moieties are extensively base-paired along the longitudinal axis of the 
assembly (Nguyen et al., 2016; Wan et al., 2016b). As a result, the intermolecular stem I and stem 
II, formed between the U4 snRNA and the U6 snRNA, are connected to the U4 5’-stem-loop in a 
three-way junction (Figure 2.5). The U4 snRNA further extends into the “head” domain, where 
the 3’ region forms an intramolecular 3’-stem-loop that precedes the Sm site and the U4 Sm ring 
(Figure 2.5). Importantly, the 5’ end of the U6 snRNA projects towards the U5-stem I/loop 1 and 
forms two additional intramolecular stem-loops – the short ACAGAGA stem-loop and the 5’-
stem-loop (Nguyen et al., 2016; Wan et al., 2016b). Thus, in the tri-snRNP, the key catalytic 
regions of the U6 snRNA, the ISL and the ACAGAGA sequence, are sequestered in intermolecular 
(U4/U6 stem II) and intramolecular (ACAGAGA stem) secondary structure elements, 
respectively. Moreover, the U5 loop 1 interacts with a single-stranded region of the U6 snRNA, in 
the proximity of the U6 5’-stem-loop. Later on, the ACAGAGA sequence base-pairs with the 5’SS 
and U5 loop 1 interacts with the 5’-exon. At the same time, the U6 ISL adopts a complex 
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Figure 2.5. Modular structures of spliceosomal snRNPs. 
(A) Structure of the isolated U1 snRNP core (PDB 4PJO) in complex with a 5’SS oligo. The interaction between 
the U1 snRNA and the 5’SS is likely stabilized/tuned by U1-C. The heptameric Sm ring is colored in magenta. 
(B) Structure of the U2 snRNP core module from the yeast B complex (PDB 5NRL) bound to the branch-site 
(BS) region of the intron. Note that the SF3A and SF3B complexes are not shown for simplicity. The U2/BS 
helix is followed by the stem-loop IIa and IIb of the U2 snRNA (green). The bulged BS adenosine (BS-A) is 
represented as spheres and colored in dark purple. The U2 Sm ring and the Lea1/U2-A’-Msl1/U2-B’’ dimer 
form a distinct module at the 3’ end of the U2 snRNA. (C) Structure of the yeast U4/U6.U5 tri-snRNP particle 
(PDB 5GAN). The AGC catalytic triad and the ACAGAGA sequence of the U6 snRNA are colored in blue and 
cyan, respectively. The U4 snRNA and the U5 snRNA are colored in light and dark purple, respectively. The 
tri-snRNP specific proteins are not shown for simplicity sake.  
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tertiary structure and resides right at the active catalytic center of the spliceosome (Galej et al., 
2016; Wan et al., 2016a; Yan et al., 2016).  
The cryo-EM reconstructions of the yeast particle (Nguyen et al., 2016; Wan et al., 2016b) provide 
additional insights into the structures and functions of the tri-snRNP specific proteins. Prp8 is the 
largest component of the U5 snRNP and one of the most conserved spliceosomal proteins (Galej 
et al., 2013; Wahl et al., 2009). It is positioned at the center of the assembly and constitutes a large 
part of the “body” domain. Its modular structure consists of (Nguyen et al., 2016; Wan et al., 
2016b): (i) an N-terminal alpha-helical domain (N); (ii) the “Large” domain (L), composed of the 
helix bundle, the reverse transcriptase (RT), the linker and the endonuclease-like (EN) regions; 
(iii) the RNaseH-like domain (RH); (iv) the Jab1/MPN domain (Jab). In the “foot” region of the 
tri-snRNP, the N-terminal domain of Prp8 stabilizes the U5 snRNA and interacts extensively with 
Snu114 bound to GTP (Nguyen et al., 2016). The flexibly linked Jab and RH domains of Prp8 
contact the N-terminal helicase domain of Brr2 and the U4/U6 helix I, respectively. Combined, 
these interactions bridge the “Large” domain of Prp8 and the “arm” module of U6, where also 
Prp4 and Snu13 reside. These tri-snRNP subunits together with the C-terminal domain of Prp3 and 
Prp31 stabilize the 3’ end of the U6 snRNA and the U4 5’-stem-loop region (Nguyen et al., 2016; 
Wan et al., 2016b). The large Brr2 RNA helicase is located close to the U4 Sm ring, in the “head” 
domain of the tri-snRNP, and is bound to a single-stranded region of the U4 snRNA (Nguyen et 
al., 2016; Wan et al., 2016b). Thus, translocation of Brr2 along this region would lead to the 
unwinding of the U4/U6 snRNA duplex and release of the U6 ISL from the U4 snRNA “trap”. 
Intriguingly, in the yeast tri-snRNP, the ACAGAGA stem of the U6 snRNA is “protected” by the 
small protein Dib1, bound to Prp8 (Nguyen et al., 2016). This, likely, provides an additional layer 
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of regulation and, potentially, prevents the premature interaction of the ACAGAGA sequence with 
the 5’SS.  
2.5 The splicing cycle – lessons from recent cryo-EM structures 
In contrast to other molecular machines, the spliceosome assembles de novo onto each pre-mRNA 
substrate in a stepwise manner (Will and Luhrmann, 2011) (Figure 2.6). In metazoans, at the 
earliest stage of spliceosome assembly, the 5’SS is recognized by the U1 snRNP via base-pairing 
with the U1 snRNA moiety, in an ATP-independent manner (Liao et al., 1990; Michaud and Reed, 
1991; Seraphin et al., 1988). At the same time, the splicing factors SF1/mBBP and the U2AF1-
U2AF2 (also known as U2AF35-U2AF65) heterodimer bind in a cooperative manner to the 3’ end 
of the intron to form the E complex (Abovich and Rosbash, 1997; Berglund et al., 1997) (Figure 
2.7). The KH-QUA2 domain of SF1 interacts in a sequence-specific manner with the BS (Berglund 
et al., 1998; Liu et al., 2001; Peled-Zehavi et al., 2001), whereas its N-terminal ULM motif (U2AF 
ligand motif) contacts the C-terminal UHM (U2AF homology motif) domain of U2AF2 (Loerch 
and Kielkopf, 2016; Selenko et al., 2003; Wang et al., 2013) (Figure 2.7). Concomitantly, the two 
tandem RRM (RNA recognition motif) domains of U2AF2 recognize the PPT (Sickmier et al., 
2006), while the N-terminal ULM motif contacts the UHM domain of U2AF1 (Kielkopf et al., 
2001) (Figure 2.7). The UHM domain of U2AF1 is flanked by two CCCH-type zinc knuckles 
which recognize the 3’SS consensus sequence (Yoshida et al., 2015). Thus, while the 5’SS is 
specified using an RNA-RNA base-pairing interaction, the 3’ intron-exon border is defined via 
multiple protein-RNA contacts (Figure 2.7). On alternatively spliced introns, a different set of 3’ 
interacting proteins may substitute for the canonical factors (Conte et al., 2000; Handa et al., 1999; 
Oberstrass et al., 2005) and their recruitment is subject to regulation by additional auxiliary factors 
(Lee and Rio, 2015).     
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In the human spliceosome, the U2 snRNP is only loosely associated with the E complex (Das et 
al., 2000; Hong et al., 1997). However, in the presence of ATP, the E complex is converted into 
the next stable complex, the pre-spliceosome (or the A complex) (Bennett et al., 1992). In the pre-
spliceosome, the U2 snRNA base-pairs with the BS region of the intron and the invariant BS-A is 
bulged out from the branch helix (Query et al., 1994; Query et al., 1996) (Figure 2.6). In the A 
complex, the displacement of SF1 from the BS is coupled to the formation of new protein-RNA 
interactions between the SF3A and SF3B subcomplexes of the U2 snRNP and the intron regions 
flanking the BS (Gozani et al., 1996; Gozani et al., 1998) (Figure 2.7). Additional protein-protein 
interactions are also established as the U2AF2 UHM domain interacts with the ULM motifs of 
SF3B1 (Cass and Berglund, 2006; Spadaccini et al., 2006; Thickman et al., 2006), whereas the N-
terminal RS (arginine/serine-rich) region of U2AF2 stabilizes the U2/BS helix (Mackereth et al., 
2005; Valcarcel et al., 1996). Importantly, the stable formation of the U2/BS duplex at the A-
complex stage requires contributions from at least two RNA helicases, Sub2/UAP56 and 
Prp5/DDX46 (Figure 2.6). In yeast, Sub2/UAP56 facilitates the displacement of SF1 from the BS 
(Cordin et al., 2012; Libri et al., 2001), whereas Prp5/DDX46, likely, remodels the U2 snRNA 
itself to expose the BSiR for BS binding, in part, through the displacement of Cus2p/Tat-SF1 
(Perriman and Ares, 2000; Perriman et al., 2003; Perriman and Ares, 2007; Yan et al., 1998) 
(Figure 2.7). In addition to its function as an unwindase/RNPase, Prp5/DDX46 might also bridge 
the U1 snRNP and the U2 snRNP across the intron (Shao et al., 2012; Xu et al., 2004).   
Recruitment of the U4/U6.U5 tri-snRNP as a preassembled particle to the pre-spliceosome leads 
to the formation of the 37S pre-B complex, a spliceosome intermediate containing all five U 
snRNPs (Boesler et al., 2016). In this intermediate complex, the 5’SS is still base-paired to the U1 
snRNP and the U4 snRNA interacts with the U6 snRNA via the intermolecular stem I and stem II, 
2 | Introduction 
 
19 
 
while the U5 loop 1 contacts the U6 snRNA, downstream of the 5’ stem-loop (Bertram et al., 
2017a; Boesler et al., 2016; Plaschka et al., 2017). It is likely that at this stage, the tri-snRNP is 
attached to the A complex mainly via the intermolecular U2/U6 helix II and, potentially, more 
Figure 2.6. The splicing cycle and spliceosome’s dynamic composition.  
The spliceosome forms onto each pre-mRNA substrate by the sequential recognition of the 5’ splice site (5’SS, 
light blue), the 3’ splice site (3’SS, orange), and the branch-site (BS, green) regions of each intron. The 
spliceosome transits through several landmark complexes: E, A, pre-B, B, B*, Bact, C, C*, P, and ILS (intron-lariat 
spliceosome). Eight spliceosomal RNA helicases (Sub2/UAP56, Prp5/DDX46, Prp28, Brr2, Prp2, Prp16, Prp22, 
Prp43) act at defined stages of the cycle to trigger the formation and the remodeling of the active site. After the 
two exons (gray boxes) are ligated, the spliceosomal snRNPs are recycled. The two insets show the organization 
of the catalytic active center of the spliceosome right after the branching reaction (C complex, PDB 5LJ3) and 
after the exon ligation step (P complex, PDB 6EXN). The two catalytic magnesium ions (M1 and M2) are 
indicated in the post-branching C complex and colored in orange. Only the M2 magnesium ion was observed in 
the post-splicing complex (Wilkinson et al., 2017) and it is not shown here for simplicity sake.                                 
NTC – NineTeen Complex, IBC – Intron-Binding Complex.  
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“fuzzy” protein-protein interactions (Bertram et al., 2017a; Boesler et al., 2016; Plaschka et al., 
2017). 
Next, the Prp28/hPrp28 RNA helicase, which in human is a core component of the U5 snRNP and 
the tri-snRNP (Teigelkamp et al., 1997), displaces the U1 snRNP from the 5’SS. As a result, the 
liberated 5’SS can interact with the ACAGAGA sequence of the U6 snRNA, to form, in human, 
an extended U6 ACAGAGA/5’SS helix (Bertram et al., 2017a). At the same time, the U5 loop 1 
contacts the 5’ exon to form the U5 loop 1/5’exon helix (Bertram et al., 2017a). Dissociation of 
the U1 snRNP from the pre-B complex is coupled with the recruitment of several B-specific 
proteins, such as RED, MFAP1, FBP21, hSmu1, hPrp38, and hSnu23, and, ultimately, leads to the 
formation of the 45S pre-catalytic B complex (Bertram et al., 2017a; Plaschka et al., 2017). The 
B-specific proteins promote a more stable integration of the tri-snRNP and reinforce the U6 
ACAGAGA/5’SS helix (Bertram et al., 2017a; Plaschka et al., 2017). Importantly, at this stage, 
the U2/U6 catalytic core of the spliceosome is not yet formed, and the U2/BS helix is located at 
~150 Å from the 5’SS (Bertram et al., 2017a; Plaschka et al., 2017).  
During spliceosome’s activation, the pre-catalytic B complex undergoes dramatic structural and 
compositional rearrangements to form the Bact complex (Figure 2.6). In part, the B to Bact transition 
is triggered by the Brr2 RNA helicase which unwinds the U4/U6 intermolecular helices. As a 
result, the U4 snRNP and most of the tri-snRNP and B-specific proteins dissociate from the 
complex. Concomitantly, the liberated U6 snRNA refolds to form the characteristic ISL. 
Downstream of the U6 ISL, the U6 snRNA base-pairs with the U2 snRNA to form the 
intermolecular helices Ia and Ib (Fica and Nagai, 2017; Shi, 2017). In yeast, the bulged nucleotides 
of the ISL adopt a contorted conformation and together with the AGC catalytic triad, base-paired 
to U2 in the U2/U6 helix Ib, coordinate the two catalytic magnesium ions (Figure 2.6). The RNA 
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catalytic core of the spliceosome, formed at this stage, will perform the two phosphoryl transfer 
reactions (i.e., branching and exon ligation), by the two-metal ion mechanism, without further 
rearrangements (Fica and Nagai, 2017). In the Bact complex, the U6 ACAGAGA/5’SS helix has 
already docked into the catalytic core and the 5’ exon is anchored by the U5 loop 1. However, the 
U2/BS helix and the reactive BS-A are located ~50 Å away from the active site, “trapped” by the 
SF3B complex in a molecular “clamp” (Rauhut et al., 2016; Yan et al., 2016). The rearrangements 
of the RNA-RNA network of the spliceosome are also coupled with the recruitment of additional 
Bact specific factors (Cwc24, Cwc27), and of the RNA helicase Prp2 with its cofactor Spp2 (Figure 
2.6). The multimeric Prp19 complex (also known as NTC), the Prp19-related factors (Rauhut et 
al., 2016; Yan et al., 2016), and, in higher eukaryotes, the intron-binding complex (IBC) (De et 
al., 2015), are also recruited at this stage. These factors, likely, help fasten the RNA catalytic core 
onto Prp8’s RT, EN, and N domains.     
For the branching reaction to occur the U2/BS helix has to dock into the active site. The result is 
the formation of the B* complex, where the first-step reaction takes place (Warkocki et al., 2009; 
Warkocki et al., 2015). Intriguingly, the cryo-EM structures of yeast Bact complexes show that the 
Prp2 RNA helicase is positioned at the 3’ end of the intron, close to the SF3B complex (Rauhut et 
al., 2016; Yan et al., 2016). The strategical location of the helicase suggests that it may “act a 
distance” to trigger the release of the branch helix (Rauhut et al., 2016; Yan et al., 2016). In turn, 
the SF3A and SF3B complexes are destabilized, and the step-one factors (Cwc25, Yju2, Isy1) join 
to fix the U2/BS helix at the active site (Galej et al., 2016; Warkocki et al., 2009; Warkocki et al., 
2015). Interestingly, the catalytic activation step might be more complicated in higher eukaryotes 
(Haselbach et al., 2018). 
2 | Introduction 
 
22 
 
After the branching reaction occurs, the resulting C complex is remodeled for the 3’ exon to be 
docked into the active site (Figure 2.6). Rearrangement of the C complex depends on the Prp16 
RNA helicase. The conserved helicase acts downstream of the BS to induce the release of the 
branching factors (Galej et al., 2016; Wan et al., 2016a). In the remodeled complex, the C* 
complex, the U2/BS helix is displaced away from the active site with help from the step-two factors 
Slu7 and Prp18, Prp17, and Prp8’s RH domain (Galej et al., 2016). As a result, the 3’SS docks at 
Figure 2.7. Stepwise recognition of the 3’ end of the intron. 
During E complex formation, the 3’ end of the intron is recognized in a cooperative manner by SF1, 
U2AF2, and U2AF1. SF1 binds to the branch-site (BS, green), U2AF2 interacts with the polypyrimidine 
tract (PPT, dark purple), while U2AF1 contacts the 3’ splice site (3’SS, orange). In the presence of ATP, 
UAP56 and Prp5/DDX46 RNA helicases, SF1 is displaced from the BS and the U2 snRNP is recruited 
instead to the BS region of the intron. Note that the U2 snRNP is not drawn to scale and only the human 
consensus sequences are shown. The schematic is, in part, adapted from (Loerch and Kielkopf, 2016). 
ULM – U2AF ligand motif, UHM – U2AF homology motif, ZNK – zinc knuckle, RS – arginine/serine-
rich. 
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the active site, where, intriguingly, its conserved AG dinucleotide engages in non-Watson-Crick 
interactions with both the 5’SS and the BS-A (Bai et al., 2017; Liu et al., 2017; Wilkinson et al., 
2017) (Figure 2.6). After the exon ligation takes place, the exon-junction complex is deposited 
onto the mature mRNA which is then released from the post-catalytic P complex through the action 
of the Prp22 RNA helicase (Bai et al., 2017; Bertram et al., 2017b; Liu et al., 2017; Wilkinson et 
al., 2017). The resulting intron lariat spliceosome (ILS) is further dismantled by the Prp43 RNA 
helicase and its cofactors, and U2, U5, and the U6 snRNP are recycled (Wan et al., 2017; Yan et 
al., 2015). 
2.6 The multimeric SF3B complex and the recognition of the branch-site region  
The U2 snRNP is critical for the accurate selection of the BS region of the intron and changes in 
the function of its components, and related splicing factors are associated with many common 
diseases (Wahl et al., 2009; Wang and Cooper, 2007). SF3B is the largest U2 subcomplex and 
plays important roles in the recognition and stabilization of BS during constitutive and alternative 
splicing (Gozani et al., 1996; Gozani et al., 1998; Will et al., 2002) (Figure 2.8). It consists of 
seven different subunits (SF3B1/SF3b155, SF3B2/SF3b145, SF3B3/SF3b130, SF3B4/SF3b49, 
SF3B5/SF3b10, SF3B6/p14, and PHF5A/SF3b14b) and has an overall molecular weight of ~ 450 
kDa (Golas et al., 2003; Will et al., 2002). An additional subunit, the DDX42/SF3b125 DEAD-
box RNA helicase, is substoichiometrically associated with the complex prior to its incorporation 
into the U2 snRNP (Uhlmann-Schiffler et al., 2006; Will et al., 2002). 
As the heteromeric complex encompasses long hydrophilic and repetitive sequences that are 
structurally disordered (Cass and Berglund, 2006; Thickman et al., 2006), and which account for 
approximately 39% of its total mass (Figure 2.9), it represents a challenge for structural analysis 
by X-ray crystallography and cryo-EM. Previous EM analyses using cryo-negative staining 
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showed that the heptameric complex has a compact architecture, with several protruding elements 
projecting away from a hollow “bivalve-like” shell (Golas et al., 2003). Although the overall 
quality of the reconstruction precluded accurate model building, three of the SF3B subunits, 
SF3B1, SF3B4, and SF3B6/p14, were tentatively assigned to several defined map regions (Golas 
et al., 2003). 
SF3B1, the largest subunit of the SF3B complex, comprises an N-terminal extended region (NTD) 
and a conserved C-terminal HEAT (Huntingtin, Elongation Factor 3, Protein phosphatase 2A, 
Target of rapamycin 1) domain (Wang et al., 1998) (Figure 2.9). Although essential for pre-
mRNA splicing, the NTD of SF3B1 (SF3B1NTD) is largely unstructured in isolation (Cass and 
Figure 2.8. SF3B contacts both the U2 snRNA and the intron at the branch-site. 
The schematic depicts an early view of the roles of SF3B subunits in the recognition of the branch-site 
(BS) and of the U2/BS helix. The model was derived mainly from protein-RNA crosslinking experiments 
(the crosslinked regions are marked with green circles). According to this model, the p14/SF3B6 subunit 
interacts directly with the BS adenosine (BS-A, dark green), whereas SF3B1 contacts intron regions 
flanking the BS-A. IIa – stem-loop IIa, IIb – stem-loop IIb; III – stem-loop III; IV – stem-loop IV; Sm – 
the Sm ring complex.  
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Berglund, 2006; Thickman et al., 2006). The extended conformation of the domain facilitates the 
multiple interactions of its linear, tryptophan-rich, ULM sequence motifs with different UHM 
domain containing splicing factors, such as U2AF2/U2AF65 (Cass and Berglund, 2006; 
Spadaccini et al., 2006; Thickman et al., 2006), SPF45/RBM17 (Corsini et al., 2007), and 
CAPERα/RBM39 (Loerch et al., 2014). The small SF3B subunit SF3B6/p14 also interacts with a 
sequence motif in SF3B1NTD  (residues 373-415), the so-called p14-interacting region (pir) 
(Schellenberg et al., 2006; Spadaccini et al., 2006), located downstream of the ULM motifs 
(Figure 2.9). 
SF3B1NTD also undergoes transient phosphorylation during spliceosome’s catalytic activation 
(Bessonov et al., 2010; Wang et al., 1998). The posttranslational modification of SF3B1NTD occurs 
after the formation of the pre-catalytic spliceosome (Bessonov et al., 2010) and is, likely, mediated 
by its interaction with Cyclin E-Cdk2 (Shi et al., 2006). The precise Ser/Thr phosphorylation sites 
were mapped by mass spectrometry to a repetitive linear motif (residues 207-374) within 
SF3B1NTD (Girard et al., 2012; Wang et al., 1998). However, as this region could not be captured 
in the structures of human spliceosomes, its relation to other SF3B subunits or other splicing 
factors is presently unclear. Intriguingly, the hyperphosphorylated SF3B1 appears to associate with 
chromatin in an RNA-dependent manner (Girard et al., 2012). Recently, direct interactions 
between SF3B1 and the exonic chromatin have been reported (Kfir et al., 2015). Thus, it is 
plausible that, in cells, phosphorylation of SF3B1NTD triggers the recruitment of the U2 snRNP 
from exonic nucleosomes to the nascent transcripts (Hollander et al., 2016). In turn, this might 
promote the co-transcriptional assembly of spliceosomes (Girard et al., 2012; Hollander et al., 
2016; Kfir et al., 2015).  
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Previous sequence predictions indicate that SF3B1’s C-terminal domain is composed of 22 
degenerated HEAT repeats (Wang et al., 1998) (Figure 2.9). In the low-resolution EM 
reconstruction of the endogenous SF3B complex, the 22 HEAT repeats were tentatively mapped 
on the outer surface of the assembly, where they form an “S-like” structure (Golas et al., 2003). 
However, the distinct α-helical features of the HEAT domain could not be discerned in this density 
map. A typical HEAT repeat (~30-50 residues) consists of two antiparallel amphiphilic α helices 
(denoted A-helix and B-helix) linked via a short turn (Conti et al., 2006; Stewart, 2006; Yoshimura 
and Hirano, 2016). The individual HEAT repeats are then connected by variable linker regions to 
form ring-like, hook-like or solenoid-like structures, as individual coils of a flexible mechanical 
spring (Conti et al., 2006). This arrangement induces the inherent helical curvature of the domain: 
the inward, concave surface of the α-α superhelix is lined by the B-helices, whereas the HEAT A-
helices face the convex side (Conti et al., 2006; Stewart, 2006). The topological properties of a 
given HEAT solenoid (curvature, helical pitch, and diameter) depend on the particular state of the 
protein and cannot be accurately predicted from sequence alone by computational methods 
(Yoshimura and Hirano, 2016). Importantly, the “molten globule-like” hydrophobic core confers 
more dynamic properties to HEAT domains compared to globular domains (Grinthal et al., 2010; 
Kappel et al., 2010; Zachariae and Grubmuller, 2008). 
In the low-resolution EM reconstruction of SF3B, the small globular subunit SF3B6/p14 was 
modeled inside the “bivalve” shell of SF3B, like a “pearl in an oyster” (Golas et al., 2003). 
SF3B6/p14 (~14 kDa) was previously linked with the recognition of the branch helix and of the 
invariant BS-A during pre-spliceosome assembly (MacMillan et al., 1994; Query et al., 1994; 
Query et al., 1996; Will et al., 2001). Its overall structure consists of an unusual RRM motif whose 
RNA recognition surface is occluded by a C-terminal helical region (Schellenberg et al., 2006; 
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Spadaccini et al., 2006) (Figure 2.9). Photo-crosslinking experiments indicate that SF3B6/p14, 
which also interacts with SF3B1NTD, contacts directly the bulged BS-A in the pre-spliceosome (A 
complex) and the later complexes (MacMillan et al., 1994; Query et al., 1996; Will et al., 2001). 
In these experiments, the pre-mRNA substrates had the BS-A labeled with benzophenone, a photo-
reactive agent which crosslinks to proteins within ~15 Å (MacMillan et al., 1994; Will et al., 2001), 
or were UV irradiated for detection of direct protein-RNA interactions (Query et al., 1996). 
Importantly, as the precise subunit composition of the human SF3B complex was not clear at that 
time, the identities of the BS-A crosslinked proteins were assigned mainly based on their relative 
migration in denaturing gels (Query et al., 1996). In apparent contradiction with the earlier studies, 
later experiments showed that SF3B6/p14 does not exhibit sequence-specificity for the BS, the 
U2/BS duplex, or for the BS-A and, overall, interacts weakly with RNA (Perea et al., 2016; 
Spadaccini et al., 2006). However, SF3B6/p14 could be crosslinked close to the BSiR in the 
isolated 17S U2 snRNP (Dybkov et al., 2006) and was co-crystallized in complex with an adenine 
base (Schellenberg et al., 2011).  
The essential SF3B4 subunit encompasses two flexibly linked RRM domains, followed by a 
variable proline-rich region, predicted to be disordered (Champion-Arnaud and Reed, 1994; Igel 
et al., 1998) (Figure 2.9). In the early EM reconstruction of human SF3B, the two RRM domains 
of SF3B4 were tentatively modeled on the periphery of the particle (Golas et al., 2003). In both 
yeast and human, SF3B4 (yeast Hsh49p) forms a stable complex with the SF3B2 subunit (yeast 
Cus1p) (Champion-Arnaud and Reed, 1994; Pauling et al., 2000). In yeast, this interaction is 
mediated by the N-terminal RRM domain of SF3B4/Hsh49p and the proline-rich C-terminal 
domain of SF3B2/Cus1p (Pauling et al., 2000; van Roon et al., 2017), recently captured in a crystal 
structure (van Roon et al., 2017). Importantly, in the purified 17S U2 snRNP, SF3B4 crosslinks to 
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the U2 stem-loop I and the stem-loop IIb (Dybkov et al., 2006). Moreover, SF3B4 crosslinks to 
intron regions upstream of the BS were detected in both human and yeast spliceosomes 
(Champion-Arnaud and Reed, 1994; Schneider et al., 2015). Overall, these observations suggest 
Figure 2.9. Composition and organization of the human SF3B complex. 
(A) Domain composition of the SF3B subunits. Well-folded regions and known domains are colored 
and labeled. WD-40 – WD-40-like β-propeller, ULM – U2AF ligand motif; pir – p14-interacting 
region; RRM – RNA-recognition motif; ZNF – zinc finger. (B) Left, protein composition of an 
endogenous human SF3B complex (Will et al., 2002). Right, the early, ~10 Å EM density map of the 
human SF3B complex (Golas et al., 2003).  
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that SF3B4, together with SF3B2, may tether the SF3B complex to the U2 snRNA in the isolated 
U2 snRNP and in fully assembled spliceosomes. 
All the other SF3B subunits, including SF3B3/SF3b130, SF3B5/SF3b10, and PHF5A/SF3b14b, 
could not be located in the early EM map, owing to the mostly unknown folds and/or flexibility 
(Golas et al., 2003) (Figure 2.9). In the more recent structures of human and yeast PHF5A/Rds3p 
(Teng et al., 2017; van Roon et al., 2008), the small SF3B subunit adopts a knotted fold, dubbed 
the “triquetra motif”. The unusual structure forms from three conserved GATA-like zinc clusters 
positioned like at the vertices of an equilateral triangle (Figure 2.9). However, it is unclear how 
the essential subunit interacts with the other SF3B components (Wang et al., 2005; Wang and 
Rymond, 2003). Although the large SF3B3 (yeast Rse1p) subunit (Figure 2.9) is predicted to 
encompass three WD40-like β-propellers (Li et al., 2006), none of these distinctive, “donut-
shaped”, domains could be identified in the published SF3B density map (Golas et al., 2003). 
Moreover, nothing is known of the structure of SF3B5/SF3b10 (yeast Ysf3p).    
2.7 Splicing factor mutations in cancers 
Sequencing of genomes from patients with hematopoietic malignancies (Papaemmanuil et al., 
2011; Quesada et al., 2011; Yoshida et al., 2011) and several types of solid tumors (Yoshida and 
Ogawa, 2014) revealed frequent somatic mutations in four different splicing factor genes: SF3B1, 
U2AF1, SRSF2/SC35 (serine/arginine-rich splicing factor), and ZRSR2/URP (zinc finger, RNA-
binding motif and serine/arginine-rich 2). Interestingly, the missense substitutions of SF3B1, 
U2AF1, and SRSF2 are always detected in heterozygous form, are mutually exclusive, and cluster 
at defined sequence hotspots, consistent with a gain-of-function/change-of-function phenotype 
(Dvinge et al., 2016). Instead, mutations in ZRSR2, a minor spliceosome component, disrupt the 
coding frame and are distributed across the entire gene (Madan et al., 2015). All these factors act 
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early in the splicing cycle, prior to or during pre-spliceosome formation (see also 2.5). Thus, 
mutations in these splicing factors, likely, impact the early stages of the spliceosome assembly 
cycle when the precise intron-exon borders are defined (Figure 2.7).  
SF3B1 and U2AF1 are constitutive splicing factors involved in the selection/recognition of the BS 
region and the 3’SS consensus sequence, respectively (see 2.5) (Figure 2.7). Recurrent mutations 
of U2AF1 affect the S34 and Q157 residues, located, correspondingly, in the N-terminal and the 
C-terminal zinc knuckles (Jenkins and Kielkopf, 2017). As these residues are predicted to interact 
with the -3 and +1 sites of the 3’SS consensus sequence (Dvinge et al., 2016; Jenkins and Kielkopf, 
2017), the hotspot mutations S34F and Q157P/R, likely, alter the sequence specificity of U2AF1. 
Thus, as observed by RNA sequencing, the affected exons are differentially included into the 
mature mRNA or skipped in a mutant U2AF1-dependent manner (Ilagan et al., 2015; Jenkins and 
Kielkopf, 2017; Shirai et al., 2015). 
SRSF2/SC35 is an SR (serine/arginine-rich) auxiliary splicing factor that binds to exonic splicing 
enhancer elements to promote the efficient exon definition (Wu and Maniatis, 1993) (Figure 2.10). 
That is, by interacting with U1 snRNP components and with U2AF1, SRSF2 couples the selection 
of the 5’SS to the recognition of the 3’SS across the exon (Shen et al., 2004; Wu and Maniatis, 
1993). SRSF2’s structure consists of an N-terminal RRM domain and a C-terminal RS (arginine-
serine-rich) region (Daubner et al., 2012; Wu and Maniatis, 1993). SRSF2’s RRM domain 
typically recognizes exonic enhancers with the CCNG or GGNG consensus sequence, where N 
represents any nucleotide (Daubner et al., 2012). Mutations of the P95 hotspot residue, frequent in 
CMML (chronic myelomonocytic leukemia, ~30-50%), induce minor structural changes which 
increase the affinity and specificity for CCNG over GGNG (Daubner et al., 2012; Kim et al., 2015). 
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This mechanism may explain, in part, the resulting transcriptome-wide splicing changes observed 
in animal models and patients (Daubner et al., 2012; Kim et al., 2015).  
SF3B1 is one the most frequently mutated splicing factor in hematological malignancies, such 
MDS (myelodysplastic syndromes, ~50-75%), CLL (chronic lymphocytic leukaemia, ~15%), 
AML (acute myeloid leukemia, 3-7%), and other myeloid leukemias (Dvinge et al., 2016; Yoshida 
and Ogawa, 2014). Recurrent SF3B1 mutations are also detected in uveal melanomas (~15-20%), 
pancreatic and bladder cancers (~4%), and several other solid tumors (Dvinge et al., 2016; Yoshida 
and Ogawa, 2014). The hotspot mutations of SF3B1 are always heterozygous and are not 
concomitantly observed with other splicing factor mutations, indicative of synthetic lethality 
effects (Dvinge et al., 2016). SF3B1’s residues mutated in cancer cluster at the C-terminal HEAT 
domain predicted to form a superhelical structure (Darman et al., 2015; Quesada et al., 2011), and 
their relative frequencies appear to be linked to a particular cancer type. Thus, the K700E, K666, 
H662, E622 and G740 substitutions are recurrent in myeloid malignancies, while the G742 
missense mutations are detected in CLL (Dvinge et al., 2016; Yoshida and Ogawa, 2014). 
Interestingly, missense substitutions of R625 are relatively frequent in solid tumors, including 
uveal melanoma, but are rare in myeloid cancers (Dvinge et al., 2016; Yoshida and Ogawa, 2014). 
Whereas mutations in U2AF1 and SRSF2 induce differential exon inclusion/skipping events, the 
cancer-linked mutations of SF3B1 lead to the selection of alternative 3’SSs and, ultimately, to 
noncanonical splicing (Alsafadi et al., 2016; Darman et al., 2015). Under a mutant SF3B1 
background, the misspliced mRNAs, are, subsequently, either targeted for degradation via 
nonsense-mediated decay or translated into aberrant proteins (Darman et al., 2015) (Figure 2.10). 
Several recent studies (Alsafadi et al., 2016; Darman et al., 2015; DeBoever et al., 2015) showed 
that the recurrent mutations in SF3B1 affect a particular subset of pre-mRNA substrates. These 
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RNA substrates are characterized by the presence of (Figure 2.10): (i) a “cryptic” 3’SS (3’SS*) 
located ~15-24 nts upstream from the canonical 3’SS; (ii) a relatively “weak” and short PPT tract 
preceding the 3’SS*; (iii) a “cryptic” and “strong” BS (BS*) located ~11-14 nts from the “cryptic” 
3’SS, exhibiting higher complementarity to the U2 snRNA than the canonical BS. Importantly, the 
noncanonical splicing by mutant SF3B1 (Figure 2.10) requires the presence of a functional PPT, 
downstream from the 3’SS*, suggesting that the alternative selection occurs in a “U2AF-dependent 
manner” (Darman et al., 2015). Although the exact molecular mechanisms are not entirely clear, 
selection of the “cryptic” sites may occur either during pre-spliceosome formation or the exon 
ligation step (Alsafadi et al., 2016; Carrocci et al., 2017; Darman et al., 2015).  
  
Figure 2.10. Mutations in SF3B1 induce an alternative branch-site usage in cancer cells. 
The 3’ end of the intron is defined by the presence of the branch-site (BS, green), the polypyrimidine tract (PPT, 
dark purple), and the 3’ splice site (3’SS, orange). The concomitant binding of the U2 snRNP, including the SF3B1 
subunit (light blue), U2AF2, and U2AF1 to the 3’ end of the intron leads to the selection of the canonical BS and 
3’SS (top panel). At the same time, SRSF2 interacts with exonic splicing enhancer elements. Cancer-related 
mutations of the SF3B1 subunit (SF3B1 mut) promote the selection of the alternative, “cryptic” BS* and 3’SS* 
(bottom panel). Overall, this results in noncanonical splicing of the pre-mRNA substrate. The misspliced product 
may be targeted for degradation by nonsense-mediated decay or translated into an aberrant protein (Alsafadi et 
al., 2016; Darman et al., 2015). The PHF5A subunit, contacting the BS adenosine in spliceosomes (Rauhut et al., 
2016; Yan et al., 2016), is colored in teal. The two exons are depicted as gray boxes. Adapted with modifications 
from (Alsafadi et al., 2016; Darman et al., 2015).  
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2.8 Therapeutic targeting of the spliceosome with small-molecule compounds 
Since the initial discovery of FR901464, a Pseudomonas sp fermentation product, more than 25 
different antitumor small-molecule compounds that modulate spliceosome assembly were 
described, engineered and synthesized (Bonnal et al., 2012; Effenberger et al., 2017; Salton and 
Misteli, 2016) (Figure 2.11). All these compounds, known as splicing modulators, target the 
multimeric SF3B complex at the same site (Effenberger et al., 2016; Teng et al., 2017) and compete 
with the stable recruitment of the U2 snRNP to canonical BSs (Corrionero et al., 2011; Folco et 
al., 2011). Binding of modulators to SF3B translates in vitro in a stalled splicing assembly 
(Corrionero et al., 2011; Effenberger et al., 2016; Folco et al., 2011; Roybal and Jurica, 2010). 
However, in cells, splicing modulators induce global changes in alternative splicing patterns (i.e., 
intron retention, exon skipping), and, finally, the cell-cycle arrest in G1 and G2/M, and apoptosis 
(Kaida et al., 2007; Kotake et al., 2007; Teng et al., 2017; Vigevani et al., 2017). Importantly, 
splicing modulators exhibit stronger cytostatic effects on cancer cells compared to normal cells 
(Lagisetti et al., 2013; Obeng et al., 2016). This effect can be exploited as a novel chemotherapeutic 
route in SRSF2, U2AF1, and SF3B1-driven hematological malignancies, and, possibly, in other 
cancers (Lee et al., 2016; Obeng et al., 2016; Seiler et al., 2018; Shirai et al., 2017).  
Based on their chemical structure, the SF3B modulators are classified into four distinct families of 
compounds (Bonnal et al., 2012; Effenberger et al., 2017) (Figure 2.11): (i) pladienolides (A-G, 
E7107); (ii) spliceostatins (A-G, FR901464, thainlanstatins, meayamycin); (iii) herboxidiene 
(GEX1A); (iv) sudemycins (C1, D6, E, F1). Importantly, it was proposed that all SF3B modulators 
share a common pharmacophore, defined by a distinctive set of functional groups required for 
activity (Lagisetti et al., 2013; Lagisetti et al., 2008; Lagisetti et al., 2014). Indeed, although the 
overall chemistry is rather diverse, all modulators have in common the conjugated diene group. 
2 | Introduction 
 
34 
 
The diene group serves as the link between two chemically complex moieties, specific for each 
family of splicing modulators (Figure 2.11). In pladienolides, the diene group connects the 12-
membered functionalized macrocycle (macrolide group) to an extended aliphatic chain which also 
includes an epoxide group (Kotake et al., 2007). Herboxidiene (GEX1A) has a similar overall 
organization, except that the macrolide cycle is substituted by a functionalized pyran core 
(Hasegawa et al., 2011). Conversely, spliceostatins and sudemycins have significantly different 
structures (Kaida et al., 2007; Lagisetti et al., 2013). That is, in these compounds, the diene group 
connects a functionalized pyran ring to a variable 6-membered cycle, further derivatized with a 
compound-specific side chain (Figure 2.11). The pyran ring of spliceostatins also contains a 
reactive epoxide group, as pladienolide’s aliphatic chain, important for the activity of this family 
of compounds (Kaida et al., 2007). Thus, it is possible that at least certain modulators might 
interact covalently with SF3B, via the epoxide group (Figure 2.11). 
Although SF3B is the sole cellular target of splicing modulators, it remains unclear how the 
structurally different compounds are recognized by the same pocket (Effenberger et al., 2016). 
Early in vitro pulldown assays using affinity and photo-affinity probes showed that pladienolide 
B binds to the SF3B3 subunit (Kotake et al., 2007), whereas spliceostatin A interacts with both 
SF3B1 and SF3B3 (Kaida et al., 2007). Consistently, herboxidiene was crosslinked to the SF3B1 
subunit (Hasegawa et al., 2011), suggesting that SF3B1 is the common target of modulators. More 
recent biochemical and chemogenomic analyses suggest that splicing modulators bind in the 
proximity of the SF3B1 and PHF5A subunits and close to the BS-A binding pocket (Teng et al., 
2017). However, it is not entirely clear how the modulator binding site on SF3B relates in structural 
terms to the BS-A pocket, observed in later spliceosomal complexes. Most importantly, the 
molecular mechanism of action of these promising chemotherapeutic agents remains elusive.  
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Figure 2.11. Chemistry of splicing modulators targeting SF3B. 
The small-molecule compounds targeting SF3B have a modular organization. The common diene 
group links different chemical moieties, specific for each family of modulators. The chemical groups 
important for the activity of the compounds are colored in purple. The SAR (structure-activity 
relationship) data for pladienolides and spliceostatins is based on (Effenberger et al., 2017). The SAR 
data for herboxidiene is adapted from (Lagisetti et al., 2014), whereas the SAR data for sudemycins 
is based on (Lagisetti et al., 2013; Makowski et al., 2017).  
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2.9 About this work 
The SF3B complex is the largest building block of the U2 snRNP and an essential component of 
both major and minor spliceosomes (Golas et al., 2003, 2005; Will et al., 2002). The heptameric 
human complex was one of the first spliceosomal components to be purified in an intact form and 
characterized by electron microscopy (Golas et al., 2003). At the beginning of this thesis project, 
detailed high-resolution structural data were available only for individual domains of SF3B6/p14 
(Schellenberg et al., 2011; Schellenberg et al., 2006), PHF5A/SF3b14b (yeast Rds3p) (van Roon 
et al., 2008), and SF3B4/SF3b49 (yeast Hsh49p) (PDB 5GVQ). Little was known in structural 
terms of the large HEAT-domain containing protein SF3B1/SF3b155 (yeast Hsh155p) or of 
SF3B3/SF3b130 (yeast Rse1p), SF3B5/SF3b10 (yeast Ysf3p), and SF3B2/SF3b145 (yeast 
Cus1p). Most importantly, it was unclear how all seven subunits assemble into a compact globular 
particle (Golas et al., 2003) and contribute to the specific recognition of the branch-site region of 
the intron as part of the U2 snRNP (Gozani et al., 1996; Gozani et al., 1998; Query et al., 1996). 
Thus, in the first part of this thesis work, we use orthogonal structural biology approaches (X-ray 
crystallography, mass spectrometry) to uncover the molecular architecture of the human SF3B 
complex.   
Abnormal changes in pre-mRNA splicing patterns, detected in different forms of cancer (Dvinge 
and Bradley, 2015), have been recently linked to mutations in several splicing factors (Dvinge et 
al., 2016), such as SF3B1, making the spliceosome complex a potential therapeutic target (Bonnal 
et al., 2012; Salton and Misteli, 2016). SF3B1 mutations are always detected in heterozygous form, 
are mutually exclusive, and induce the aberrant splicing of a selected subset of transcripts (Alsafadi 
et al., 2016; Darman et al., 2015). This global “spliceosome sickness” further drives/favors the 
proliferation of cancer cells through a still unknown mechanism (Darman et al., 2015). 
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Independently, several antitumor compounds (Bonnal et al., 2012) and promising 
chemotherapeutic agents (Eskens et al., 2013; Seiler et al., 2018), belonging to the pladienolide, 
spliceostatin/sudemycin, and herboxidiene families, were shown to target the very same subunit 
of the SF3B complex (Effenberger et al., 2016; Teng et al., 2017). These splicing modulatory 
compounds have a complex chemistry and knowledge of the precise features of their binding site 
on SF3B and of their mode of action shall provide support for ongoing structure-activity, in vitro, 
and in vivo studies (Seiler et al., 2018; Teng et al., 2017), and, thus, facilitate the transition from 
“bench to bedside”. In the second part of this work, we sought to determine crystal structures of 
optimized SF3B constructs in complex with different splicing modulators. Combined with 
biochemical and functional studies, this may reveal the structural basis of their modulatory effects 
on pre-mRNA splicing.  
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3 Results 
 
The results section of this thesis work is largely based on two first-authored publications: 
(i) “Molecular architecture of SF3b and structural consequences of its cancer-related 
mutations” (Cretu et al., Molecular Cell, 2016); 
(ii) “Structural basis of splicing modulation by antitumor macrolide compounds” 
 (Cretu et al., Molecular Cell, 2018) 
The two publications are attached below in their original form (i.e., as available on publisher's 
website).   
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3.1 Molecular architecture of SF3b and structural consequences of its cancer-
related mutations (published manuscript) 
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SUMMARY
SF3b is a heptameric protein complex of the U2 small
nuclear ribonucleoprotein (snRNP) that is essential
for pre-mRNA splicing. Mutations in the largest
SF3b subunit, SF3B1/SF3b155, are linked to cancer
and lead to alternative branch site (BS) selection.
Here we report the crystal structure of a human
SF3b core complex, revealing how the distinctive
conformation of SF3b155’s HEAT domain is main-
tained by multiple contacts with SF3b130, SF3b10,
and SF3b14b. Protein-protein crosslinking enabled
the localization of the BS-binding proteins p14 and
U2AF65 within SF3b155’s HEAT-repeat superhelix,
which together with SF3b14b forms a composite
RNA-binding platform. SF3b155 residues, the muta-
tion of which leads to cancer, contribute to the ter-
tiary structure of the HEAT superhelix and its surface
properties in the proximity of p14 and U2AF65. The
molecular architecture of SF3b reveals the spatial or-
ganization of cancer-related SF3b155 mutations and
advances our understanding of their effects on SF3b
structure and function.
INTRODUCTION
During splicing, non-coding introns are excised from pre-mRNA
by the spliceosome, a multi-megadalton protein-RNA enzyme
that orchestrates the accurate recognition and excision of in-
trons, and concomitant ligation of exons to form mature mRNA
(Wahl et al., 2009). The spliceosome assembles de novo and in
a stepwise manner onto each pre-mRNA intron from five small
nuclear ribonucleoproteins (snRNPs) (U1, U2, U4/U6, U5) and
additional non-snRNP factors that often are organized as hetero-
meric complexes (Wahl et al., 2009). Splicing catalysis involves
two transesterification steps. In the first step, the branchpoint
adenosine from the branch site (BS) carries out a nucleophilic
attack at the 50 splice site (SS) of the intron, leading to 50 SS
cleavage and intron lariat formation. In the second step, the 30
overhang (OH) of the cleaved 50 exon acts as the nucleophile,
and the 30 SS is cleaved with concurrent ligation of the two exons
(Wahl et al., 2009).
At the earliest stage of spliceosome assembly, the BS, 30 SS,
and the intervening polypyrimidine (Py) tract are recognized
cooperatively by several splicing factors. Thus, splicing factor
1 (SF1) binds the BS, the U2 auxiliary factor U2AF65 binds
the Py tract and makes additional contacts to the BS, while
U2AF35 binds the 30 SS (Arning et al., 1996; Valca´rcel et al.,
1996; Zamore et al., 1992). In the next step, the U2 snRNP re-
places SF1 in an ATP-dependent manner, and the U2 snRNA
forms a duplex with the BS (MacMillan et al., 1994). The branch-
point adenosine in the U2/BS helix is bulged out, enabling it
to act as the nucleophile in the first transesterification step of
splicing (Berglund et al., 2001; MacMillan et al., 1994). Interac-
tion of the U2 snRNA with the BS is rather weak and requires
additional factors for stabilization.
SF3b is a multi-protein component of the U2 snRNP that is
essential for pre-mRNA splicing. Human SF3b can be isolated
as a stable complex that contains seven subunits: SF3b155,
SF3b130, SF3b145, SF3b49, SF3b14b, p14/SF3b14a, and
SF3b10 (Will et al., 2002). In the spliceosome, SF3b proteins
contact the pre-mRNA at or near the BS, reinforcing the U2
snRNA/BS base-pairing interaction (Gozani et al., 1996, 1998;
Query et al., 1997; Will et al., 2001), and thereby play a key role
in BS recognition and selection during constitutive and alterna-
tive splicing (Alsafadi et al., 2016; Corrionero et al., 2011; Darman
et al., 2015).
SF3b155 is the largest subunit and encompasses a long,
intrinsically unstructured N-terminal domain (NTD) and a C-ter-
minal HEAT-repeat domain (HD) (Cass and Berglund, 2006;
Wang et al., 1998). NTD plays important roles at different
stages of the splicing cycle, and several discrete regions of
functional importance were narrowed down. SF3b155NTD con-
tains linear sequence motifs named ULM (UHM-ligand motif)
that interact with the UHM (U2AF-homology motif) domains of
U2AF65 (Cass and Berglund, 2006; Spadaccini et al., 2006;
Thickman et al., 2006) and of the alternative splicing regulator
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SPF45/RBM17 (Corsini et al., 2007). An adjacent short region of
SF3b155NTD (373–415) interacts with p14 (Schellenberg et al.,
2006; Spadaccini et al., 2006), an SF3b subunit that directly con-
tacts the BS adenosine of the intron in the prespliceosome and in
subsequently formed spliceosomal complexes (MacMillan et al.,
1994; Query et al., 1996). SF3b155 can be crosslinked to nucle-
otides directly upstream and downstream of the BS, suggesting
that SF3b155, together with its BS-binding partners p14 and
U2AF65, acts cooperatively in the recognition of the BS (Gozani
et al., 1998; Will et al., 2001).
Erroneous recognition of the BS by the U2 snRNA can lead to
the accumulation of aberrant transcripts in the cell and to cancer
(Alsafadi et al., 2016; Darman et al., 2015; DeBoever et al., 2015).
SF3b155 is the most frequently mutated spliceosomal protein in
a variety of cancer cells and thus a major drug target for therapy
(Yoshida and Ogawa, 2014). Point mutations in the HD of
SF3b155 detected recurrently in patients lead, via an unknown
mechanism, to the selection of alternative BSs and, as a conse-
quence, to the use of cryptic pre-mRNA 30 SSs and the genera-
tion of aberrantly spliced mRNA (Alsafadi et al., 2016; Darman
et al., 2015; DeBoever et al., 2015). The mechanism of this alter-
native selection is not understood in structural terms (Darman
et al., 2015). Moreover, alterations in the contacts between
SF3b155 and the pre-mRNA by tumor inhibitors such as spli-
ceostatin A result in reduced fidelity of BS and 30 SS recognition
by U2 snRNP and thus in changes in alternative splicing (Corrio-
nero et al., 2011). How SF3b is organized as a composite module
and the structural basis whereby it recognizes the BS and proof-
reads the U2 snRNA/BS interface is presently unclear.
The structure of a late-stage spliceosome from S. pombe was
recently reported at near atomic resolution (Yan et al., 2015). This
spliceosome lacks SF3b proteins, and aside from a low-resolu-
tion electron microscopic reconstruction of human SF3b (Golas
et al., 2003), little is known about SF3b’s spatial organization.
Here, we crystallized and determined the structure of the human
SF3b155-SF3b130-SF3b14b-SF3b10 complex (i.e., SF3b core)
and Chaetomium thermophilum (ct) ctSF3b130-SF3b10 dimer.
The SF3b structure reveals how the distinctive conformation of
SF3b155 is induced by the multiple interfaces that it shares
with other SF3b core components, which act as a scaffold. Pro-
tein-protein crosslinking data indicate that the SF3b core adopts
the same fold in solution and enabled us to position p14/
SF3b14a and U2AF65, which in the spliceosome contact the
BS adenosine, within the SF3b155 HEAT superhelix. The struc-
ture of the SF3b core reveals the location of numerous cancer-
related SF3b155 mutations and indicates how they affect the
structure of SF3b and thereby its function in splicing.
RESULTS AND DISCUSSION
Structure Determination and Overall Fold of the Human
SF3b Core
We reconstituted human SF3b by co-expression of its seven
proteins (SF3b155, SF3b130, SF3b145, SF3b49, SF3b14b,
p14/SF3b14a, and SF3b10) in insect cells (Figure 1A). The puri-
fied complex restored splicing activity to HeLa nuclear extract
depleted of endogenous SF3b (Figure 1B). On the basis of bioin-
formatics predictions and limited proteolysis, we removed intrin-
sically disordered regions from SF3b (Figure S1A, available
online). The resulting SF3b core complex formed crystals
and enabled de novo structure determination by combining
single isomorphous replacement with anomalous scattering
(SIRAS) and molecular replacement-single-wavelength anoma-
lous dispersion (MR-SAD) (Figures S1B–S1E). The final model
was refined against a native data set to 3.1 A˚ resolution and
exhibits excellent stereochemistry (Table 1). One molecule is
present in the asymmetric unit and comprises SF3b155 residues
463–1,304 (the HEAT domain), SF3b130 residues 1–1,217,
SF3b14b residues 7–95, and SF3b10 residues 15–80 (Figures
1C–1F). The structure reveals a compact and bipartite architec-
ture, dominated by the intimate association of SF3b130 and the
HEAT domain of SF3b155 (Figures 1C–1E). The overall structure
is further consolidated by the presence of the smaller subunits
SF3b10 and SF3b14b (Figures 1C and 1D).
SF3b130 Exhibits a b-Propeller Structure Similar to
DDB1 and Accommodates SF3b10 and the C Terminus
of SF3b155 in Its V Cleft
Human SF3b130 in the SF3b core contains three intertwined
seven-bladed b-propeller domains (BPA, BPB, and BPC from
the N to C terminus), followed by an a-helical C-terminal domain
(CTD; 1,133–1,217) that contacts the other three domains (Fig-
ures 2A and S2A). The overall fold of the protein closely resem-
bles that of DDB1, a multifunctional protein scaffold and core
component of the cullin4A-RING E3 ubiquitin ligase complexes
(CRL4A) (Angers et al., 2006; Li et al., 2006). The similarity ex-
tends also to the manner how SF3b130 and DDB1 proteins
bind other interacting partners, revealing a general interaction
principle for members of this protein family. That is, SF3b130
binds SF3b10 by way of a clam-shaped cavity (i.e., a V cleft),
framed by the tightly connected BPA (11–404) and BPC (1–10,
405–441, and 773–1,132) domains (Figure 2A). SF3b10 interacts
mainly with BPA and is folded as a conserved hairpin-like
element comprised of three a helices (Figure 2B). This is highly
analogous to the way in which DDB1 interacts with its different
binding partners, including DDB2 (Scrima et al., 2008). However,
in contrast to DDB1, which interacts with its ligands by way of
BPC, SF3b130 interacts with SF3b10 via BPA. Noteworthy, the
interaction between SF3b10 and BPA is stabilized by a hairpin
element that protrudes from the fourth blade of the BPA b-pro-
peller (Figures 2A and 2B). This insert is present in SF3b130
and absent from DDB1. In the human SF3b core, the V cleft
also accommodates the C-terminal region of SF3b155 (denoted
the anchor) that together with SF3b10 occupies most of the cav-
ity (Figures 2B and 2C). Intriguingly, SF3b130 alone is a stable
subunit of the chromatin remodeling TFTC (Brand et al., 2001)
and STAGA complexes (Martinez et al., 2001), suggesting that
the protein, similarly to DDB1, represents a versatile scaffold
acting in various cellular contexts. The notable functional and
structural similarities between SF3b130 and DDB1 suggest
evolutionary divergence from a common ancestor.
We also determined the structure of SF3b130 in complex with
solely SF3b10. For this purpose, we crystallized the ctSF3b130-
SF3b10 dimer and solved its structure by SAD. The final model
contains two molecules in the asymmetric unit and was refined
against a native data set to 2.9 A˚ resolution (Table S1), and
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comprises ctSF3b130 residues 7–1,213 and ctSF3b10 res-
idues 27–81 (Figures S1F and S2A). The former exhibits the
typical fold of its homolog DDB1, and also accommodates
ctSF3b10 in its inner cavity (Figure S2B). Comparison of
ctSF3b130-SF3b10 with its human orthologs within the SF3b
core shows that the structures and relative orientations of
BPA, BPC, CTD, and of SF3b10 are virtually identical (Fig-
ure S2A; Data S1). Conversely, the BPB domain (442–772) is ori-
ented differently in SF3b130 orthologs, suggesting that, as in
DDB1 structures (Li et al., 2006; Scrima et al., 2008), it is flexibly
connected to BPC (Figure S2A). In CRL4A complexes the BPA-
BPCmodule of DDB1 serves as an adaptor for various substrate
receptors while the BPB domain tethers the E3 ligase subunits
(Angers et al., 2006). By analogy, the mobile BPB domain of
SF3b130 could sample other SF3b interactors and thus recruit
additional splicing factors to U2 snRNP at later stages of the
splicing cycle.
SF3b155 Conformation Is Achieved by Multiple
Contacts with SF3b130, SF3b14b, and SF3b10
The HEAT domain of SF3b155 is composed of 20 tandem
repeats (Figure 2D), in contrast to 22 repeats as previously
proposed based solely on its sequence (Wang et al., 1998).
It is organized as a right-handed superhelix with a pitch of
Figure 1. Structure of the Human SF3b Core Complex
(A) SDS-PAGE of the recombinant full-length human SF3b complex after affinity purification and size exclusion chromatography. Note that SF3b155 and
SF3b145, as well as p14/SF3b14a and SF3b14b, co-migrate on the gel.
(B) Recombinant SF3b complex (rSF3b), like native SF3b (nSF3b), supports splicing in nuclear extract (NE) depleted (D) of SF3b.
(C–E) Three views of a ribbon representation of the SF3b core (middle views rotated relative to top right view). Proteins are shown in different colors. The small
inset depicts the overall architecture.
(F) Schematic of the domain arrangement of the crystallized SF3b core proteins. The a-helical insert from the BPC domain and the zinc-finger domain of SF3b14b
are labeled I and ZnF, respectively; A, anchor.
See also Figure S1.
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65 A˚ and a mean diameter of 100 A˚ (Figures 1C and 1D),
which represents a unique conformation for a HEAT-repeat
superhelix. Generally, HDs possess structural plasticity, with
their conformation influenced by their binding partners (Grin-
thal et al., 2010; Zachariae and Grubmu¨ller, 2008). Indeed,
the distinctive conformation of SF3b155’s HD appears to be
induced by multiple interfaces that it shares with SF3b130,
SF3b10, and SF3b14b (Figure 2E), consistent with its lack of
solubility when expressed on its own (data not shown).
HEAT repeats H3 and H5–H6 contact SF3b130 BPA, H18–
H20 contact the CTD of SF3b130, and H20 binds both the
BPA and BPC b-propellers (Figure 2D). The C-terminal anchor
region of the HD lacks a-helical structure and is deeply in-
serted into the V cleft, where it makes extensive contacts
with SF3b130 BPC and with SF3b10 (Figures 2B and 2C).
The latter acts as an adaptor that reinforces the tight packing
of the anchor within the V cleft. The structure is consistent
with a yeast two-hybrid interaction between yeast SF3b10
and SF3b155 (Wang et al., 2005) and explains SF3b10’s
essential role in the assembly and stability of yeast SF3b
and in prespliceosome formation (Wang et al., 2005). More-
over, SF3b10 residues 33–85, essential for yeast viability
(Wang et al., 2005), correspond to those residues of the hu-
man ortholog that are located inside the V cleft and are closely
associated with SF3b155 (Data S1).
SF3b155 interacts extensively also with SF3b14b, a highly
conserved protein required for proper assembly of yeast U2
snRNP and stable spliceosomes (Wang and Rymond, 2003). Hu-
man SF3b14b is folded as a triple knot, similar to the previously
reported nuclear magnetic resonance model of the yeast homo-
log (van Roon et al., 2008) (Figure S2C). In a manner reminiscent
of Ran bound to HEAT-repeat nuclear transport receptors,
SF3b14b contacts the concave surface of SF3b155 in two highly
conserved places, bridging diametrically opposed residues from
H2–H3 (contact site I) at the N terminus and H15, H17, and H18
(contact site II) at the C terminus of the superhelix (Figures 2D,
S2D, and S2E). By the way of these contacts, SF3b14b appears
to contribute inducing an 90 tilt between H1–H3 and H4 at
contact site I as well as between H15 and H17–H20 at contact
site II (Figure S2F). These observations suggest that SF3b14b
contacts the superhelix at two dynamic hinge regions (H3–H4
and H15–H16) and thus fixes the HD of SF3b155 in a defined
conformation. As in other HEAT-repeat proteins (Zachariae and
Grubmu¨ller, 2008), the presence of dynamic hot spots in the
HD superhelix would permit additional conformational rear-
rangements of SF3b upon transiting different stages of the
splicing cycle (Golas et al., 2005). Taken together, the structure
of SF3b indicates that the distinctive conformation of SF3b155
is induced and maintained by a multipartite scaffold composed
of SF3b130, SF3b10, and SF3b14b.
Table 1. X-Ray Data Collection and Refinement Statistics
SF3b Core Ta6Br12 Derivatized—Ta Peak Native I—SIRAS Native II—Zn K-Edge Native III
Data Collection
Space group P 21 21 21 P 21 21 21 P 21 21 21 P 21 21 21
Cell dimensions: a, b, c (A˚) 105.68, 153.39, 210.32 105.25, 154.01, 209.81 104.61, 154.37, 210.56 105.05, 154.44, 210.42
Cell dimensions: a, b, g () 90.0, 90.0, 90.0 90.0, 90.0, 90.0 90.0, 90.0, 90.0 90.0, 90.0, 90.0
Wavelength 1.254 1.0 1.282 0.918
Resolution (A˚) 49.74–4.27 (4.56–4.27) 48.45–3.39 (3.51–3.39) 49.54–3.09 (3.17–3.09) 47.04–3.1 (3.18–3.1)
Rmerge (%) 20.1 (>100) 15.9 (>100) 14.3 (>100) 21.3 (>100)
I/sI 9.9 (2.4) 9.9 (1.5) 11.2 (1.4) 10.5 (1.2)
CC1/2 0.998 (0.736) 0.997 (0.727) 0.998 (0.465) 0.995 (0.412)
Completeness (%) 99.3 (96.7) 99.5 (95.0) 98.4 (87.2) 99.9 (98.9)
Redundancy 12.4 (12.2) 6.6 (6.2) 11.1 (10.1) 8.3 (8.4)
Refinement
Resolution (A˚) – – – 47.04–3.1
No. reflections – – – 62,754
Rwork/Rfree – – – 0.230/0.259
No. atoms: protein – – – 17,099
No. atoms: ligand/ion – – – 4
B-factors: protein – – – 77.64
B-factors: ligand/ion – – – 72.73
RMS deviations: bond
lengths (A˚)
– – – 0.002
RMS deviations: bond
angles ()
– – – 0.55
Ramachandran plot: favored (%) – – – 95.43
Ramachandran plot: outliers (%) – – – 0.05
Values for the highest-resolution shell are given in parentheses. RMS, root-mean-square. See also Figure S1.
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The HEAT-Repeat Superhelix Defines a Composite RNA-
Binding Platform for BS Recognition
To validate the architecture of the SF3b core, we treated full-
length SF3b complexes with BS3 (bissulfosuccinimidyl suber-
ate) and identified crosslinked pairs of lysines by mass spec-
trometry (MS) (Table S2). A total of 365 intermolecular unique
crosslinks were identified for the entire complex. More than
95% of crosslink-assigned spectra were consistent with the
crystal structure, indicating that the SF3b core adopts the
same fold in solution (Figure 3A). SF3b49 crosslinks were
limited to its binding partner SF3b145 (Champion-Arnaud and
Reed, 1994), which was mainly crosslinked to SF3b155 (Fig-
ure 3B), suggesting that SF3b145 mediates the interaction
of SF3b49 with the SF3b complex. Because of its largely un-
known structure, we could not model SF3b145 into the core
complex.
Figure 2. Intermolecular Interactions in the
SF3b Core
(A) Superposition of DDB1-DDB2 (PDB: 3EI4)
complex on SF3b130-SF3b10. For simplicity, only
the DDB2 region that interacts with DDB1 is shown.
Note thatwhile SF3b10contacts theBPAdomain of
SF3b130, DDB2 interacts with the BPC domain of
DDB1. Interaction between SF3b10 and BPA is
further stabilized by an insertion that protrudes from
the fourth blade of the BPA b-propeller.
(B) Overview of the V cleft organization and the
manner in which it mediates binding of SF3b10
and the SF3b155 anchor.
(C) Polar contacts between SF3b10, the SF3b155
anchor, and the interior of the V cleft.
(D) Overview of the interaction between the
HEAT repeats (H1–H20) and other SF3b core
components.
(E) Molecular interfaces between SF3b130,
SF3b155, and the other core components. In-
terfaces are computed with PISA and colored
like their interaction partners. The corresponding
buried surface areas (A˚2) are indicated on the
surface.
See also Figure S2 and Data S1.
SF3b14a/p14 is regarded as a marker
of the branchpoint adenosine, to which
it crosslinks within prespliceosomes
and subsequent spliceosomal complexes
(Query et al., 1997; Will et al., 2001). BS3
crosslinking data for p14 (Figure S3A; Ta-
ble S2) allowed us to model its average
position in the SF3b core. The p14 struc-
ture was previously determined in com-
plex with a short SF3b155 fragment
(residues 373–415) from its unstructured
N-terminal region, which assumes an
ensemble of conformations in solution
(Figure S4). SF3b155373–415 is necessary
and sufficient for stable binding of p14
(Schellenberg et al., 2006; Spadaccini
et al., 2006). Surprisingly, in addition to
several expected crosslinks with SF3b155373–415 (Figure S3A),
56 unique crosslinks were detected between p14 and the HD,
indicating that p14 is located within the circular perimeter of
the latter, close to SF3b14b (which is also crosslinked to p14
by 13 unique crosslinks; Figures 3B and 3C). A similar p14 cross-
linking pattern could be detected in the 17S U2 snRNP particles,
suggesting that the p14-HD interface does not undergo major
rearrangements upon integration of SF3b into U2 snRNP (data
not shown).
As an independent means of demonstrating that p14 does
indeed share interfaces with SF3b155HD, we performed cross-
linking of SF3b with the carbodiimide EDC, a compound that en-
ables direct formation of covalent bonds between carboxy and
amino groups of exposed residues (Table S2). Importantly, the
distance restraints derived from the EDC crosslinking experi-
ment, as in the case of BS3, enabled us to again localize p14
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in the perimeter of the HEAT superhelix (Figure S3B). The pres-
ence of direct contacts between p14 and SF3b155HD-SF3b14b
is further supported by in vitro binding assays showing
that p14 interacts with a SF3b core complex devoid of
SF3b155373–415 (Figures S3C and S3D). These data indicate
that although SF3b155373–415 suffices for tethering of p14 to
SF3b, additional contacts with the HD are required to position
p14 in a structurally defined location.
The location of the BS-binding, RNA recognition motif (RRM)
domain of p14 in the center of the SF3b155HD (Figure 3C) sug-
gests that the latter might form a composite RNA-binding plat-
form together with SF3b14b. To identify RNA-binding regions
within the SF3b core complex we exposed to UV irradiation
in vitro-assembled RNP complexes and detected crosslinked
peptide-RNA conjugates by MS (Figures 4A–4C). Notably, four
of the photo-crosslinked residues were located in the H3, H14,
and H17 repeats of SF3b155, two in the amino-terminal region
of SF3b10 (Y5, G20), and one residue (Y100) in the flexible C ter-
minus of SF3b14b (Figures 4A and S5). Consistent with previous
data (Gozani et al., 1998), we could not detect crosslinked pep-
tides derived from SF3b130, suggesting that, most likely, the
protein scaffold does not contribute to RNA binding (Figure 4A).
Although these experiments are not performed in the context
of the spliceosome, they show that SF3b155HD-SF3b14b
Figure 3. Position of p14 in the SF3b Core
(A) Distribution of the Ca-Ca distances between crosslinked residues in the SF3b core complex. Euclidean distances were computed between the Ca atoms of
BS3 or EDC crosslinked residues using the atomic coordinates of the SF3b core complex. Chemical crosslinking data at FDR = 1% were not further filtered.
(B) Protein-protein interaction network of the seven-subunit SF3b complex as revealed by BS3 crosslinking experiments. Subunits of the human SF3b complex
are shown as nodes of the graph (SF3b155, light blue; SF3b130, pale orange; SF3b14b, magenta; SF3b10, green; p14/SF3b14a, yellow). The total number of
unique intermolecular crosslinks (FDR = 1%, unfiltered) between the subunits of the complex is indicated on the connecting lines.
(C) Two orientations of the model derived from the BS3 crosslinking data, showing the average location of p14 relative to SF3b155 and SF3b14b. Crosslinked
residues from p14, SF3b155, and SF3b14b are depicted as magenta, yellow, and yellow starred spheres, respectively.
(D) Surface-charge distribution of SF3b155 and SF3b14b around p14. The crystal structure of p14 (yellow) complexed with a short SF3b155 NTD fragment (PDB:
2F9J) is shown.
See also Figures S3 and S4 and Table S2.
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possesses the biophysical properties required for RNA accom-
modation. In agreement with previously observed SF3b155
crosslinks to intron nucleotides flanking the BS adenosine (Go-
zani et al., 1998), p14 is flanked by positively charged patches
of the HD and SF3b14b (Figure 3D).
U2AF65 Is Located on the SF3b Core and in the
Proximity of p14
Another important interaction partner of SF3b155 that partici-
pates in the BS recognition is U2AF65, an essential and
conserved splicing factor (Zamore et al., 1992; Valca´rcel et al.,
1996). U2AF65 has a modular architecture: an arginine/serine
(RS)-rich domain that contacts the BS (Valca´rcel et al., 1996),
two tandem RRM domains that bind cooperatively the Py tract
sequence (Sickmier et al., 2006), and a UHM domain that recog-
nizes SF3b155NTD (Gozani et al., 1998; Wang et al., 2013). To
examine how U2AF65 is positioned relative to the SF3b core
and p14, we reconstituted the SF3b-U2AF65 complex and sub-
jected it to crosslinking and mass-spectrometric analysis (Fig-
ure 5). The overall crosslinking pattern of the SF3b core remained
the same in the presence of U2AF65, indicating a similar struc-
tural organization.
The N-terminal region of U2AF65 that contains the functional
RS dipeptides (20–63) was crosslinked to residues located in
the immediate vicinity of p14 and belonging to SF3b155HD
(H14–H15), SF3b130 CTD and BPA, and SF3b14b (Table S2;
Figures 5C and 5D). The preferential crosslinking of the RS re-
gion is consistent with its described ability to contact the BS
and promote the BS-U2 snRNA interaction (Valca´rcel et al.,
Figure 4. Protein-RNA Photo-Crosslinks
Identified in the SF3b Core Complex
(A) Overview of residues in the SF3b core complex
crosslinked to RNA upon UV irradiation. RNA-
crosslinked residues are mapped onto the struc-
ture of the SF3b core and are shown as colored
spheres.
(B) UV-induced peptide-RNA conjugates detected
in the SF3b core complex. The sequence of the
crosslinked peptides as identified by MS is shown,
and the crosslinked amino acids are highlighted in
orange.
(C) Representative MS/MS fragmentation spec-
trum of a photo-crosslinked peptide. The cross-
linked peptide sequence and its corresponding
y- and b-type fragment ions are indicated at the
top, referring to the ions that retain the charge
on the N or C terminus, respectively. #Observed
as an adduct with [fragment of U = -C3O =
52]; #3observed as an adduct with [U-H3PO4];
#4observed as an adduct with [U-H2O].
See also Figure S5.
1996). The RRM domains of U2AF65
were crosslinked to the p14-binding side
of the HEAT superhelix (Figure 5C). A
reliable docking was difficult given that
relatively few pairs of crosslinks were
detected (Figures S6A and S6B). Most
crosslinks detected between UHM and
SF3b155 were established with the ULM-rich region of NTD
(188–357), confirming the previously demonstrated interactions
between these regions (Cass and Berglund, 2006; Gozani
et al., 1998) (Figures 5B and 5C). Remarkably, eight and seven
high-confidence crosslinks were detected between the UHM
domain SF3b155HD and p14, respectively, indicative of its prox-
imity to HEAT-repeats H5–H8, the area that contains the most
hot spot mutations (Figure 5D).
The crosslinking pattern of the SF3b-U2AF65 complex is
consistent with previously reported interactions and indicates
that, via its contacts with the SF3b core, U2AF65 adopts a struc-
turally defined location. The revealed role of the HEAT superhelix
as a scaffold element that bridges p14 andU2AF65 underlines its
importance in the stable recruitment of U2 snRNP and accurate
selection of the BS.
Residues Mutated in Cancer Cells Are Important for the
Tertiary Structure and Surface Properties of SF3b155
SF3b155 is the most frequently mutated spliceosomal protein in
several types of cancer (Yoshida and Ogawa, 2014). Recurrent
point mutations have the highest incidence in myelodysplastic
syndrome (MDS) and chronic lymphocytic leukemia (CLL) and
lower frequency in various types of solid cancers (Yoshida and
Ogawa, 2014). Although more than 40 residues reported to be
mutated in human cancer cells are distributed along the entire
superhelix (Figures 6A–6C), 33 are clustered in HEAT repeats
H4–H7, in the immediate vicinity of the UHM domain of
U2AF65, and of p14 (Figure 5D). Except for E592, none are
located at interfaces with other components of the SF3b core,
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Figure 5. Location of U2AF65 in the SF3b Core
(A) Distribution of the Ca-Ca distances between the observed crosslinked residues in the SF3b-U2AF65 complex. Euclidean distances were computed between
the Ca atoms of BS3 crosslinked residues. BS3 crosslinking data at FDR = 1% was filtered (ScoremaxR 2, spectral countR 3; Table S2).
(B) Protein-protein crosslinking network of the SF3b-U2AF65 complex. Subunits of the human SF3b complex are shown as nodes of the graph. The number of
high-confidence intermolecular crosslinks is indicated on the connecting lines.
(C) Crosslink map depicting the interaction between SF3b155 and U2AF65. The known domains are indicated, and only high-confidence inter-protein
crosslinks are shown (ScoremaxR 2, spectral countR 3). Intermolecular crosslinks between the N-terminal region of U2AF65 (1–94) and SF3b155 are in deep
blue. Inter-protein crosslinks between the two RRM domains of U2AF65 (RRM1, RRM2) and SF3b155 are in green, and intermolecular crosslinks between
U2AF65 UHM and SF3b155 are shown in cyan.
(legend continued on next page)
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whose disruption may destabilize entirely the SF3b155 fold and
lead to the total arrest of splicing (Figure 6C).
Many residues whosemutation is linked to cancer are involved
in the tertiary structure of SF3b155. Thus, 15 residues are
involved in intramolecular hydrogen bonds (e.g., R625, N626,
R630, T663, K666; Figures 6A–6C). Twelve are tightly packed
in hydrophobic interfaces and thus substitutions would result
in sterical clashes (e.g., I704, G742, L747). Three residues are
located in a helices, and thus mutation to proline would not be
structurally tolerated (Q534, A744, A745). Substitution of these
residues likely induces changes in the conformation and specific
curvature of the HEAT superhelix. This in turn could diminish the
interaction of SF3b155 with the pre-mRNA and other spliceoso-
mal proteins such as p14 or U2AF65, leading to the selection of
alternative BS sequences that exhibit greater complementarity
to the U2 snRNA and are thus less dependent on the stabilizing
effect of SF3b (Alsafadi et al., 2016; Darman et al., 2015).
Notably, some of the residues important for the tertiary structure,
such as K666 and R625, are among the most frequently mutated
in splicing-related cancers (i.e., mutational hot spots) (Yoshida
and Ogawa, 2014).
In addition to the residues that contribute to the structure,
nine residues in H4–H8, including the hot spot residue K700,
are exposed to the solvent and are clustered in or close to
the positively charged patch in the immediate vicinity of p14
and U2AF65 (Figures 3C and 5D), suggesting they may affect
SF3b155 interactions with the intron at the BS and/or spliceo-
somal proteins. For instance, it was suggested that hot spot
mutations lead to the cryptic 30 SS selection by altering the
contacts with U2AF65 (DeBoever et al., 2015). Indeed, accord-
ing to our crosslinking, the UHM domain of U2AF65 is located
in the proximity of the basic surface patch that includes K700
(Figure 5D). However, we showed by protein-protein crosslink-
ing and in vitro binding assays that the K700E mutation does
not affect the stability of the SF3b-U2AF65 complex (Figures
S7E and S7F). At the same time, we found that K700E does
not decrease the affinity to RNA (Figures S7A and S7B)
compared with the wild-type, suggesting that the mechanism
(D) Two orientations of the model derived from the BS3 crosslinking data, showing the average location of the UHM domain (375–475; PDB: 4FXW) relative to the
SF3b core. Inter-protein crosslinks are depicted as red lines and crosslinked residues as spheres. Side chains of the residues crosslinked to the RS domain are
colored light green.
See also Figure S6.
Figure 6. Residues Mutated in Cancer and Pladienolide-Resistant Cells
(A) Overview of residues mutated in various cancers (colored spheres) with mutations associated most frequently with MDS (red), CLL (pink), MDS and CLL
(purple), or other cancers (yellow). Mutational hot spot residues are bold, and R1074 is green.
(B) Selected polar residues mutated in human cancers, some are solvent exposed, and some are involved in intermolecular contacts.
(C) Selected polar residues mutated in human cancers, involved in inter- and intramolecular contacts. Other residues are depicted in blue.
(D) Polar contacts between R1074 (green) and other residues of SF3b155. Residues that form the pocket between SF3b155 and SF3b14b are indicated. The
unassigned electron density (black mesh) from the pocket is contoured at 3.0s and may potentially originate in components of the crystallization cocktail or
peptides generated by limited proteolysis (data not shown).
See also Figure S7.
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is more complex and may involve additional splicing factors
(Figures S7C and S7D).
The SF3b155 mutation R1074H impairs binding of the tumor
suppressor pladienolide B (PB) (Yokoi et al., 2011). R1074H
forms polar contacts with the backbone of A1068 and H1069,
suggesting that it may indirectly impair PB binding by propa-
gated distortions in the HEAT domain. On the other hand,
R1074 together with other residues from H15–H17 and Y36
from SF3b14b form a pocket where an unassigned density is
visible (Figure 6D). Future investigations are required to fully un-
derstand the relevance of this pocket for binding anti-tumor
drugs.
Conclusions
SF3b is a multimeric module of the U2 snRNP that plays an
essential role in BS recognition and selection, stabilizing the
short U2 snRNA-BS RNA duplex that forms at an early stage of
spliceosome assembly. The fact that the SF3b subunits p14
and SF3b155 interact directly with one another and also contact
adjacent positions at or near the BS has led to the suggestion
that the two proteins function during BS recognition in a cooper-
ative manner (Gozani et al., 1998; MacMillan et al., 1994; Query
et al., 1996). The structural basis of the latter and the role of other
SF3b subunits in the function of SF3b as an integrated unit
remained largely unknown. The crystal structure of the SF3b
core shows that SF3b130, SF3b10, and SF3b14b form a multi-
partite scaffold that induces and maintains the specific superhe-
lical conformation of SF3b155. The SF3b155’s HD and SF3b14b
exhibit RNA-binding properties, and the HD accommodates
the BS-binding p14 protein at its center, indicating that the
three proteins form a composite RNA-binding platform for BS
recognition.
In addition to p14, U2AF65 is another splicing factor that con-
tacts the BS and plays an important role in its selection (Valca´rcel
et al., 1996). Both proteins bind the intrinsically unfolded NTD of
SF3b155, in a protein-protein interaction network required for
the early steps of BS recognition. Complementary to this view,
our crosslinking experiments indicate that the SF3b core, owing
to its structured nature, acts as a scaffold to define the positions
of both U2AF65 and p14.
The architecture of SF3b provides structural insight into how
cancer-related mutations of SF3b155 or the binding of splicing
inhibitors alter BS recognition by the U2 snRNP. That is, most
residues mutated in cancer cells contribute to the tertiary struc-
ture of SF3b155’s HD, while others are located on the outer side
of SF3b, where SF3b155 is associated with p14 and U2AF65.
Therefore, substitution of SF3b155 residues likely affects not
only the conformation of the HD and its surface properties but
may also have consequences for positioning p14 and U2AF65
at the BS. The position of other splicing factors that contact
SF3b155 at a later stage may also be affected. Changes in the
conformation and specific curvature of the HEAT superhelix
could diminish the interaction of SF3b with the pre-mRNA and
thus destabilize the U2/BS interaction. This in turn may lead to
the selection of alternative BS sequences that exhibit greater
complementarity to the U2 snRNA (Alsafadi et al., 2016; Darman
et al., 2015). Thus, the structural plasticity of the SF3b155 HEAT
domain tolerates discrete changes induced by point mutations
and tumor inhibitors, at the cost of a loss of BS selection fidelity,
aberrant splicing, and cancer.
EXPERIMENTAL PROCEDURES
Detailed protocols can be found in Supplemental Experimental Procedures.
Crystallization and Structure Determination of the Human SF3b
Core Complex
The protease-resistant SF3b core complex (see Supplemental Information)
was concentrated by ultrafiltration to6.5mg/mL and subjected to crystalliza-
tion screening. Initial needle-like crystals appeared after 5–7 days at 20C.
Larger single plates were grown at 20C in 3 mL hanging drops over reservoirs
containing 50 mM HEPES-NaOH (pH 6.91–7.05), 200 mM KCl, and 40% (v/v)
pentaerythritol propoxylate 5/4. Diffraction data were collected at 100 K
on PILATUS 6M detectors at the X10SA (Swiss Light Source) or BL14.1
(BESSY II) beamlines. Data were indexed, integrated and scaled with XDS
(Kabsch, 2010), and reduced with POINTLESS, AIMLESS, and CTRUNCATE
in CCP4 (Evans, 2011). Initial phases of the SF3b core complex were obtained
by SIRASwith autoSHARP (Vonrhein et al., 2007) using data collected at the Ta
peak wavelength from a crystal derivatized with Ta6Br12 heavy-atom cluster
(see Supplemental Information) and a native data set (native I). Density modi-
fication with SOLOMON (Abrahams and Leslie, 1996) yielded an initial electron
density map where a partial model could be built with the Autobuild module in
Phenix (Adams et al., 2010). Next, the partial model was used to solve the Zn-
substructure by MR-SAD (as implemented in Autosol) using weaker data
collected at the K edge from a native crystal (native II). The improved experi-
mental map enabled automatic model building with Buccaneer (Cowtan,
2006), followed by iterative rebuilding in COOT (Emsley and Cowtan, 2004)
and refinement with Phenix.refine (Afonine et al., 2012). The final model was
refined against amore complete data set collected from a native crystal (native
III) to an Rfree value of 25.9% (see Table 1). The quality of the final model was
assessed with MOLPROBITY (Chen et al., 2010), and statistics are provided
in Table 1. One molecule is present in the asymmetric unit, and the model
comprises the C-terminal HEAT domain of SF3b155 (residues 463–1,304),
SF3b130 (residues 1–1,217), SF3b10 (residues 15–80), and SF3b14b (residues
7–95). SF3b145 (439–706) and SF3b49 (1–203) were not visible in the electron
density, possibly because of low occupancy (caused by partial dissociation
during crystal formation) or relative mobility. The macromolecular interfaces
between the subunits of the SF3b core complexwere analyzedwith PISA (Kris-
sinel and Henrick, 2007), and the figures were generated with PyMOL (version
1.7.6, Schro¨dinger). Multiple sequence alignments were produced with Clustal
Omega (Sievers et al., 2013) and annotated with ESPript (Gouet et al., 2003).
The sequence conservation was mapped onto the protein structures with
ConSurf (Ashkenazy et al., 2010). The electrostatic potentials were computed
with APBS (Unni et al., 2011) and visualized in PyMOL.
Crystallization and Structure Determination of the ctSF3b130-
ctSF3b10 Complex
SF3b130-SF3b10 dimer was expressed in High Five insect cells (see Supple-
mental Information). Crystals of the proteolysed complex were grown at 4C in
sitting drops by mixing 0.2 mL of protein with 0.2 mL of reservoir solution (0.1 M
HEPES-NaOH [pH 7.5], 0.1 M NaCl, 0.1 M CaCl2, 8% [v/v] PEG 4000). Initial
crystals appeared after 5 days and grew to full size after 3 weeks. Crystals
were cryo-protected in reservoir solution supplemented with 25% (v/v)
2-methyl-2,4-pentanediol and flash-frozen in liquid nitrogen. The structure
of the complex was determined by SAD using a crystal derivatized with
Ta6Br12. The final model was refined against a native data set to an Rfree of
25% (Table S1).
Immunodepletion of SF3b
HeLa nuclear extract was prepared essentially as described (Dignam et al.,
1983). Immunodepletion of the SF3b complex was performed using anti-pep-
tide antibodies specific for SF3b155 (Will et al., 2001). Antibodies (10 mg) were
coupled to protein A-Sepharose (1 mL) beads using dimethyl pimelimidate
(Sigma). Two hundred microliter beads equilibrated in G-750 buffer (750 mM
316 Molecular Cell 64, 307–319, October 20, 2016
KCl, 1.5 mM MgCl2, and 20 mM HEPES-KOH [pH 7.9]) were divided into
two equal portions and sequentially incubated with HeLa nuclear extract in
G-750 buffer for 2 hr at 4C with end-over-end rotation. The extract was
subsequently dialyzed for 5 hr against buffer containing 100 mM KCl,
1.5 mM MgCl2, 20 mM HEPES-KOH (pH 7.9), and 10% (v/v) glycerol. Mock
depleted extract was treated in the same manner except the antibody was
omitted.
In Vitro Splicing Reactions
Uniformly 32P-labeled MINX pre-mRNAwas produced by in vitro transcription.
Splicing reaction contained 6 nM pre-mRNA, 40% (v/v) HeLa nuclear extract,
3 mMMgCl2, 60mMKCl, 20mMHEPES-KOH (pH 7.9), 2 mMATP, and 20mM
creatine phosphate. Two hundred nanograms per microliter of recombinant
SF3b or native purified SF3b was added to immunodepleted nuclear extract
to restore splicing. The reaction mixture was incubated at 30C for 90 min.
RNA was resolved on an 8 M urea-10% polyacrylamide gel.
RNA-Binding Assays
Electrophoretic mobility shift assays were performed using 30-Cy3 fluores-
cently labeled probes (see Supplemental Information).
In Vitro Binding Assays
In vitro binding assays were performed with GST-p14 or His14-MBP-U2AF65
fusion proteins and recombinant SF3b complexes. Bound proteins were
eluted from the affinity resins under native conditions and analyzed by SDS-
PAGE (see Supplemental Information).
Chemical Crosslinking and Crosslink Identification by Mass
Spectrometry
Purified SF3b was crosslinked either with 150 mM BS3 (pH 7.9) or 4 mM EDC/
1 mMNHS (pH 6.0–6.5) and purified further by size exclusion chromatography
using a Superose 6 10/300 column (GE Healthcare). Approximately 100 pmol
of crosslinked SF3b from the peak fraction was concentrated to 40 mL using
Amicon Ultra with Ultracell-100 membrane (Millipore) and analyzed essentially
as described before (Leitner et al., 2012), with the following modifications: the
complexes were denatured in 4 M urea/50 mM ammonium bicarbonate,
reduced with DTT, alkylated with iodoacetamide, diluted to 1 M urea, and di-
gested with trypsin (1:20 w:w). Peptides were reverse-phase extracted and
fractionated by gel filtration on Superdex Peptide PC3.2/30 column (GE
Healthcare). Fifty microliter fractions corresponding to an elution volume of
1.2–1.8 mL were analyzed in duplicates on Orbitrap Fusion Tribrid (data
set 1) and Q Exactive HF (data set 2) mass spectrometers (Thermo Fisher Sci-
entific). Protein-protein crosslinks were identified by pLink1.22 search engine
and filtered at a false discovery rate (FDR) of 1% according to the recommen-
dations of the developers (Yang et al., 2012). Euclidean distances between
Ca atoms of crosslinked residues were visualized, measured in PyMOL and
analyzed with Mathematica 9 (Wolfram) and OriginPro 9.1 (OriginLab). The
BS3 or EDC crosslinks were mapped on the amino acid sequences with xiNET
(Combe et al., 2015).
Protein-RNA Crosslinking and Mass Spectrometric Analysis
Protein-RNA crosslinking was performed using UV irradiation at 254 nm fol-
lowed by the enrichment of crosslinked peptide–RNA heteroconjugates (see
Supplemental Information).
ACCESSION NUMBERS
The accession numbers for the structural models and structure factors
reported in this paper are PDB: 5IFE (SF3b155-SF3b130-SF3b14b-SF3b10)
and 5HY7 (ctSF3b130-SF3b10).
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 Supplemental Figures 
Figure S1. Electron density maps of the human SF3b core complex. Related to Figure 1.  
A. SDS-PAGE of the truncated human SF3b complex before and after (left and right, respectively) limited 
proteolysis with chymotrypsin.  
B. Initial electron density map of the SF3b core complex contoured at 1.2σ level. The final model is depicted as 
a Cα backbone trace and is superimposed on the map. 
 C. View of the experimental map of the SF3b core (contour level 1.2σ) with the HEAT domain of SF3b155 and 
SF3b14b superimposed (red and blue ribbons, respectively). 
 D. View of SF3b130 and SF3b10 (red and blue ribbons, respectively) superimposed on the initial electron 
density map (contour level 1.2σ).  
E.  Anomalous difference Fourier map of the SF3b core complex showing the location of three Zn atoms (orange 
mesh, contour level 5σ). The difference map was computed from data collected at the Zn K-edge. The final 
structure is superimposed on the map (blue, ribbon). 
F. SDS-PAGE analysis of Chaetomium thermophilum (ct) SF3b130-SF3b10 before and after digestion with 
thermolysin (left and right, respectively). 
Figure S2. Interactions and conservation of SF3b proteins. Related to Figure 2.  
 
A. Superposition of human SF3b130-SF3b10 and ctSF3b130-SF3b10 (r.m.s.d=2.42Å, 877 Cα for SF3b130; 
r.m.s.d=0.7Å, 50 Cα for SF3b10). 
 
B. Superposition of the two ctSF3b130-SF3b10 dimers from the asymmetric unit (r.m.s.d=0.47Å, 865 Cα for 
ctSF3b130; r.m.s.d=0.11Å, 48 Cα for ctSF3b10). Note that the BPB domain of ctSF3b130 is slightly tilted 
(~9.5
o
), suggesting relative mobility. 
 
C.  Superposition of human SF3b14b on Rds3p (PDB entry 2K0A, r.m.s.d=0.79Å, 74 Cα). 
 
D. Interactions between SF3b14b and SF3b155. The latter is depicted with surface coloured according to the 
sequence conservation. Conserved residues of SF3b14b that contact SF3b155 are coloured in green. 
 
E. Side-by-side comparison between SF3b14b-SF3b155 (left) and another HEAT-repeat protein importin13 in 
complex with RanGTP (PDB: 2X19, right). The surfaces of the HEAT repeats are coloured as a rainbow from 
the N- (blue) to the C-termini (red). SF3b14b and Ran are coloured magenta. 
 
F. Distinctive conformation of the HEAT domain of SF3b155. The HEAT repeats H1-H20 are coloured as a 
rainbow from the N- (blue) to the C-termini (red). SF3b14b is coloured magenta.  Note the unusual open cavity 
framed by SF3b14b and the HEAT domain of SF3b155 that accommodates p14/SF3b14a and the two pivoting 
points in the HEAT superhelix (arrows) at the two contact sites with SF3b14b. For simplicity, SF3b130 and 
SF3b10 are not shown. 
 
Figure S3. Chemical crosslinking of the human SF3b complex. Related to Figure 3. 
 
A. BS3 crosslinks between SF3b155
377-415
 and the HEAT domain of SF3b155 (left) or p14 (middle). 
Intermolecular crosslinks between p14 and the HEAT domain of SF3b155 are shown for comparison. BS3 
crosslinks are depicted as red lines. Proteins are coloured as in Figure 3.  
 
B. Intermolecular EDC crosslinks between SF3b155
377-415
 and p14 (left), p14 and the HEAT domain of SF3b155 
(middle), and between p14 and SF3b14b (right). EDC crosslinks are depicted as blue lines.  
  
C. Direct interaction between the SF3b core complex and p14 shown by GST pull-down assays. The purified 
SF3b core complex (SF3b155 (468-1304)-SF3b130-SF3b14b-SF3b10) was incubated with either GST-p14 or 
 GST. After extensive washing, the bound proteins were eluted from the beads and analysed by SDS-PAGE.  The 
input sample is shown for comparison. M – protein marker.  
 
D. GST-SF3b14b can pull-down both SF3b155 and p14 under high salt conditions. The pentameric SF3b155-
SF3b130-GST-SF3b14b-p14-SF3b10 was purified on a glutathione resin and eluted by competition. Several 
elution fractions are shown. Under these conditions, full-length SF3b155 and p14 elute with the other subunits as 
part of a stoichiometric complex.   
 
Figure S4. Chemical crosslinking pattern of the N-terminal domain of SF3b155. Related to Figure 3. 
 
A. SF3b155 residues crosslinked with BS3 to SF3b155
1-376
. The BS3 crosslinking patterns of SF3b155
K333
 and 
SF3b155
K240
 are shown below. BS3 crosslinked lysines are depicted as red spheres (FDR=1%, Scoremax≥2, 
Spectral count≥3, Table S2). The HEAT repeats of SF3b155 are labelled H1-H20. SF3b core subunits are 
colour-coded as in Figure 1. Note that individual lysine residues of the NTD crosslink to multiple lysines of 
SF3b155 HD, resulting in similar overall patterns. This crosslinking pattern indicates that the unstructured NTD 
assumes an ensemble of numerous conformations in solution. 
 
 B. SF3b155 residues crosslinked with EDC to SF3b155
1-376
. The EDC crosslinking patterns for SF3b155
K333
 and 
SF3b155
D69
 are shown below. EDC crosslinked residues are depicted as blue spheres (FDR=1%, Scoremax≥2, 
Spectral count≥3, Table S2). 
   
Figure S5. MS/MS fragmentation spectra of the photo-crosslinked peptides identified in the SF3b core 
complex. Related to Figure 4.  
In each spectrum, the crosslinked peptide sequence and its corresponding y- and b- type fragment ions are 
indicated at the top, referring to the ions which retain the charge on the N- or C- terminus, respectively. The 
cross-linked amino-acid residues are highlighted in yellow. Some of the b- and y- ions were observed with a 
mass shift of #, #
1
, #
2
, #
3
, #
4
 and #
5
 corresponding to -C3O (a fragment of Uracil), U’-H2O, U’, U-H3PO4, U-H2O 
and U respectively. IM: Immonium ions; U’: Base of U, 112.0273 Da. 
 
Figure S6. Crosslinks of U2AF65 with the SF3b core complex and p14. Related to Figure 5. 
A. Crosslinks of the RRM1 domain of U2AF65 (149-231) with the SF3b core complex and p14. BS3 crosslinked 
residues are shown as spheres and coloured green (FDR=1%, Scoremax≥2, Spectral count≥3, Table S2). 
 
 B. Crosslinks of the RRM2 domain of U2AF65 (259-337) with the SF3b core complex and p14. BS3 
crosslinked residues are shown as spheres and coloured deep green (FDR=1%, Scoremax≥2, Spectral count≥3, 
Table S2). 
      
Figure S7. Biochemical and structural analysis of the K700E mutant of SF3b. Related to Figure 6. 
A. Reconstitution of the human SF3b complex carrying the K700E mutation. SDS-PAGE analysis (left) of the 
K700E mutant of SF3b after size exclusion chromatography (right). The size exclusion profile of the wild-type 
complex is shown for comparison (dashed blue line).  
 
B. Electrophoretic mobility shift assay of BS-PPT (left) or BS (right) RNA oligomers with increasing 
concentrations of SF3b or the K700E mutant of SF3b. The BS-PPT ssRNA oligomer contains both the BS and 
the Py tract regions of the intron, while the BS oligomer includes only the BS sequence. Both SF3b and SF3b 
K700E form stable RNP complexes with BS-PPT, but not with the BS RNA oligo. 
 
C. Distribution of the C-C distances between crosslinked residues in the SF3b or SF3b K700E complexes. 
Euclidean distances were computed between the C atoms of BS3 crosslinked residues using the atomic 
coordinates of the SF3b core complex (Table S2). Chemical crosslinking data at FDR=1% were not further 
filtered. 
 
D. K700E mutation does not induce re-localization of p14. Intermolecular crosslinks between p14 and the HEAT 
domain of SF3b155 and between p14 and SF3b14b are depicted as red lines (FDR=1%, Scoremax≥2, Spectral 
count≥3, Table S2). Crosslinked residues are shown as spheres. K700 is coloured orange.  
 
 E. Distribution of the C-C distances between crosslinked residues in the wild-type SF3b-U2AF65 or SF3b 
K700E-U2AF65 complexes. Euclidean distances were computed between the C atoms of BS3 crosslinked 
residues. Chemical crosslinking data at FDR=1% was filtered (Scoremax ≥2, Spectral count≥3, Table S2). 
 
F. K700E mutation does not affect the stability of the SF3b-U2AF65 complex. Purified SF3b or SF3b K700E 
mutant were incubated with MBP-tagged U2AF65 and amylose beads. The bound proteins were eluted by 
competition with maltose and analysed by SDS-PAGE. The input samples are shown for comparison. M – 
protein marker.  
 
   
 
  
 Supplemental Tables 
 
Table S1. X-ray data collection and refinement statistics. Related to Experimental Procedures.    
  
 
ctSF3b130-SF3b10 Native Ta6Br12-derivatized 
Data collection  
Space group P 61 2 2 P 61 2 2 
Cell dimensions  
a, b, c (Å) 197.1,197.1,446.4 198.5, 198.5, 447.9 
α, β, γ ()  90.0, 90.0, 120.0 90.0, 90.0, 120.0 
Wavelength 1.0 1.254 
Resolution (Å) 49.27–2.90  
(3.00 – 2.90)* 
49.02–3.48  
(3.60 – 3.48)  
Rmerge (%) 16 (>100)  21 (>100)# 
I/σI 19.41 (0.89) 22.02 (2.45) 
CC1/2 0.99 (0.36) 1.00 (0.77) 
Completeness (%) 100 (100) 100 (97) 
Redundancy 20.1 (20.0) 39.0 (37.6)# 
   
Refinement  
Resolution (Å) 2.90  
No. reflections 113502  
Rwork/ Rfree 0.22/ 0.25  
No. atoms  
  Protein 19201  
  Ligand/ion 9  
B-factors  
  Protein 91.63  
  Ligand/ion 147.99  
R.m.s deviations  
  Bond lengths (Å)  0.006  
  Bond angles (º) 0.73  
Ramachandran Plot   
  Favored (%) 94%  
  Outliers (%) 0.2%  
*Highest resolution shell is shown in parenthesis; 
 #Friedel mates treated separately 
 
 Table S2 (separate file). Descriptive statistics for the crosslinking data of the human SF3b and SF3b-
U2AF65 complexes. Related to Figure 3 and Figure 5.  
 
Residue 1 and Residue 2 columns refer to the absolute position of the crosslinked residues in Protein 1 and 
Protein 2, respectively. Euclidean distances were computed between the Cα atoms of the crosslinked residues 
present in the crystal structure of the SF3b core complex. "Inter" and "Intra" denote intermolecular and 
intramolecular crosslinks, respectively. Higher score indicates a higher confidence of crosslink identification. 
 
Supplemental Data S1 (separate file). Multiple sequence alignments for the SF3b core subunits. Related to 
Figure 2. 
 
SF3b130 (A), SF3b10 (B), SF3b14b (C), and SF3b155 (D) regions present in the crystal structure of the human 
SF3b core are marked with a coloured line. Secondary structure elements, as present in the crystal structure of 
the human SF3b core complex, are depicted above the sequences. Triangles indicate residues of the HEAT 
domain of SF3b155 mutated in human cancers or pladienolide-resistant cells. H1-H20 - HEAT repeats 1-20 of 
SF3b155; BPA, BPB, BPC - β-propeller domains  of SF3b130; CTD - carboxy-terminal domain of SF3b130; Hs 
- Homo sapiens; Xl - Xenopus laevis; Xt - Xenopus tropicalis; Tr - Takifugu rubripes; Dm - Drosophila 
melanogaster; At - Arabidopsis thaliana; Nc - Neurospora crassa; Sp - Schizosaccharomyces pombe; Sc - 
Saccharomyces cerevisiae; Ct - Chaetomium thermophilum;  Ce - Caenorhabditis elegans 
 
 
  
 Supplemental Experimental Procedures 
 
Expression and purification of the human SF3b complex 
The human SF3b complex was produced by co-expression in High Five or SF-9 cell lines using optimized 
synthetic genes (GeneArt, Life Technologies). To enable the purification of the complex, SF3b130 was cloned in 
frame with a cleavable N-terminal poly-His10 tag and with a C-terminal FLAG tag. SF3b14b was fused to a 
cleavable GST tag, whereas SF3b145 was cloned in frame with a C-terminal Strep-II tag. The cells 
overexpressing SF3b were harvested 72-84h after infection and resuspended in ice-cold buffer A1 (50 mM 
HEPES-KOH, pH 7.9, 600 mM KCl, 15% (v/v) glycerol, 5 mM 2-mercaptoethanol (2-ME), 25 mM imidazole) 
supplemented with a cocktail of protease inhibitors (Roche) and disrupted by sonication. The cleared lysate was 
loaded on a HisTrap HP 5 mL column (GE Healthcare) equilibrated with buffer A2 (50 mM HEPES-KOH, pH 
7.9, 600 mM KCl, 10% (v/v) glycerol, 5 mM 2-ME, 25 mM imidazole). Proteins were eluted by a gradient 
formed between buffer A2 and buffer B (50 mM HEPES-KOH, pH 7.9, 600 mM KCl, 10% (v/v) glycerol, 5 mM 
2-ME, 500 mM imidazole). Fractions containing SF3b were re-buffered in buffer C (50 mM HEPES-KOH, pH 
7.9, 500 mM KCl, 10% (v/v) glycerol, 2  mM DTT (dithiothreitol)) using a HiPrep 26/10 column (GE 
Healthcare). Afterwards, the His-tag was removed by overnight cleavage with TEV protease (1:100 (w:w), 4-8° 
C). Next, the sample was loaded on Glutathione Agarose 4B (Macherey-Nagel) equilibrated in buffer C. The 
recombinant complex was eluted with buffer D (50 mM HEPES-KOH, pH 7.9, 500 mM KCl, 10% (v/v) 
glycerol, 2 mM DTT, 30 mM L-glutathione reduced) and the GST affinity tag removed by overnight cleavage 
[1:100 (w:w), 4-8°C] with PreScission Protease. Next, the sample was re-buffered in buffer E (20 mM HEPES-
KOH, pH 7.9, 200 mM KCl, 10% (v/v) glycerol, 2 mM DTT) using a HiPrep 26/10 column (GE Healthcare) and 
further purified on MonoQ (GE Healthcare). The complex was eluted from the anion-exchanger using a linear 
gradient formed between buffer E and buffer F (20 mM HEPES-KOH, pH 7.9, 1 M KCl, 10% (v/v) glycerol, 2 
mM DTT). Fractions containing the SF3b complex were concentrated by ultrafiltration using Amicon Ultra-15 
(Millipore) and further applied to a sizing column (Superose 6 10/300 GL, GE Healthcare) equilibrated with 
buffer G (20 mM HEPES-KOH, pH 7.9, 200 mM KCl, 5% (v/v) glycerol, 2 mM DTT). Peak fractions were 
pooled, concentrated by ultrafiltration to ~1.5-2mg/mL (when used in splicing assays) or ~4-6 mg/mL (for 
crystallization trials) and snap frozen in liquid nitrogen. The identities of the purified proteins were confirmed by 
mass spectrometry and Western blot analyses (data not shown). The K700E mutation was introduced with the 
QuickChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies) and verified by DNA sequencing and 
mass spectrometry. The human SF3b complex harbouring the K700E mutation was overexpressed in High Five 
insect cell line and purified using the same procedure established for the wild-type complex. Analytical gel 
filtration analyses were performed on a Superose 6 PC 3.2/30 sizing column (GE Healthcare) equilibrated with 
buffer G.  
 
Crystallization and structure determination of the human SF3b core complex 
The full-length SF3b complex did not form crystals. Guided by proteolysis experiments and bioinformatics, we 
removed regions predicted to be disordered from SF3b145 (439-706) and SF3b49 (1-203). This truncated 
complex was overexpressed and purified using the same procedure established for the full-length complex. As 
the truncated complex still did not crystallize, we treated it with chymotrypsin (1:250 (w:w), on ice for 4h), 
stopped the reaction with a cocktail of protease inhibitors (Roche) and further purified the protease-resistant core 
complex by size-exclusion chromatography on Superdex 200 10/300 GL (GE Healthcare) equilibrated with 
buffer G (20 mM HEPES-KOH, pH 7.9, 200 mM KCl, 5% (v/v) glycerol, 2 mM DTT). Peak fractions were 
concentrated by ultrafiltration using Amicon Ultra-15 (Millipore) to ~6.5mg/mL and subjected to crystallization 
screening. The crystals of the SF3b core complex were harvested after 10 days at 20
0
C and transferred 
sequentially to the reservoir solution containing 42% (v/v) pentaerythritol propoxylate 5/4 before flash cooling in 
liquid nitrogen. For experimental phasing, native crystals were transferred to reservoir solution containing 2 mM 
Ta6Br12 (Jena Bioscience). After incubation for 90 min at 20
o
C the derivatized crystals were back-soaked in 
reservoir solution, and then transferred to a reservoir solution containing 42% (v/v) pentaerythritol propoxylate 
5/4 and snap frozen in liquid nitrogen. 
 
Expression and purification of the Chaetomium thermophilum SF3b130-SF3b10 complex 
Optimized synthetic genes (GeneArt, Life Technologies) coding for the proteins SF3b130 and SF3b10 from 
Chaetomium thermophilum (ct) were cloned  in frame with a cleavable N-terminal poly-His10 tag and a cleavable 
N-terminal GST tag, respectively and expressed in High Five insect cells. The cells were resuspended in lysis 
buffer A1 (50 mM Tris-HCl, pH 7.7, 400 mM NaCl, 5 mM imidazole, 2 mM 2-ME, 15% (v/v) glycerol), 
supplemented with an EDTA-free cocktail of protease inhibitors (Roche), and disrupted by sonication and loaded 
onto a Ni-NTA column. After elution with lysis buffer supplemented with 300 mM imidazole (buffer B1), the 
eluate was loaded onto GSH-sepharose 4B column (GE Healthcare). The proteins were eluted with buffer B2 (50 
mM Tris-HCl, pH 7.7, 200 mM NaCl, 2 mM DTT, 15% (v/v) glycerol, 30 mM L-glutathione reduced). The 
His10 and GST tags were cleaved by TEV and PreScission proteases, respectively and removed by applying the 
 sample to a Q Sepharose HP column (50 ml) equilibrated in buffer A2 (50 mM Tris-HCl, pH 7.7, 150 mM NaCl, 
2 mM DTT, 5% glycerol). The complex was eluted using a linear gradient between A2 and B3 buffer (50 mM 
Tris-HCl, pH 7.7, 1 M NaCl, 2 mM DTT, 5% (v/v) glycerol). The protein complex was preparatively 
proteolysed with thermolysin (1:225 (w:w) for 22 hours at 4°C) and the reaction was stopped with EDTA. The 
protease stable complex was further purified by size exclusion chromatography on Superdex 200 16/600 (GE 
Healthcare) equilibrated with buffer A3 (20 mM HEPES-NaOH, pH 7.5, 150 mM NaCl, 2 mM DTT, 5% (v/v) 
glycerol). The fractions containing monomeric complexes were pooled, concentrated to ~4.5 mg/ml, flash frozen 
and stored at -80°C. 
 
Crystallization and structure determination of the ctSF3b130-ctSF3b10 complex 
The crystals of the full-length complex diffracted poorly X-rays. Crystals of the proteolysed complex were 
grown at 4°C in sitting drops by mixing 0.2 µl of protein with 0.2 µl of reservoir solution (0.1M HEPES-NaOH, 
pH 7.5, 0.1 M NaCl, 0.1 M CaCl2, 8% (v/v) PEG 4000). Diffraction data were collected at the X10SA beamline 
(SLS, Villigen, Switzerland) and processed with XDS (Kabsch, 2010). The structure of the complex was solved 
by single anomalous dispersion (SAD) using a crystal derivatized with Ta6Br12. Determination of the heavy atom 
substructure was performed with SHELXD (Sheldrick, 2010). Initial SAD phase calculation was carried out with 
SHELXE and initial models were built with Buccaneer (Cowtan, 2006) and with the Autobuild module in 
Phenix. The model was further improved by iterative manual rebuilding in COOT (Emsley and Cowtan, 2004) 
and refinement with Phenix.refine (Afonine et al., 2012). The final model was refined against a native dataset to 
an Rfree of 25% (Table S1). Two nearly identical molecules are present in the asymmetric unit, and the model 
comprises ctSF3b130 residues 7-1213 and ctSF3b10 residues 27-81. 
 
RNA binding assays 
RNA binding of the wild-type SF3b complex and of SF3b
K700E
 was assayed by electrophoretic mobility shift 
assays. Single-stranded 3’-Cy3 labelled RNA oligomers corresponding to the BS (CGAUACUAACACCG) or 
BS-PPT (GGGUGCUGACUGGCUUCUUCUCUCUUUUUCCCUC) regions of the intron were obtained from 
Sigma. A typical reaction (10µL) contained 50nM labelled probe and 50-2000nM protein in Binding buffer (20 
mM HEPES-KOH, pH 7.9, 150 mM KCl, 2mM DTT, 1.5 mM MgCl2, 5% (v/v) glycerol). Reactions were 
incubated for 1h on ice and then loaded onto a 3-8% polyacrylamide nondenaturing gel (NuPAGE, Thermo 
Fisher Scientific). Gels were run in 1x Tris-glycine buffer for 3h at 4
o
C and visualized with a Typhoon Trio+ 
imager (GE Healthcare).  
 
In vitro binding assays 
GST-tagged SF3b14a/p14 was overexpressed in E. coli and purified as previously described (Spadaccini et 
al., 2006) with minor modifications: the fusion protein was concentrated to ~5mg/ml and stored in buffer A (20 
mM HEPES-KOH, pH 7.9, 100 mM KCl, 2mM DTT and 5% (v/v) glycerol). SF3b155 (468-1304)-SF3b130-
SF3b14b-SF3b10 complex was expressed in High Five insect cell line and purified using the procedure 
established for the full-length assembly. The purified core complex was incubated with GST-p14 or GST and 
glutathione-agarose resin (Macherey-Nagel) for 1h at 4
o
C in buffer A. Bound proteins were eluted by 
competition with 20mM L-glutathione in binding buffer and analysed by SDS-PAGE and mass spectrometry. 
The SF3b155-SF3b130-GST-SF3b14b-p14-SF3b10 complex was expressed in High Five insect cells and 
purified first on HisTrap HP (GE Healthcare) and then on GSH-agarose (Macherey-Nagel), as described for the 
7-subunit SF3b complex. The pentameric complex was eluted from GSH-agarose under high salt conditions  
with buffer D (50 mM HEPES-KOH, pH 7.9, 500 mM KCl, 10% (v/v) glycerol, 2 mM DTT, 30 mM L-
glutathione reduced) and analysed by SDS-PAGE and mass spectrometry.  
U2AF65 isoform 2 was overexpressed in BL21(DE3)pLysS E. coli cells as a His14-MBP-fusion protein. The 
cells were resuspended in lysis buffer (50mM HEPES-K, pH 7.9, 600mM KCl, 15% (v/v) Glycerol, 5mM 2-
ME), supplemented with an EDTA-free cocktail of protease inhibitors (Roche) and disrupted by sonication. The 
cleared lysate was incubated with 3mL amylose resin (NEB) for 2h at 4-8
o
C and the bound proteins were eluted 
with elution buffer (20mM HEPES-KOH, pH 7.9, 200mM KCl, 10% (v/v) glycerol, 2mM DTT, 50mM 
maltose). MBP-tagged U2AF65 was further purified on Q Sepharose HP (GE Healthcare) and by size exclusion 
chromatography on Superdex 200 Increase 10/300 (GE Healthcare) equilibrated in buffer G (20 mM HEPES-
KOH, pH 7.9, 200 mM KCl, 5% (v/v) glycerol, 2 mM DTT). For the reconstitution of the SF3b-U2AF65 
complex, the His14-MBP tag was removed by cleavage with TEV protease. Peak fractions were pooled and 
concentrated by ultrafiltration to ~5.5 mg/mL. Purified MBP-U2AF65 was incubated with the wild-type SF3b or 
SF3b
K700E 
in buffer G containing 150mM KCl for 1h on ice in 50µL. The samples were then incubated with 
25µL amylose resin (NEB) in 200µL for 1h at 4-8
o
C. The bound proteins were eluted with 50µL elution buffer 
containing 150mM KCl and analysed by SDS-PAGE. The identities of the bound proteins were verified by mass 
spectrometry (data not shown).       
 
 
 
 Chemical crosslinking of SF3b-U2AF65 and crosslink identification by mass spectrometry 
The SF3b-U2AF65 (or SF3b
K700E
-U2AF65) complex was assembled in vitro by mixing SF3b (or SF3b
K700E
) and 
U2AF65 in a 1:2 molar ratio, and further purified on Superose 6 10/300 (GE Healthcare) equilibrated in buffer G 
(20 mM HEPES-KOH, pH 7.9, 200 mM KCl, 5% (v/v) glycerol, 2 mM DTT). The purified SF3b
K700E
, SF3b-
U2AF65 and SF3b
K700E
-U2AF65 complexes were crosslinked with 150µM BS3 and purified by size-exclusion 
chromatography using Superose 6 10/300 (GE Healthcare). The samples were processed and analyzed in 
duplicates on Q Exactive HF (Thermo Fisher Scientific), essentially as described above. For simplicity, the 
crosslink Score is represented as a negative value of the common logarithm of the original pLink Score, that is 
Score=–log10 (“pLink Score”). 
 
Protein-RNA crosslinking and mass spectrometric analysis 
Protein-RNA crosslinking was performed essentially as described in (Kramer et al., 2014; Sharma et al., 2015). 
The SF3b core (SF3b155 (468-1304)-SF3b130-SF3b14b-SF3b10)- polyU25 RNP complex was assembled in 
vitro and then UV irradiated at 254 nm for 10 minutes as described in (Sharma et al., 2015). The samples were 
ethanol precipitated and the pellet was dissolved in 4 M Urea and 50 mM Tris-HCl, pH 7.9. The final 
concentration of urea was then adjusted to 1 M with 50 mM Tris-HCl, pH 7.9 and the RNA was hydrolysed 
using 1 µg RNase A (Ambion, Applied Biosystems) for 2 hours at 52 °C. The proteolysis was carried out with 
trypsin (Promega) at 37 °C, overnight. The sample was desalted to remove non cross-linked RNA fragments 
using an in-house prepared C18 (Dr. Maisch GmbH) column and the cross-linked peptides were enriched on an 
in-house prepared TiO2 (GL Sciences) column using the protocol described in (Sharma et al., 2015). Following 
the enrichment of peptide-RNA cross-linked heteroconjugates, the samples were dried and resuspended in 5% 
v/v ACN, 1% v/v FA for mass spectrometry analysis. The sample was injected onto a nano-liquid 
chromatography system (Dionex, Ultimate 3000, Thermo Fisher Scientific) coupled with Q Exactive HF 
instrument (Thermo Fisher Scientific) (Sharma et al., 2015). Online ESI-MS was performed in data-dependent 
mode using a TOP20 HCD method. All precursor ions as well as fragment ions were scanned in the Orbitrap, the 
resulting spectra were measured with high accuracy (< 5 ppm) both in the MS and MS/MS level. Data analysis 
was done using a dedicated data base search tool as described in (Kramer et al., 2014) and by implementing the 
freely available  plugin for RNP
xl 
in the recently released version 2.1 of Proteome Discoverer
TM
 (manuscript in 
preparation). 
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SUMMARY
SF3B is a multi-protein complex essential for branch
site (BS) recognition and selection during pre-mRNA
splicing. Several splicing modulators with antitumor
activity bind SF3B and thereby modulate splicing.
Here we report the crystal structure of a human
SF3B core in complex with pladienolide B (PB), a
macrocyclic splicing modulator and potent inhibitor
of tumor cell proliferation. PB stalls SF3B in an
open conformation by acting like a wedge within a
hinge, modulating SF3B’s transition to the closed
conformation needed to form the BS adenosine-
binding pocket and stably accommodate the BS/U2
duplex. This work explains the structural basis for
the splicing modulation activity of PB and related
compounds, and reveals key interactions between
SF3B and a common pharmacophore, providing a
framework for future structure-based drug design.
INTRODUCTION
Pre-mRNA splicing is an essential step of gene expression
required for the removal of non-coding introns and ligation of cod-
ing exons that generate a mature mRNA. Splicing of each pair of
exons occurs in two consecutive chemical reactions, both of
which involve reactive groups from three locations of the intron:
an adenosine from the so-called branch site (BS) and nucleotides
from the 50 and 30 splice sites (SS, corresponding to the exon/
intron junctions at the two ends of an intron). The entire process
occurs within the spliceosome, a multi-megadalton protein-RNA
complex that assembles by the stepwise recruitment of five ribo-
nucleoprotein particles (snRNPs), named U1, U2, and U4/U6.U5,
plusnumerousnon-snRNPproteins, to thepre-mRNA (Wahl et al.,
2009).During its cyclic assembly, activation, andsplicing catalysis
pathway,which is drivenbyATP, the spliceosomepasses through
several landmark stages, referred to as the E, A, B, Bact, B*, C, C*,
P, and intron-lariat spliceosomal complexes (Fica and Nagai,
2017; Shi, 2017; Wahl et al., 2009).
U2 snRNP plays an important role in the recognition of the BS
during constitutive and alternative splicing (Lee and Rio, 2015;
Will and L€uhrmann, 2011). It is composed of U2 snRNA, the mul-
timeric splicing factors SF3A and SF3B, and several other asso-
ciated proteins (Will et al., 2002). In higher eukaryotes, SF3B is
a hetero-heptameric complex containing SF3B1/SF3B155,
SF3B2/SF3B145, SF3B3/SF3B130, SF3B4/SF3B49, SF3B5/
SF3B10, SF3B6/SF3B14a, and PHF5A/SF3B14b (Will et al.,
2002). In the pre-spliceosomal A complex, U2 snRNA interacts
via base pairing with the BS (Wu and Manley, 1989; Zhuang
and Weiner, 1989). At the same time, the U2/BS interaction is
stabilized by subunits of the SF3B complex that interact with
the intron, including the SF3B1 protein that contacts intron
nucleotides flanking the BS adenosine (BS-A) (Gozani et al.,
1996, 1998).
Several compounds with antitumor properties, such as pladie-
nolide B (PB) (Kotake et al., 2007), herboxidiene (GEX1A) (Hase-
gawa et al., 2011), and spliceostatin A (SSA) (Kaida et al., 2007),
bind the SF3B complex and inhibit normal pre-mRNA BS usage,
inducing changes in alternative splicing patterns (Corrionero
et al., 2011; Folco et al., 2011; Teng et al., 2017). Thus, SF3B is
a promising target for anti-cancer therapy (Bonnal et al., 2012;
Salton and Misteli, 2016). The aforementioned compounds,
which are splicing inhibitors/modulators, are derived from bacte-
rial sources (Pseudomonas sp and Streptomyces sp) and have
served as templates for the synthesis of various analogs, some
of which have been used in clinical trials (Bonnal et al., 2012;
Lagisetti et al., 2013; Webb et al., 2013). Although their chemistry
is rather diverse, all modulators from these families contain a cen-
tral pharmacophore represented by a conjugated diene, flanked
by two variable moieties (Bonnal et al., 2012; Effenberger et al.,
2017; Lagisetti et al., 2014). However, the significance of this
common organization is presently not clear.
Splicing modulators that bind SF3B (Hasegawa et al., 2011;
Kaida et al., 2007; Kotake et al., 2007) arrest spliceosome as-
sembly prior to the ATP-dependent formation of a stable A
complex, leading to an ‘‘A-like’’ complex where U2 snRNP is
less stably bound and the base pairing interactions between
U2 and the intron are altered (Corrionero et al., 2011; Effenberger
et al., 2014; Roybal and Jurica, 2010). By modulating BS recog-
nition and selection in cells, these compounds lead to intron
retention and exon skipping (Corrionero et al., 2011; Teng
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et al., 2017; Vigevani et al., 2017). The resulting changes in a sub-
set of alternative splicing patterns provide an explanation for the
pronounced/preferential cytotoxic activity of these compounds
toward malignant versus normal cells (Lee et al., 2016; Obeng
et al., 2016; Shirai et al., 2017). Cryoelectron microscopy (cryo-
EM) structures of spliceosomes that are formed after the A com-
plex, including the spliceosomal B and Bact complexes (Bertram
et al., 2017; Plaschka et al., 2017; Rauhut et al., 2016), revealed a
‘‘closed’’ conformation of SF3B relative to its more ‘‘open’’
conformation in the isolated SF3B complex (Cretu et al., 2016).
In the ‘‘closed’’ conformation, the terminal HEAT repeats of
SF3B1 embrace the BS/U2 helix, while the reactive BS-A is
shielded from the 50 splice site in a conserved SF3B1-PHF5A
pocket (Plaschka et al., 2017; Rauhut et al., 2016; Yan et al.,
2016). Recent biochemical and chemogenomic analyses sug-
gest that PB, SSA, and herboxidiene share a common binding
site on SF3B, in the proximity of the BS-A-binding pocket (Effen-
berger et al., 2016; Teng et al., 2017). However, the precise na-
ture of the binding site of these splicing modulators and the
mechanistic consequences of their binding remain unclear.
Here we have determined the crystal structure of SF3B in
complex with PB, providing a paradigm for key principles that
govern molecular recognition of SF3B modulators. Together
with biochemical analyses, our work reveals the mechanism
whereby these compounds affect the function of SF3B and
thus modulate pre-mRNA splicing.
RESULTS AND DISCUSSION
Pladienolide B Is Accommodated within an Hourglass-
Shaped Tunnel that Matches the Tripartite Organization
of Various SF3B Modulators
We have engineered a human SF3B core complex, comprising
the HEAT domain of SF3B1/SF3B155, SF3B3/SF3B130,
SF3B5/SF3B10, and PHF5A/SF3B14b, that binds a tritiated PB
Figure 1. Overall Structure of the Human
SF3B Core in Complex with PB
(A) Side view of the SF3B-PB complex. SF3B
subunits are shown in different colors. The PB
ligand is shown as spheres and the carbon atoms
are depicted in orange.
(B) Structure of PB in the SF3B1-PHF5A pocket.
PB is shown as orange sticks. The 2mFo-DFc map
(brownmesh) is contoured at 1.0s and is displayed
around PB. The SF3B1 (light blue) and PHF5A
(pink) subunits are shown as a surface represen-
tation.
(C) Domain composition of the SF3B core. SF3B
regions forming the SF3B1-PHF5A tunnel are
colored cyan and boxed in orange.
Related to Figure S1.
derivative ([3H]-PB) in solution (Figures 1,
S1A, and S1B). The complex forms crys-
tals in the presence of PB under similar
crystallization conditions as used for the
previously reported apo form of the
SF3B core (Cretu et al., 2016). The struc-
ture of the SF3B core complexed with PB was determined at
3.1 A˚ by molecular replacement using the apo form as a search
model (Figures 1 and S1C–S1E; Table 1), and validated using se-
lenium marker sites (Table 1; Figures S1F and S1G). One mole-
cule is present in the asymmetric unit and, except for a few local
changes (Figures S2A and S2B), the SF3B core complex binds
PB without significant rearrangement (Figures S2C–S2F). In the
crystal structure, PB is accommodated within an 15 A˚-long
hourglass-shaped tunnel defined by seven residues from the
HEAT repeats H15-H17 of SF3B1, and two residues from the
trefoil-folded protein PHF5A (Figures 2A and 2B). Each ‘‘funnel’’
of the hourglass accommodates one of the two large moieties of
PB—the macrolide head (12-membered macrocyclic group) and
the aliphatic chain—while the conjugated diene that connects
the twomoieties is located in the constricted neck region. Impor-
tantly, the size of the tunnel suffices to accommodate all types of
known SF3B modulators, and its distinctive shape can explain
the common organization of the compounds in two moieties
separated by a diene (Figure S3A).
The Common Pharmacophore Represented by the
Conjugated Diene Is Essential for Molecular
Recognition
The diene group is a key pharmacophore feature of the pladieno-
lide, spliceostatin, and herboxidiene families of splicing modula-
tors (Lagisetti et al., 2008, 2014) (Figure S3A). Alteration of this
group (C12-C15)or changes in its immediate vicinity lead tosignif-
icant decreases in activity (Bonnal et al., 2012; Effenberger et al.,
2014; Lagisetti et al., 2014). Within the neck of the SF3B1-PHF5A
tunnel, the five coplanar carbon atoms of the conjugated diene
(C12-C15) are within interacting distances from PHF5A-Y36 and
SF3B1-R1074 (Figures 2B and 2C). The diene plane is nearly
perpendicular to the aromatic ring of PHF5A-Y36, indicative of
p-p interactions established between these two moieties. The
required molecular geometry appears to be favored by the steric
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constrains exertedbyR1074,which flanks the diene plane on one
side (Figure 2C). This distinctive ternary arrangement, where two
moieties interact in a directional manner, while a third one assists
inproviding the requiredgeometry,might explainwhysubstitution
ofY36 (PHF5A)has largely thesame impact onPBbindingas sub-
stitution of R1074 (SF3B1), as we show by scintillation proximity
assays with [3H]-PB (Figures 3A and S3B). Consistent with this,
we also observed in viability assays that the HCT116 cancer cell
lines carrying mutations in any of these residues (PHF5A-Y36C
andSF3B1-R1074H) are resistant to treatmentwithPB (Figure3B)
and other SF3Bmodulators (Teng et al., 2017). Overall, the struc-
ture shows that the invariant conjugated diene acts as a chemical
rigid spacer that constrains the larger PB moieties to the hour-
glass-shaped tunnel, and is also an important element for molec-
ular recognition by SF3B (Figure 2D), due to its specific interac-
tions in the distinctive microenvironment of the neck region.
The Macrolide Ring and Aliphatic Arm Are Recognized
by Shape Complementarity and a Network of
Hydrophobic and Weak Polar Contacts
The 12-atom macrolide ring is largely complementary to the
shape of the funnel that faces the SF3B3 subunit, where five res-
idues provide an even distribution of contacts along its circum-
ference (Figures 2A and 2D). Thus, several contacts are estab-
lished with hydrophobic regions of SF3B1 residues F1153,
K1071, and V1078, which is consistent with the detrimental ef-
fects of chemical modifications of the C3 and C6 groups, with
which they interact, on the activity of PB (Effenberger et al.,
2014, 2017). The C7 oxycarbonyl group of the macrolide head,
regarded as an important constituent of PB’s pharmacophore
(Lagisetti et al., 2008), is simultaneously engaged in a hydrogen
bond with the backbone amide of PHF5A-R38, and a non-polar
interaction with SF3B1-Y1157 (Figures 2A and 2D). Epimeriza-
tion of the C7 group leads to a strong reduction in PB activity
(M€uller et al., 2011), and removal of the C7 oxycarbonyl group,
which yields PB-OH, results in a loss of SF3B affinity and po-
tency in cells (Figures 3B–3D). Of note is that the relatively large
size of the macrolide head and the presence of the narrow neck
are indicative of the likely directionality of how PB accesses the
tunnel.
The aliphatic arm of PB (C16-C23) is oriented at an70 angle
relative to the diene plane, similar to the structure of its analog
herboxidiene (GEX1A) in isolation (Edmunds et al., 2000) (Figures
4A and 4B). Although this conformation is favorable for matching
the shape of the tunnel, an additional 40 rotation about the
C16-C17 bond is induced in PB by the contacts with the
SF3B1 residues V1110, V1114, and F1153, and PHF5A-Y36 (Fig-
ures 2A, 4C, and 4D). The latter two residues simultaneously
contact both the aliphatic arm and the other PB moieties, likely
leading to additional restrictions in the conformational freedom,
which enhances stable binding of the compound to SF3B. These
‘‘bridging’’ interactions can explain why chemical modifications
at distant positions of PB reduce its activity only when they occur
simultaneously (Effenberger et al., 2014, 2017). Thus, removal of
the methyl groups from C16 and C20 or modification of the
epoxy group (C18-C19) and of the C11-C12 bond decreases
PB activity substantially (Effenberger et al., 2014, 2017).
PBBlocks aConformational Change in SF3B, Preventing
Formation of the BS-A Pocket and Accommodation of
the BS/U2 Duplex
In the crystal structure of isolated complexes, SF3B has been
observed in an ‘‘open’’ conformation, whose functional impor-
tance was unclear as it could not be clearly assigned to a precise
step of the splicing cycle (Cretu et al., 2016). In the ‘‘open’’
conformation, the distance between the terminal HEAT repeats
is too large to stably accommodate the U2/BS helix (Cretu
et al., 2016). In contrast, SF3B1 adopts a ‘‘closed’’ conformation
in fully assembled spliceosomes, where it ‘‘clamps down’’ on the
U2/BS helix and likely stabilizes the U2/BS interaction (Bertram
et al., 2017; Plaschka et al., 2017; Yan et al., 2016). The ‘‘closed’’
SF3B1 conformation is likely to arise within A complexes where
U2 snRNA pairs with the BS and SF3B1 contacts nucleotides
flanking the BS-A (Gozani et al., 1996, 1998). Importantly, in
the presence of PB, SF3B1 exhibits the ‘‘open’’ conformation
that is likely to be also present in the ‘‘A-like’’ complexes stalled
by SF3B modulators (Corrionero et al., 2011; Folco et al., 2011;
Roybal and Jurica, 2010). Structural comparison between the
‘‘open’’ and ‘‘closed’’ conformations of SF3B1 (Rauhut et al.,
2016; Yan et al., 2016) revealed that the two structures differ sub-
stantially with respect to the position of HEAT repeats H1-H15
Table 1. Data Collection and Refinement Statistics
SF3Bcore-PB
(PDB: 6EN4) SF3Bcore SeMet
Data Collection
Space group P212121 P212121
Wavelength (A˚) 1.0 0.979
Cell dimensions: a, b, c (A˚) 106.07, 154.57,
210.21
105.59, 153.82,
209.30
Cell dimensions: a, b, g (o) 90.0, 90.0, 90.0 90.0, 90.0, 90.0
Resolution (A˚) 48.79-3.08
(3.16-3.08)a
49.80-3.25
(3.34-3.25)a
Rmeas (%) 15.7 (>100) 28.1 (>100)
I/sI 15.4 (1.0) 10.1 (0.9)
CC1/2 (%) 99.9 (46.2) 99.7 (44.6)
Completeness (%) 100 (99.8) 99.9 (99.7)
Redundancy 13.4 (13.8) 13.3 (13.1)
Refinement
Resolution (A˚) 48.79-3.08 –
No. reflections 64,404 –
Rwork/Rfree 0.23/0.26 –
No. atoms: protein 17,205 –
No. atoms: ligand/ion 41 –
No. atoms: water 0 –
B factors (A˚2): protein 105.59 –
B factors (A˚2): ligand/ion 95.86 –
B factors (A˚2): water – –
RMSD: bond lengths (A˚) 0.004 –
RMSD: bond angles (o) 0.97 –
Related to STAR Methods. RMSD, root-mean-square deviation.
aStatistics for the highest resolution shell are shown in parentheses
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relative to the rest of the SF3B core (including H16-H20 and the
other three proteins) (Figures S4A–S4E). This large conforma-
tional difference is due to the pivoting (23 rotation) of
H1-H15 via a hinge located in the H15-H17 region of SF3B1 (Fig-
ures 5A and S4A–S4E). Intriguingly, the binding sites of both PB
and the BS-A are present within the same SF3B1 hinge region, in
the ‘‘open’’ and ‘‘closed’’ conformation, respectively (Figures 5A
and 5B). In spite of their partial overlap, the sites are significantly
different in the two states of SF3B1. Thus, SF3B1 residues that
form the binding site of PB in the ‘‘open’’ conformation are repo-
sitioned in the ‘‘closed’’ state (Figures 2D, 5C, and 5D), where
several of them become part of the BS-A pocket (i.e., V1114,
K1071, V1078, and R1074; Figures S4F and S4G). At the same
time, PHF5A-Y36 is also reoriented in the ‘‘closed’’ conformation
to form a hydrogen bond with SF3B1-K1071, which in turn con-
tacts the 30-hydroxyl moiety of the reactive adenosine (Figures
S4F and S4G).
Overall, the structural comparison indicates that a transition of
SF3B1 from the ‘‘open’’ to the ‘‘closed’’ state, likely occurring
during the assembly of the A complex, would entail the pivoting
of HEAT repeats H1-H15 via the hinge region, with concomitant
deconstruction of the PB-binding tunnel and formation of the
Figure 2. PB Binding to the SF3B1-PHF5A
Tunnel
(A) PB is engaged in multiple contacts with resi-
dues that define the tunnel. PB (orange) is shown
in stick representation and the carbon atoms of the
conjugated diene moiety are shown in yellow.
SF3B side chains within 4 A˚ of PB are shown as
sticks. V37 side chain was omitted for clarity.
(B) Overview of the PB-binding tunnel. The inter-
face between SF3B1 H15-H17 HEAT repeats (light
blue) and PHF5A (pink) is shown as a surface
model and the superimposed PB ligand is repre-
sented as orange sticks.
(C) The interactions of the Y36 (PHF5A) and R1074
(SF3B1) residues with the diene moiety of PB. The
p-p interactions are colored dark green and are
shown as stacked disks, while hydrophobic in-
teractions are depicted as gray dotted lines.
(D) Schematic of the PB interaction with SF3B1
(light blue) and PHF5A (pink). SF3B residues within
4 A˚ of PB are shown. Chemical groups that are
important for the activity of PB are colored purple.
Hydrogen bonds are depicted as dotted green
lines; hydrophobic and weak polar contacts are
shown as gray and blue semicircles, respectively.
Thep-p interactions are colored dark green. In the
closed SF3B conformation found in the spliceo-
some, PB’s binding site is reconfigured, such that
those residues marked with an asterisk are dis-
placed from the unmarked ones.
Related to Figure S2.
BS-A pocket (Figures 5, S4F, and S4G).
By occupying the tunnel, the modulator
stabilizes SF3B1 in the ‘‘open’’ conforma-
tion, acting as a ‘‘wedge’’ that prevents
rotation of the SF3B1 hinge. Conse-
quently, the induced fit transition to the
‘‘closed’’ conformation is impaired, inhibiting formation of the
BS-A pocket and stable accommodation of the BS/U2 duplex,
and possibly even its formation (Corrionero et al., 2011; Folco
et al., 2011) (Figure 5E). Conversely, once the ‘‘closed’’ confor-
mation is achieved, SF3B should no longer be able to bind PB.
Indeed, purified B complexes, which have been shown to
contain SF3B with a ‘‘closed’’ conformation (Bertram et al.,
2017; Plaschka et al., 2017), can be chased into catalytically
active spliceosomes even in the presence of PB (Figure S5),
consistent with the idea that PB can no longer bind SF3B.
Variations in the Affinity of Modulators for SF3B Lead to
Differential Splicing Inhibition with Different Pre-mRNA
Substrates
The ability of PB, as well as of other splicingmodulators, to block
the conformational change in SF3B1 during A complex formation
explains the inhibitory effect of these compounds on pre-mRNA
splicing observed in vitro (Corrionero et al., 2011; Effenberger
et al., 2016; Folco et al., 2011). However, introns exhibit differen-
tial sensitivity to SF3B modulators in cells, resulting in intron
retention and/or exon skipping rather than a general arrest of
splicing (Corrionero et al., 2011; Teng et al., 2017). We thus
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next investigated whether there is a correlation between the af-
finity of a modulator for wild-type SF3B and its ability to inhibit
the splicing in vitro of different pre-mRNAs. To this end, we
tested splicing of substrates that differ with respect to the
‘‘strength’’ of the BS and/or poly-pyrimidine tract (PPT, i.e., the
extent to which the BS and PPT differ from the consensus se-
quences). To produce the ‘‘weakest’’ BS variant, we incorpo-
rated an adjacent ‘‘decoy’’ sequence (Corrionero et al., 2011),
meant to provide an alternative, unproductive site for binding
of U2 snRNA. Notably, PB inhibits splicing efficiently, regardless
of the ‘‘strength’’ of the BS or PPT, or the presence of a ‘‘decoy’’
sequence (Figures 6A and S6A). However, a PB derivative with
reduced affinity for SF3B, such as PB-OH, is still able to inhibit
splicing of pre-mRNAwith a ‘‘weak’’ BS, but it is much less effec-
tive when a ‘‘strong’’ BS is present (Figures 6B and S6A). In
contrast, there was no difference observed with the wild-type
versus ‘‘weak’’ PPT (Figures 6B and S6A). This suggests
that the correlation between affinity and the ‘‘strength’’ of the
Figure 4. Comparison of PB and HB Struc-
tural Features
(A and C) Structural superposition of PB (orange)
with the small molecule crystal structure of her-
boxidiene (HB, teal). The superposition was carried
out using the common C12-C16 moiety as a refer-
ence. The aliphatic arm adopts different positions
in the two structures, while the functionalized
pyran ring of HB superimposes onto the PB
12-membered macrocycle. In (C), the structure is
depicted as in (A) and rotated as indicated.
(B and D) Tentative location of HB in the SF3B1-
PHF5A tunnel. The pyran ring of HB (teal) likely
occupies the top SF3B ‘‘funnel,’’ as observed with
the PBmacrocycle. The aliphatic arm of HB is likely
located in the bottom ‘‘funnel’’ and may rearrange
upon binding to SF3B1-PHF5A. SF3B1 (light blue)
and PHF5A (pink) are displayed and colored as in
Figure 2A. In (D), the structure is depicted as in (B)
and rotated as indicated.
Related to Figure S3.
Figure 3. Structure-Guided Probing of the
SF3B1-PHF5A PB-Binding Tunnel
(A) Monitoring of [3H]-pladienolide B ([3H]-PB) bind-
ing to the full-length wild-type (WT) SF3B complex or
to recombinant complexes containing point muta-
tions in the PB-binding tunnel (R1074H [SF3B1],
Y36A [PHF5A], and R1074A/Y36A [SF3B1/PHF5A]).
The scintillation proximity assays were carried
out using 1 nM (left set of bars) or 10 nM (right set)
[3H]-PB and 10 nM recombinant FLAG-tagged SF3B
complexes. Error bar indicates SD, n = 3.
(B) Cell growth inhibition assays of parental HCT116
cells or of HCT116 cells harboring the PHF5A-Y36C
or the SF3B1-R1074H point mutations. HCT116 cell
viability was monitored for 72 hr in the presence of
PB (orange) or of the less potent PB-OH derivative
(purple). Error bar indicates SD, n = 3.
(C) Competitive titration of [3H]-labeled pladienolide
B ([3H]-PB, 1 nM) with PB (orange) or PB-OH
(magenta) by scintillation proximity assay (SPA) us-
ing an endogenous SF3B complex purified by im-
munoaffinity from HeLa nuclear extract. PB-OH derivative, which lacks the C7 oxycarbonyl group, displays a reduced affinity toward SF3B compared to PB
(IC50 = 78 nM versus IC50 = 5 nM for PB). Error bar indicates SD, n = 3.
(D) Competitive titration of [3H]-PB (1 nM) with PB (orange) or PB-OH (magenta) by SPA using the recombinant full-length SF3B complex (12.5 nM). The
PB-OH derivative lacks the C7 oxycarbonyl group and, as a result, exhibits reduced affinity for SF3B (IC50 = 378 nM versus IC50 = 97 nM for PB). Error bar
indicates SD, n = 3.
Related to Figure S3.
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substrate’s BS enables these compounds to act as modulators
rather than mere blockers of splicing (Figure S6B), consistent
with their ability to selectively modulate splicing patterns in cells
(Corrionero et al., 2011; Teng et al., 2017). Importantly, themodel
that we derived from our structural data indicates that a direct
competition between the BS-A and themodulator is unlikely (Fig-
ure 5E) because the binding sites of the two ligands do not exist
simultaneously (i.e., one is present in the ‘‘open’’ and the other in
the ‘‘closed’’ conformation). Therefore, our model supports the
idea that the intron and the modulator compete for the same
conformation (‘‘open’’ form) of SF3B1, rather than for the same
binding site. That is, ‘‘strong’’ substrates exhibit higher base
pair complementarity within the U2/BS duplex, favoring a shift
of the equilibrium from the ‘‘open’’ toward the ‘‘closed’’ state,
Figure 6. Differential Splicing Inhibition of
Various Pre-mRNA Substrates Is Depen-
dent on the Affinity of the Modulator
for SF3B
In vitro splicing assays of substrates derived from
the Ad2 model pre-mRNA, in the presence of PB
(A) or PB-OH (B). Formation of spliced products
was monitored by qRT-PCR and the splicing effi-
ciency (%) was determined relative to the DMSO-
treated samples. PB exerts its inhibitory action in a
30 SS sequence-independent manner, whereas
the less potent compound, PB-OH, exhibits an
apparent sequence-dependent inhibition profile.
Related to Figure S6.
Figure 5. PB and the BS-A Bind SF3B1 in the
Same Hinge Region in the Open and Closed
Conformation
(A) The SF3B1 HEAT domain (‘‘open’’ conforma-
tion) in complex with PB (orange sticks) and that of
S. cerevisiae Hsh155p (‘‘closed’’ conformation,
gray) are aligned via the equivalent H16-H20 region
(cyan). H1-H15 repeats are shown in light blue. The
inset depicts a schematic of the superposition
with the centroids of each HEAT repeat shown as
spheres.
(B) Structural superposition of H1-H15 and H16-
H20 regions of SF3B1 (as separate rigid bodies)
with the equivalent regions of Hsh155p. The U2/BS
helix and the downstream region of the intron,
as seen in the yeast activated spliceosome, are
shown in gray. The bulged BS adenosine (BS-A) is
highlighted in deep green.
(C) The H15-H17 hinge region of SF3B1 (light blue)
in the presence of PB.
(D) The H15-H17 hinges of SF3B1 and Hsh155p
(gray) superimposed as in Figure 4A. PB is omitted
for clarity and the BS-A is shown. Several residues
of PB’s binding pocket, as well as the equivalent
residues from Hsh155p in the ‘‘closed’’ confor-
mation, are shown in the left and right figures,
respectively.
(E) Schematic overview of themechanism of action
of PB. The ‘‘open’’ conformation of SF3B1 is likely
found in the U2 snRNP, prior to the stable forma-
tion of the A complex. The splicing modulator PB
(orange) binds SF3B1 in the ‘‘open’’ state, pre-
venting the stable accommodation of the U2/BS
helix and the BS-A, which requires a ‘‘closed’’
conformation of the protein. The hinge (two rect-
angular elements connected by a ring) and the
HEAT repeats H16-H20 (teal) and H1-H15 (light
blue) are indicated.
Related to Figures S4 and S5.
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likely via an induced fit mechanism, if the modulator binds with
sufficiently weak affinity and therefore cannot act as an effective
‘‘wedge’’ (Figure S6B). Conversely, potent antagonists (such as
PB), with high affinity for the ‘‘open’’ state of SF3B1, would shift
the equilibrium toward a tightly bound ‘‘open’’ state and there-
fore compete efficiently with a wider range of pre-mRNAs.
Similar differential effects were recently observed for the more
potent modulator spliceostatin A versus sudemycins (Vigevani
et al., 2017).
In lightof thismodel, thecorrelationbetween theaffinityofmod-
ulators for the SF3B-binding tunnel and their ability to selectively
alter splicing of various pre-mRNA substrates suggests future
strategies for manipulating/tuning their splicing modulation prop-
erties by structure-guided modification of their binding affinity.
Concluding Remarks
The crystal structure of the SF3B core in complex with PB
advances a unified view on the structural definition of SF3Bmod-
ulators, and on the structural basis for their inhibitory and modu-
latory effects on splicing. The hourglass-shaped SF3B tunnel
and the contacts with PB explain the tripartite organization of
SF3B modulators into two chemically variable moieties con-
nected by an invariant diene—the key components for molecular
recognition. From a mechanistic perspective, the structural and
biochemical analyses reveal the significance of an early open
SF3B conformation and of its conversion to the closed confor-
mation, and indicate how modulators exploit the presence of a
functional hinge to inhibit BS usage and modulate splicing.
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KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Anti-FLAG antibody Sigma-Aldrich Cat#F3165, lot #SLBQ7119V, clone M2
Anti-SF3B3 antibody Abcam Cat#AB209403, clone EPR18441
Anti-SF3B1 antibody MBL Cat#D221-3, clone 16
Bacterial and Virus Strains
Escherichia coli BW23474 Dr. Imre Berger, EMBL,
Grenoble
N/A
Escherichia coli DH10MultiBacY Dr. Imre Berger, EMBL,
Grenoble
N/A
Escherichia coli XL-10 Gold Agilent Technologies Cat#200314
Escherichia coli Rosetta 2 (DE3) Merck Cat#71397
Chemicals, Peptides, and Recombinant Proteins
Pladienolide B (PB), used in crystallization trials Santa Cruz Biotechnology Cat#sc-391691
Pladienolide B (PB), used in viability assays,
scintillation proximity assays, and in vitro
splicing assays
This work, Kotake et al., 2007 N/A
[3H]-labeled pladienolide B ([3H]-PB), used in
scintillation proximity assays
This work, Kotake et al., 2007 N/A
Pladienolide A (PB-OH), used in viability assays,
scintillation proximity assays, and in vitro
splicing assays
This work, Kotake et al., 2007 N/A
cOmplete Protease Inhibitor Cocktail Roche Cat#11836145001
Ampicillin Carl Roth Cat#K029.3
Gentamycin Carl Roth Cat#0233.4
Kanamycin Carl Roth Cat#T832.3
Spectinomycin Sigma-Aldrich Cat#S4014
Tetracycline Sigma-Aldrich Cat#T8032
IPTG Carl Roth Cat#2316.5
X-Gal Sigma-Aldrich Cat#B4252
Imidazole Sigma-Aldrich Cat#56750
Maltose Sigma-Aldrich Cat#M5885
L-Glutathione reduced Sigma-Aldrich Cat#G4251
Seleno-L-methionine Sigma-Aldrich Cat#S3132
Pentaerythritol propoxylate (5/4 PO/OH) Sigma-Aldrich Cat#418749
MS2-MBP in-house N/A
T7 RNA polymerase in-house N/A
Pfu DNA polymerase in-house N/A
RNasin Promega Cat#N2511
RQ1 RNase-Free DNase Promega Cat#M6101
TEV (Tobacco Etch Virus) protease in-house N/A
PreScission protease GE Healthcare Cat#27-0843-01
Cre Recombinase New England Biolabs Cat#M0298
Sf-900 III SFM insect cell culture medium Thermo Fisher Scientific Cat#12658019
ESF 921 insect cell culture medium Expression Systems Cat#96-001-01
ESF 921 D, methionine deficient insect cell
culture medium
Expression Systems Cat#96-200
(Continued on next page)
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HisTrap HP resin GE Healthcare Cat#17524802
Glutathione Sepharose 4B resin GE Healthcare Cat#17075605
HiTrap Q HP resin GE Healthcare Cat#17115401
HiLoad 16/600 Superdex 200 pg resin GE Healthcare Cat#28989335
Amylose resin New England Biolabs Cat#E8021L
Anti-mouse PVT SPA beads PerkinElmer Cat#RPNQ0017
Critical Commercial Assays
QuickChange II XL Site-Directed Mutagenesis Kit Agilent Technologies Cat#200521-5
MEGAscript T7 Transcription Kit Invitrogen Cat#AM1334
MEGAclear Transcription Clean-Up Kit Invitrogen Cat#AM1908
Xtreme-GENE 9 DNA Transfection Reagent Roche Cat#06365787001
TaqMan RNA-to-Ct 1-Step Kit Life Technologies Cat#4392653
CellTiter-Glo Luminescent Cell Viability Assay Promega Cat#G7570
Deposited Data
PDB coordinates of the human SF3bcore-PB complex This work PDB: 6EN4
PDB coordinates of the protease-resistant core of the
human SF3b complex
Cretu et al., 2016 PDB: 5IFE
Cryo-EM model of the yeast Bact complex Rauhut et al., 2016 PDB: 5LQW
Cryo-EM model of the yeast Bact complex Yan et al., 2016 PDB: 5GM6
Cryo-EM model of the human B complex Bertram et al., 2017 PDB: 5O9Z
Cryo-EM model of the yeast B complex Plaschka et al., 2017 PDB: 5NRL
Experimental Models: Cell Lines
Hive Five cells (BTI-TN-5B1-4) (Trichoplusia ni) Thermo Fisher Scientific Cat#B85502
Sf9 cells (Spodoptera frugiperda) Thermo Fisher Scientific Cat#11496015
HeLa S3 cells (isolation of spliceosomes) (Homo sapiens) Helmoltz Center for Infection
Research, Brunswick
N/A
HCT116 cells (Homo sapiens) ATCC Cat#CCL-247
HeLa S3 cells (Homo sapiens) ATCC Cat#CCL-2.2
Oligonucleotides
Primer: SF3B1-fwd-del CCGAGGAGTCGACCATGAAGT
CTGTCAACG
This work N/A
Primer: SF3B1-rev-del AGGCTCTAGATTACAGGATGTA
GTCCAGTTCGTAGC
This work N/A
Primer: SF3B1-fwd-R1074H CCCACAAGAAGGCCATCC
ATCGCGCTACCGTCAACAC
This work N/A
Primer: SF3B1-rev-R1074H GTGTTGACGGTAGCGCGA
TGGATGGCCTTCTTGTGGG
This work N/A
Primer: SF3B1-fwd-R1074A CACAAGAAGGCCATCGCG
CGCGCTACCGTCAA
This work N/A
Primer: SF3B1-rev-R1074A TTGACGGTAGCGCGCGC
GATGGCCTTCTTGTG
This work N/A
Primer: PHF5A-fwd-del GATCTCGAGCCATGGCCAAGC
ACCACCCTGA
This work N/A
Primer: PHF5A-rev-del GCGCTAGCATTACAGGTCGGT
CTTAGAAG
This work N/A
Primer: PHF5A-fwd-Y36A GAAAGTGCGTCATCTGCGA
CTCTGCCGTCAGGCCTTG
This work N/A
Primer: PHF5A-rev-Y36A CAAGGCCTGACGGCAGAGTC
GCAGATGACGCACTTTC
This work N/A
(Continued on next page)
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Primer: SF3B3-fwd-del
TCTCAAAAGGCCGAAGTCATCATGAACTA
This work N/A
Primer: SF3B3-rev-del
GTCCACTTCGTCGTTGGTGTTAGGAGGCA
This work N/A
Primer: Ad2-fwd ACTCTCTTCCGCATCGCTGT This work N/A
Primer: Ad2-rev CCGACGGGTTTCCGATCCAA This work N/A
Primer: Ad2-probe CTGTTGGGCTCGCGGTTG This work N/A
Primer: Ftz-fwd TGGCATCAGATTGCAAAGAC This work N/A
Primer: Ftz-rev ACGCCGGGTGATGTATCTAT This work N/A
Primer: Ftz-probe CGAAACGCACCCGTCAGACG This work N/A
Recombinant DNA
Plasmid: pFL Dr. Imre Berger, EMBL,
Grenoble
N/A
Plasmid: pIDS Dr. Imre Berger, EMBL,
Grenoble
N/A
Plasmid: pFL-10xHIS-TEV This work, Cretu et al., 2016 N/A
Plasmid: pIDS-GST-PP This work, Cretu et al., 2016 N/A
Plasmid: pFL-10xHIS-TEV-SF3B3-FLAG/SF3B5/
GST-PP-PHF5A/SF3B1/SF3B6 (H. sapiens full-length
codon-optimized synthetic genes, SF3B3 has a TEV
protease cleavable N-terminal 10xHIS tag and a
C-terminal FLAG tag; PHF5A has an N-terminal
PreScission protease (PP) cleavable GST tag)
This work, Cretu et al., 2016 N/A
Plasmid: pFL-10xHIS-TEV-SF3B2-Strep/SF3B4
(H. sapiens full-length codon-optimized synthetic
genes, SF3B2 has a TEV protease cleavable
N-terminal 10xHIS tag and a C-terminal Strep-tag II)
This work, Cretu et al., 2016 N/A
Plasmid: pFL-10xHIS-TEV-SF3B3-FLAG/SF3B5/GST-
PP-PHF5A/SF3B1 (R1074H)/SF3B6 (H. sapiens
full-length codon-optimized synthetic genes, SF3B3
has a TEV cleavable N-terminal 10xHIS tag and a
C-terminal FLAG tag, PHF5A has an N-terminal
PreScission protease (PP) cleavable GST tag, SF3B1
residue R1074 mutated to H)
This work N/A
Plasmid: pFL-10xHIS-TEV-SF3B3-FLAG/SF3B5/GST-
PP-PHF5A (Y36A)/SF3B1 (R1074A)/SF3B6 (H. sapiens
full-length codon-optimized synthetic genes, SF3B3 has a
TEV cleavable N-terminal 10xHIS tag and a C-terminal
FLAG tag, PHF5A has an N-terminal PreScission protease
(PP) cleavable GST tag, SF3B1 residue R1074 mutated to
A, PHF5A residue Y36 mutated to A)
This work N/A
Plasmid: pFL-10xHIS-TEV-SF3B3-FLAG/SF3B5/GST-
PP-PHF5A (Y36A)/SF3B1/SF3B6 (H. sapiens full-length
codon-optimized synthetic genes, SF3B3 has a TEV
cleavable N-terminal 10xHIS tag and a C-terminal FLAG
tag, PHF5A has an N-terminal PreScission protease (PP)
cleavable GST tag, PHF5A residue Y36 mutated to A)
This work N/A
Plasmid: pFL-10xHIS-TEV-SF3B3 (D 1068-1085)-FLAG/
SF3B5/GST-PP-PHF5A (1-98)/SF3B1 (453-1304)
(Homo sapiens codon-optimized synthetic genes, SF3B3
has a TEV cleavable N-terminal 10xHIS tag and a
C-terminal FLAG tag, PHF5A has an N-terminal
PreScission protease (PP) cleavable GST tag, SF3B1
lacks residues 1-452, SF3B3 lacks residues 1068-1085,
PHF5A lacks residues 99-110)
This work N/A
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CONTACT FOR REAGENT AND RESOURCE SHARING
Requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Vladimir Pena (vlad.pena@
mpibpc.mpg.de). Requests for cell lines and RNA substrates should be addressed to Silvia Buonamici (silvia_buonamici@
h3biomedicine.com) and MTA will be required.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell lines
HCT116 and HeLa S3 cell lines were obtained from the American Type Culture Collection (ATCC). These cell lines were authenticated
using ATCC and tested for mycoplasma contamination tested at IDEXX using IMPACT1 testing. HeLa S3 cells used for isolation of
human spliceosomes were obtained from Helmoltz Center for Infection Research (Brunswick) and tested negative for mycoplasma
contamination. HeLa S3 cells used for the isolation of spliceosomes were cultured in DMEM/F12 (1:1) medium supplemented with
5% NCS serum at a density of 6.5 3 106 cells/ml. Sf9 (Spodoptera frugiperda) and Hive Five (Trichoplusia ni) insect cell lines were
purchased fromThermo Fisher Scientific and cultured in suspension in Sf-900 III SFM (Thermo Fisher Scientific) and ESF 921medium
(Expression Systems), respectively, at 27C and 90 rpm. For cloning and bacmid production, we used the Escherichia coli BW23474
and DH10MultiBacY strains (gift from Dr. Imre Berger, EMBL, Grenoble), and the Escherichia coli XL-10 Gold strain (Agilent Technol-
ogies). MBP-MS2 fusion protein used for MS2 affinity selection of spliceosomes was expressed in the Escherichia coli strain Rosetta
2 (DE3) (Merck) in 2YT medium at 37C.
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Plasmid: pMBP-MS2 Josep Vilardell lab Addgene Cat#65104
Plasmid: pT7-MINX-M3 Bertram et al., 2017 N/A
Plasmid: pcDNA3.1(+) Thermo Fisher Scientific Cat#V79020
Plasmid: pSP65-Ftz Luo and Reed, 1999 Addgene Cat#11243
Plasmid: pcDNA3.1(+)-Ad2 (wild-type) This work, Pellizzoni
et al., 1998
N/A
Plasmid: pcDNA3.1(+)-Ad2.1 (‘‘enhanced’’ BS) This work N/A
Plasmid: pcDNA3.1(+)-Ad2.11 (‘‘weak’’ BS, ‘‘strong’’ PPT) This work N/A
Plasmid: pcDNA3.1(+)-Ad2.12 (‘‘strong’’ BS, ‘‘weak’’ PPT) This work N/A
Plasmid: pcDNA3.1(+)-Ad2.15 (‘‘weak’’ BS, ‘‘weak’’ PPT) This work N/A
Plasmid: pcDNA3.1(+)-Ad2.2 (‘‘decoy’’ BS, ‘‘strong’’ PPT) This work N/A
Software and Algorithms
CCP4 Winn et al., 2011 http://www.ccp4.ac.uk/
PHENIX suite Adams et al., 2010 https://www.phenix-online.org/
XDS Kabsch, 2010 http://xds.mpimf-heidelberg.mpg.de/
PyMOL Schro¨dinger LCC https://pymol.org/2/
UCSF Chimera Pettersen et al., 2004 https://www.cgl.ucsf.edu/chimera/
Coot Emsley et al., 2010 https://www2.mrc-lmb.cam.ac.uk/
personal/pemsley/coot/
Grade Web Server Global Phasing Limited http://grade.globalphasing.org/
cgi-bin/grade/server.cgi/
Arpeggio Web Server Jubb et al., 2017 http://biosig.unimelb.edu.au/arpeggioweb/
PLIP Web Server Salentin et al., 2015 https://projects.biotec.tu-dresden.de/
plip-web/plip/
ALBULA Dectris Ltd. https://www.dectris.com/products/
albula-software/
Prism v.6.0 GraphPad Software https://www.graphpad.com/
scientific-software/prism/
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METHOD DETAILS
Expression and purification of recombinant SF3B complexes
The engineered human SF3B core complex was overexpressed in insect cell lines using optimized synthetic genes (GeneArt, Life
Technologies), as previously described (Cretu et al., 2016). Briefly, the SF3B3 subunit was cloned in frame with a Tobacco Etch Virus
(TEV) protease cleavable N-terminal 10xHIS tag and with a C-terminal FLAG tag. The internal 1068-1085 residues of SF3B3 were
removed by ‘‘round-the-horn’’ PCR mutagenesis (Key Resources Table). PHF5A (1-98) was amplified by PCR and fused to a
PreScission protease (PP) cleavable GST tag. SF3B5 (full-length) and SF3B1 (453-1304) were cloned by PCR without addition of af-
finity tags. All four SF3B subunits were placed on a single acceptor vector by the sequential use of the multiplication and the Cre
recombination cassettes, as implemented in the Multibac baculovirus/insect cell expression system (Fitzgerald et al., 2006). High
Five insect cells (Thermo Fisher Scientific) overexpressing the human SF3B core complex were harvested 72h after infection with
recombinant baculoviruses and lysed by sonication in ice-cold buffer A1 (50 mM HEPES-KOH, pH 7.9, 600 mM KCl, 15% (v/v) glyc-
erol, 5 mM 2-mercaptoethanol (2-ME), 30 mM imidazole, pH 8.0) supplemented with a cocktail of protease inhibitors (Roche). The
cleared lysate was loaded on a HisTrap HP column (GE Healthcare) equilibrated with buffer A2 (50 mM HEPES-KOH, pH 7.9,
600 mM KCl, 10% (v/v) glycerol, 5 mM 2-ME, 30 mM imidazole, pH 8.0). The bound proteins were eluted by a linear gradient formed
between buffer A2 and buffer B (50 mM HEPES-KOH, pH 7.9, 600 mM KCl, 10% (v/v) glycerol, 5 mM 2-ME, 400 mM imidazole,
pH 8.0) and incubated with 20 mL glutathione resin (Glutathione Sepharose 4B, GE Healthcare) in batch for 2h at 4-8C. The
SF3B core complex was eluted from the resin with buffer C (50 mM HEPES-KOH, pH 7.9, 200 mM KCl, 10% (v/v) glycerol, 2 mM
DTT, 30 mM L-glutathione reduced) and both the 10xHIS and the GST affinity tags were removed by overnight cleavage with TEV
and PP (GE Healthcare) proteases, respectively. The sample was further purified on a HiTrap Q HP column (GE Healthcare) and
eluted from the resin using a linear gradient (0%–30%, 50 mL) formed between buffer D (20 mM HEPES-KOH, pH 7.9, 200 mM
KCl, 10% (v/v) glycerol, 2 mM DTT) and buffer E (20 mM HEPES-KOH, pH 7.9, 1 M KCl, 5% (v/v) glycerol, 2 mM DTT). SF3B
peak fractions were concentrated using an Amicon Ultra-15 centrifugal filter (Millipore) and further purified by size-exclusion chro-
matography (HiLoad 16/600 Superdex 200 pg, GE Healthcare) in buffer SB (20 mMHEPES-KOH, pH 7.9, 200mMKCl, 5% (v/v) glyc-
erol, 2 mMDTT). The SF3B core fractions were subsequently concentrated and used fresh in crystallization screening or snap frozen
in liquid nitrogen and stored at 80C. The engineered SF3B core complex contained SF3B1, SF3B3, PHF5A, and SF3B5 in appar-
ently stoichiometric amounts (Figure S1A) and displayed nanomolar affinity for pladienolide B (PB) as also observed with the full-
length recombinant SF3B complex (Figure S1B). For the production of selenomethionine-derivatized SF3B core complex, Hive
Five insect cells were grown for 48h in ESF 921Dmethionine deficient medium (Expression Systems) and then infected with recom-
binant baculoviruses. After 12h, the suspension cultures were supplemented with seleno-L-methionine (Sigma) to 0.1g/L and
cultured for an additional 60h. R1074H (SF3B1), R1074A (SF3B1), and the Y36A (PHF5A) mutations in the SF3B1-PHF5A tunnel
were introduced using a modified protocol based on the QuickChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies).
Full-length heptameric human SF3B complexes (SF3B1-SF3B2-SF3B3-SF3B4-SF3B5-SF3B6-PHF5A), used in radioligand binding
assays, were overexpressed and purified as previously described (Cretu et al., 2016). All SF3B preparations were analyzed by mass
spectrometry (data not shown).
Crystallization and structure determination of the human SF3B core in complex with PB
The engineered human SF3B core complex (SF3B3 (D1068-1085)-SF3B1 (453-1304)-PHF5A (1-98)-SF3B5) was concentrated by ul-
trafiltration to 6 mg/ml, complexed with PB (purchased from Santa Cruz Biotechnology), added in a 3-fold molar excess over pro-
tein, and subjected to initial crystallization screening. Optimized single trapezoidal plates were grown at 2.5-3mg/mL at 20C in 1+1ml
hanging drops using reservoir solutions containing 50mMHEPES-NaOH, pH 7-7.4, 200mMKCl, and 38%–39% (v/v) pentaerythritol
propoxylate (5/4 PO/OH). The best diffracting SF3B-PB co-crystals appeared after 1 day and reached full size after 5 days. The
SF3B core crystals were harvested directly from themother liquor at 20C and flashed cooled in liquid nitrogen. Selenium-derivatized
crystals, obtained under similar crystallization conditions, were harvested from the mother liquor at 4C. Diffraction data were
collected at 100K on PILATUS 6M-F (25 Hz) at the X10SA beamline (SLS, PSI Villigen, Switzerland). Diffraction data collected
from a single crystal were indexed, integrated and scaled with XDS (Kabsch, 2010), and merged with AIMLESS (Evans and Murshu-
dov, 2013), in CCP4 (Winn et al., 2011). The SF3B-PB co-crystal structure was solved by molecular replacement with Phaser-MR
(McCoy, 2007) using the previously reported crystal structure of the protease-resistant SF3B core (PDB: 5IFE) (Cretu et al., 2016)
as a search model. Like the protease-resistant core complex (Cretu et al., 2016), the 254 kDa engineered SF3Bcore-PB complex
crystallized in the P212121 space group (Table 1).
The initial search model was iteratively rebuilt in Coot (Emsley and Cowtan, 2004), followed by refinement with phenix.refine
(Adams et al., 2010). As independent means of validating the residue register of the SF3B core model, we collected SAD (single-
wavelength anomalous dispersion) data at the Se K-edge (12.662 keV) from selenium-derivatized crystals (Table 1). Careful inspec-
tion of the anomalous difference map revealed strong anomalous peaks for 53 out of 54 modeled methionine side chains, in good
agreement with our SF3b core-PB structural model (Figures S1F and S1G). We could not assign a Se marker site for SF3B1-M620,
likely because of the relative flexibility of the residue (located in the H4 repeat turn). Inspection of the residual mFo-DFc map of
the refined SF3B core model revealed a strong positive electron density at the interface between SF3B1 and PHF5A. Importantly,
the observed positive density differed significantly from the previously reported density, located close to the site (Cretu et al.,
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2016). The PB ligand was manually fit into the mFo-DFc difference electron density map in Coot with the macrolide moiety of the
splicingmodulator facing the SF3B3 side (Figures S1C–S1E). In agreement with previous photo-affinity labeling experiments (Kotake
et al., 2007), the SF3B3CTD domain is located17A˚ from themacrolide cycle, within the effective distance of the reactive probe. The
location of the PB ligand was confirmed using both unbiasedmFo-DFc and polder omit maps (Liebschner et al., 2017) (Figures S1C–
S1E). The Grade Web server (Global Phasing Limited) was used to generate geometric restraints for PB refinement. The final model
was refined using individual B factors for protein and ligand atoms to a Rwork value of23% and a Rfree value of26% and exhibited
good stereochemistry (Table 1). The higher B factors of the macrolide lactone (C1) are consistent with its likely susceptibility to ra-
diation damage.Moreover, this observation also agrees with the described tendency of pladienolides to undergo hydrolysis of the C1
bond in aqueous media (Villa et al., 2013). The final model comprises the HEAT domain of SF3B1 (residues 463-1304), SF3B3
(residues 1-1217, lacking the 1068-1085 loop region), SF3B5 (residues 15-79) and PHF5A (residues 6-98). The 453-462 N-terminal
residues of SF3B1, as well as several internal SF3B3 loop regions (646-661; 692-694; 829-832), could not be traced in the electron
density, likely, owing to relative flexibility/disorder. All structural figures were generated with PyMOL (versus 1.8.4.1, Schro¨dinger
LLC). The contact sites between PB and the SF3B core were identified with Arpeggio (Jubb et al., 2017) and PLIP (Salentin et al.,
2015), and analyzed in PyMOL. The SF3B1-PHF5A tunnel was computed using a modified HOLLOW script (Abe and Hiraki, 2009)
and rendered in PyMOL. Structural alignment of herboxidiene (Edmunds et al., 2000) and PB (Figure 4) was carried out in UCSF
Chimera (Pettersen et al., 2004).
Structural superposition of SF3B1 and Hsh155p
Comparison of the SF3B1 HEAT helix in the PB-bound state (open) with the yeast ortholog in the Bact spliceosome (closed) shows
major conformational differences (rmsd of 5.2A˚, 710 Ca) (Figure S4A). Analyses of individual pairs of HEAT repeats (Figure S4E)
showed small differences at the interfaces between H2-H3, H7-H8, H11-H12, while major variations are present at the interfaces
of H15-H16 (rmsd of 2.06, 66 Ca) and H16-H17 (rmsd of 1.22, 72 Ca). In contrast, the intramolecular interfaces of H15 and H17
with the neighboring repeats remained largely unchanged (H14-H15 – rmsd of 0.67 (71 Ca), H17-H18 – rmsd of 0.64 (69 Ca). As a
result, the 23 rotation of the H15 repeat over the H16 hinge, toward the convex side of SF3B1, would induce a counterclockwise
movement of the entire H1-H15 arch. Except for the flexible BPB domain of SF3B3, all other SF3B modules behave as rigid bodies
with respect to the H17-H20 repeats and superimpose onto the yeast proteins without major clashes (Figures S4D and S4E).
The large-scale reconfiguration of the SF3B1 superhelix after rotation of the H15-H17 hinge would shorten the distance between
the terminal HEAT repeats to a similar extent as observed when comparing the ‘‘open’’ and ‘‘closed’’ conformation (from 25A˚ to
18A˚). However, smaller additional rearrangements at the H2-H3 and H7-H8 interfaces – likely, induced upon interaction with the
BS and polypyrimidine regions of the intron and/or with additional splicing factors – might be required to achieve a state that is virtu-
ally identical to the ‘‘closed’’ state.
Changes in the configuration of the SF3B1 helix are also coupled with additional rearrangements that occur at the interfaces be-
tween SF3B1 and PHF5A and between SF3B1 and the BPA domain of SF3B3. At the second contact site, the C-terminal extension of
PHF5A (aa 91-98), undergoes a forward movement with respect to its globular domain. As a result, it interacts with the H2 repeat of
SF3B1 replacing previous contacts of the E48, Y51 and Y54 residues (E48-H550; E48-K554; Y51-Q547; Y54-Q547); these residues
are now involved in contacts with the H5-H6 repeats (E48-C677, Y51-E714). Because in isolation the C terminus of PHF5A (Rds3p in
yeast) is disordered, this region likely folds to an a helix, as seen in the yeast spliceosome, upon simultaneous binding to SF3B1 and
to the minor groove of the U2/BS helix. Consistent with a rotation around the H16 hinge, the interfaces between the BPA domain of
SF3B3 and PHF5A are not significantly changed.
Cell viability assays
For CellTiter-Glo analysis, 500 cells (HCT116 parental, HCT116 Y36C and HCT116 R1074H generated as described in Teng et al.,
2017) were seeded in each well of a 384-well plate the day before compound addition. An 11 pt serial dilution was used starting
with a top final dosage of 10 mM for 10 additional doses. DMSO percentage was maintained throughout and a DMSO-only control
was included. Seventy-two hours post compound addition, CellTiter-Glo reagent was added to the medium, incubated and assayed
on EnVision Multilabel Reader (PerkinElmer). The luminescence value from each treatment sample was normalized to the average
value of the respective DMSO control. The dosage response curve plots were generated using Prism 6 (GraphPad) and fit using
nonlinear regression analysis and the log (inhibitor) versus response-variable slope (four parameters).
HeLa nuclear extract preparation
HeLa S3 cell pellets were resuspended in hypotonic buffer (10 mM HEPES pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.2 mM PMSF, and
0.5 mM DTT) and the suspension was brought up to a total of 5 packed cell volume (PCV). After centrifugation, the supernatant was
discarded, and the cells were brought up to 3 PCVwith hypotonic buffer and incubated on ice for 10minutes. Cells were lysed using a
Dounce homogenizer and then centrifuged. The supernatant was discarded, and the pellet was resuspended with ½ packed nuclear
volume (PNV) of low salt buffer (20 mM HEPES pH 7.9, 1.5 mM MgCl2, 20 mM KCl, 0.2 mM EDTA, 25% glycerol, 0.2 mM PMSF,
0.5mMDTT), followed by½PNV of high salt buffer (same as low salt buffer except 1.4MKCl was used). The nuclei were gently mixed
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for 30 minutes before centrifuging. The supernatant (nuclear extract) was then dialyzed into storage buffer (20 mM HEPES pH 7.9,
100 mM KCl, 0.2 mM EDTA, 20% glycerol, 0.2 mM PMSF, 0.5 mM DTT). Protein concentration was determined using NanoDrop
8000 UV-Vis spectrophotometer (Thermo Fisher Scientific).
In vitro splicing assays
All Ad2-derived (Pellizzoni et al., 1998) sequences were cloned into the pcDNA3.1(+) vector (Promega) using 50 EcoRI and 30 XbaI
restriction sites. The plasmids were linearized using XbaI and used as DNA templates in the in vitro transcription reactions. The FtzDi
intron-less plasmid (Luo and Reed, 1999) was linearized using EcoRI. All RNAs were in vitro transcribed and then purified using
MEGAscript T7 (Invitrogen) and MEGAclear (Invitrogen) kits, respectively. For splicing reactions using Ad2 variant pre-mRNAs,
1 mL reactions were prepared using 8 mg nuclear extracts prepared from HeLa S3, 2 ng pre-mRNA, 0.2 ng FTZDi, and varying con-
centrations of PB, PB-OH or DMSO. After a 15-minute pre-incubation at 30C, 1 mL splicing activation buffer (0.5 mM ATP, 20 mM
creatine phosphate, 1.6 mM MgCl2) was added, and the reactions were incubated for 90 minutes at 30
C. The reactions were then
quenched with 13 mL DMSO, and 25 nL was used for RT-qPCR. RT-qPCR reactions were prepared using TaqMan RNA-to-CT 1-step
kit (Life Technologies), RNA from splicing reactions, Ad2 (forward: ACTCTCTTCCGCATCGCTGT; reverse: CCGACGGGTTTCC
GATCCAA; probe: CTGTTGGGCTCGCGGTTG) and Ftz (forward: TGGCATCAGATTGCAAAGAC; reverse: ACGCCGGGTGATG
TATCTAT; probe: CGAAACGCACCCGTCAGACG) mRNA primer-probe sets. Prism 6 (GraphPad) was used for non-linear regression
curve fitting of the formed spliced product and normalized to the control (DMSO) sample.
Scintillation proximity assays/competitive binding assay
Batch immobilization of anti-FLAG antibody (Sigma-Aldrich) to anti-mouse PVT SPA scintillation beads (PerkinElmer) was prepared
as follows. For every 1.5mg of beads, 10mg antibody was prepared in 150ml PBS. The antibody–bead mixture was incubated for
30min at RT and centrifuged at 18,000g for 5min. 150ml PBSwas used to resuspend every 1.5mg antibody–beadmixture. The purified
SF3B full-length complexes were tested for [3H]-labeled pladienolide probe binding ([3H]-PB), synthesized as previously described
(Kotake et al., 2007). 100ml binding reactions were prepared with 50ml bead slurry and 0 or 10nMprotein in buffer (20mMHEPES pH 8,
200mM KCl, 5% glycerol). The mixture was incubated for 30min, and 1 nM or 10 nM [3H]-probe was added. The mixture was incu-
bated for 30min, and luminescence signals were read using a MicroBeta2 Plate Counter (PerkinElmer). Compound competition
studies were performed with the full-length heptameric SF3B and the SF3B core complex immobilized using anti-SF3B3 antibody.
100ml binding reactions were prepared with 50ml bead slurry, 12.5nM protein in buffer and compounds PB and PB-OH at varying
concentrations. After a 30-min pre-incubation, 1 nM [3H]-PB was added. The reactions were incubated for 30min, and luminescence
signals were read. SF3B complexes from HeLa nuclear extracts were immunoprecipitated using anti-SF3B1 antibody. Batch immo-
bilization of anti-SF3B1 antibody (MBL) to anti-mouse PVT SPA scintillation beads (PerkinElmer) was prepared as follows: for every
2.5mg of nuclear extracts, 5mg anti-SF3B1 antibody and 1.5mg of beads were mixed in 150ml PBS. The antibody–bead mixture was
incubated for 30min at RT and centrifuged at 18,000g for 5min. The beads were suspended and added to the prepared nuclear ex-
tracts. The slurry was incubated for 2h at 4C with gentle mixing. The beads were then collected by centrifuging at 18,000g for 5min
and washed twice with PBS+0.1% Triton X-100. After a final centrifugation step, every 1.5mg of beads was suspended with 150ml of
PBS. 100 mL binding reactions were prepared by adding varying concentrations of PB or PB-OH, and after 30min pre-incubation,
2.5nM [3H]-probe was added. The mixture was incubated for 30min, and luminescence signals were read. Prism 6 (GraphPad)
was used for non-linear regression curve fitting of the data.
Affinity purification of B complexes and splicing chase experiments
In vitro assembled spliceosomal B complexes were purified by gradient centrifugation, followed by MS2 affinity-selection using
amylose beads (New England Biolabs) as previously described (Bessonov et al., 2008). Briefly, 32P-labeled MINX containing MS2
aptamers at its 30 was incubated with a 20-fold molar excess of MS2-MBP protein. Standard splicing reactions containing 10 nM
pre-mRNA were incubated at 30C for 6 min and chilled on ice. Splicing complexes were subsequently separated on a linear
10%–30% (v/v) glycerol gradient containing G-150 buffer (20 mM HEPES-KOH, pH 7.9, 150 mM KCl, 1.5 mMMgCl2) by centrifuga-
tion for 16 h at 23000 rpm in a Sorvall Surespin 630 rotor. Complexes in the 45S peak fractions were loaded onto amylose beads
(NEB), and after washing with G-75 buffer (G buffer with 75 mM KCl), bound spliceosomal complexes were eluted with 20 mM
maltose in G-75 buffer. RNA was recovered from the purified complexes, separated on a denaturing polyacrylamide gel and visual-
ized by silver staining (Figure S5A). For in vitro chase experiments, HeLa nuclear extract was treated with micrococcal nuclease (MN)
as described previously (Makarov et al., 2002). Affinity-purified B complexes formed on 32P-labeled MINX-MS2 pre-mRNA were
incubated with splicing buffer alone (60 mM KCl, 3 mM MgCl2, 2 mM ATP, 20 mM creatine phosphate, 20 mM HEPES-KOH,
pH 7.9), or in the presence of 20% (v/v) MN-treated HeLa nuclear extract containing 0 or 6 mM PB or purified B complexes were
pre-incubated with 1.5 or 6 mM PB for 30 min on ice prior to addition of MN-treated nuclear extract. A 10-fold molar excess of un-
labelled MINX-MS2 pre-mRNA was added to prevent the reassembly of snRNPs (that potentially dissociate from the purified com-
plexes) on the radiolabeled pre-mRNA. The reaction was incubated at 30C for 0, 30 or 60 min. RNA was recovered, separated on a
14% denaturing polyacrylamide gel, and visualized with a Typhoon phosphoimager (GE Healthcare) (Figure S6B). The % mRNA
formed was quantified using ImageQuantTL (GE Healthcare) and calculated by dividing the amount of mRNA by the amount of
pre-mRNA, lariat-intermediate and splicing products (Figure S5B).
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QUANTIFICATION AND STATISTICAL ANALYSIS
All statistical analyses were carried out with Prism 6 (GraphPad). For the biochemical (binding and in vitro splicing assay) and viability
assays each concentration was tested in triplicate and each experiment was repeated multiple times (2 times for the biochemical
assays and 3 times for the viability assay). The compound concentrations used for the assay window was estimated such that the
IC50 was near the center of the fitted curve. All the experiments were repeated multiple times (2 times for the biochemical assays
and 3 times for the viability assays). No data were excluded from the analysis. No randomization was required. Clear description
of statistics (central tendency, variation, exact sample size) is included in figure legends.
DATA AND SOFTWARE AVAILABILITY
The accession number for the coordinates reported in this paper is PDB: 6EN4.
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Figure S1. Crystal structure of an engineered human SF3B core in complex with 
pladienolide B (PB).   Related to Figure 1. 
(A) Coomassie-stained SDS-PAGE analysis of an engineered human SF3B core complex, 
reconstituted by co-expression in insect cells, after size-exclusion chromatography. SF3B3 
(lacking residues 1068-1085), SF3B1 (residues 453-1304), PHF5A (residues 1-98), and 
SF3B5 (full-length) appear to be present in stoichiometric amounts. (B) Scintillation 
proximity assays of the human SF3B core in the presence of a tritiated PB derivative ([
3
H]-
PB) and unlabelled PB or PB-OH as competitors. The engineered SF3B core binds [
3
H]-PB 
suggesting that the minimal complex contains an intact PB binding site (IC50 = 130 nM for PB 
and IC50 = 1070 nM for PB-OH). (C) Electron density maps of the PB ligand calculated from 
the refined structure. Residual mFo-DFc (contoured at 3σ) and polder (contoured at 6σ) omit 
maps are displayed next to a 2mFo-DFc map (contoured at 1σ). The PB ligand is depicted as 
orange sticks. (D) Electron density map of SF3B1 at the PB binding site. The 2mFo-DFc map 
(grey mesh, 1σ) is displayed around SF3B1 (light blue) and the PB ligand is shown as orange 
sticks (see also Figure 1B). (E), Electron density map of the SF3B1-PHF5A PB binding 
tunnel. The 2mFo-DFc map (grey mesh, 1σ) is shown around SF3B1 (light blue), PHF5A 
(pink), and PB (orange). Key residues lining the SF3B1-PHF5A tunnel are depicted as sticks. 
(F), (G) Selenium marker sites validate the residue register of the SF3B core structure. 
Selenium sites were identified using SAD log-likelihood gradient maps and are shown as 
yellow spheres. The modeled methionine side chains are shown as sticks. SF3B1, SF3B3, 
SF3B5, and PHF5A are colored as in Figure 1.  
 
Figure S2. Structural rearrangements of the SF3B core complex in the presence of 
pladienolide B (PB). Related to Figure 2. 
(A)  Superposition of the SF3B1 and PHF5A SF3B subunits in the presence and absence of 
the PB ligand. SF3B1 and PHF5A from the PB co-crystal structure are coloured light blue and 
pink, respectively, while the subunits from the apo SF3B core structure (PDB 5IFE) are 
coloured dark purple. The individual HEAT repeats of SF3B1 are labelled H1-H20. PB is 
depicted as sticks and is coloured orange. PHF5A’s Zn atoms are indicated as spheres. (B)  
Superposition of the SF3B3-SF3B5 module of the SF3B core in the presence and absence of 
PB. SF3B3 and SF3B5 subunits are coloured as in Figure 1, while the SF3B3-SF3B5 module 
from the apo structure (PDB 5IFE) is in dark purple. The engineered SF3B3 has a shorter 
insertion loop in the 6th blade of the BPC β-propeller domain as a result of the removal of 
residues 1068-1085. (C), (D) Comparison of SF3B1 and PHF5A crystal structures at the PB 
binding site. The SF3B1 HEAT domain and PHF5A from the apo SF3B core structure (PDB 
5IFE) are depicted as cartoons and are coloured in dark purple. The PB ligand is represented 
as orange sticks. SF3B1 and PHF5A subunits from the PB co-crystal structure are coloured 
light blue and pink, respectively. Key SF3B1 and PHF5A residues lining the PB binding 
tunnel are shown as sticks. SF3B1-K1071, SF3B1-R1074, and SF3B1-R1075 residues from 
the SF3B1-PHF5A tunnel are rearranged to accommodate the ligand (arrows), while PHF5A-
Y36A and PHF5A-R38 residues adopt similar positions in both crystal structures. (E) Cartoon 
representation of SF3B1 and PHF5A subunits from the apo SF3B core crystal structure (PDB 
5IFE) coloured according to the local B-factors (blue-green-red). Note that HEAT repeat H16 
shows higher B factors compared to the neighbouring HEAT repeats of SF3B1. (F) Cartoon 
representation of SF3B1 and PHF5A subunits from the SF3B-PB co-crystal structure 
coloured according to their local B-factors (blue-green-red). The PB ligand (orange spheres) 
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binds SF3B1 in the proximity of the H16 repeat, apparently stabilizing this more dynamic 
region of SF3B1.   
 
Figure S3. Chemical structures of SF3B modulators. Related to Figures 3 and 4. 
(A) Representative compounds belonging to the pladienolide (PB), herboxidiene (GEX1A), 
and spliceostatin (SSA) families of splicing modulators are shown. All compounds share a 
common diene group (light green) which connects two larger moieties, specific for each 
family of modulators. Herboxidienes have in common with pladienolides a similar aliphatic 
arm and with spliceostatins a 6-membered functionalized pyran ring. Chemical groups 
required for the activity of the compounds are highlighted in purple. (B) Structures of PB 
derivatives used in this study.  
 
Figure S4. Structural comparison of the human SF3B-PB co-crystal structure with the 
yeast SF3B core. Related to Figure 5. 
(A)  Three different views of the human SF3B-PB structure superimposed onto the yeast 
SF3B core in the activated spliceosome. Human SF3B subunits are coloured and displayed as 
in Figure 1A. The yeast SF3B core (containing the Hsh155p HEAT domain, Rse1p, Rds3p, 
Ysf3p) is coloured dark purple. PB is depicted as orange spheres. Note that SF3B3, with the 
exception of its flexible BPB domain, SF3B1 H16-H20, PHF5A, and SF3B5 superimpose 
onto the yeast proteins without major clashes. The H1-H15 arch of SF3B1 behaves largely as 
a rigid body with respect to the SF3B1 (H16-H20)-PHF5A-SF3B3 (BPA-BPC)-SF3B5 
module and is arranged differently in the two structures. (B) Superposition of PHF5A onto 
Rds3p as part of the SF3B1 (H16-H20)-PHF5A-SF3B3 (BPA-BPC)-SF3B5 module. Note 
that PHF5A residues located at the PB binding tunnel (Y36, V37, R38) face the same side, but 
adopt different conformations in the two structures. (C) Superposition of SF3B5 onto Ysf3p 
as part of the SF3B1 (H16-H20)-PHF5A-SF3B3 (BPA-BPC)-SF3B5 module. (D) 
Superposition of SF3B1 (H16-H20), SF3B5, and PHF5A onto the yeast SF3B core (dark 
purple) as part of the SF3B1 (H16-H20)-PHF5A-SF3B3 (BPA-BPC)-SF3B5 module. Note 
that the major difference between the two structures results from the different arrangement of 
the SF3B1 H1-H15 arch with respect to the SF3B1 (H16-H20)-PHF5A-SF3B3 (BPA-BPC)-
SF3B5 module. SF3B3 is not shown. (E) Comparison of SF3B1’s intramolecular interfaces 
between consecutive pairs of HEAT repeats in the SF3B-PB and yeast SF3B core structures. 
The largest difference between the two structures was detected at the H15-H16 interface 
(r.m.s.d. = 2.06, 66 Cα). Corroborated by the higher B-factor values (Figure S2F), this reveals 
the location of the hinge region. (F), (G) Structural superpositions of the H15-H17 hinge 
regions of SF3B1 (blue) and Hsh155p (dark grey), shown in two different orientations (left 
and right). PB is omitted for clarity sake and the BS-A is shown as sticks (green). PHF5A and 
the S. cerevisiae orthologue are coloured pink and light grey, respectively. SF3B1 residues 
that belong to the PB-binding site and the equivalent residues from Hsh155p are depicted in 
blue and dark purple, respectively.  
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Figure S5. Addition of PB to purified spliceosomal B complexes has no substantial effect 
on their ability to catalyse pre-mRNA splicing in the presence of MN-treated extract. 
Related to Figure 5. 
(A) RNA composition of the affinity-purified B complexes. RNA was analyzed by denaturing 
PAGE and visualized by staining with silver. B complexes formed on 
32
P-labelled MINX-
MS2 pre-mRNA were affinity purified as described in the Online Methods.  Asterisk, RNA in 
the loading well of the gel. The presence of the U1, U2, U4, U5, and U6 snRNAs confirms 
that spliceosomal B complexes were isolated. (B) Purified B complexes were incubated at 
30°C for the indicated times (0, 30, 60 min) under splicing conditions in the presence of 
buffer alone (lanes 1-3) or micrococcal nuclease-treated HeLa nuclear extract (MNext) (lanes 
4-14). PB (1.5 or 6 µM) was added directly to the purified B complexes, followed by a 30 min 
incubation on ice, prior to performing the chase with MN-treated extract (lanes 6-9) or PB (6 
µM) was added to the MN-treated extract (lanes 10-11). As a control for complete MN-
digestion, no splicing was observed when 
32
P-labelled MINX-MS2 pre-mRNA was incubated 
with MNext (lanes 12-14). RNA was analysed by denaturing PAGE and visualized with a 
Phosphorimager. The positions of the pre-mRNA, splicing intermediates and products are 
indicated on the right. The % mRNA formed (quantitated with a Phosphorimager) is indicated 
below selected lanes. Addition of PB had no substantial effect on the ability of B complexes 
to catalyse splicing after chasing with MNext. This is consistent with the idea that once SF3B 
has adopted a closed conformation, as observed in the B complex, PB no longer can bind and 
inhibit splicing. 
 
Figure S6. Splicing modulators may act as competitive BS antagonists. Related to Figure 
6. 
(A) Summary of the substrates and in vitro splicing assays carried out in the presence of PB or 
PB-OH. The IC50 values were obtained from non-linear regression curve fitting. 
(B) The discriminatory action of splicing modulators towards various 3’SS sequences is a 
consequence of the competition between substrates and modulators for the “open” 
conformation of SF3B1 (see also Figure 5E). Potent modulators, such as PB, exhibit high 
affinity for the “open” conformation of SF3B1, inhibiting the transition to the “closed” 
conformation even for “strong” substrates. Conversely, modulators that display lower 
affinities for the “open” state of SF3B1, such as PB-OH, can inhibit efficiently only “weak” 
substrates. PB is colored in orange, while PB-OH is colored in pink. All the other elements 
are depicted and labeled as in the Figure 5E. 
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4 Discussion and Perspectives 
By combining X-ray crystallography with structural mass spectrometry and biochemistry, the 
work presented here revealed: (i) the overall molecular architecture of the human SF3B core 
complex (SF3B1HEAT-PHF5A-SF3B3-SF3B5, PDB 5IFE), one of the largest building blocks of 
the human spliceosome determined by X-ray crystallography (Cretu et al., 2016); (ii) the 
structural-consequences of SF3B1’s cancer-related mutations (Cretu et al., 2016); (iii) the 
structural basis for the modulatory effects of splicing inhibitors from the pladienolide and 
herboxidiene families (Cretu et al., 2018; unpublished data). Also, our work provides further 
molecular insights into the early events of the splicing cycle and the functional dynamics of SF3B1 
and p14. From a methodology perspective, we have established a pipeline for the routine 
determination of SF3B structures in complex with splicing modulators and, potentially, other 
compounds.  
4.1 Molecular architecture and structural dynamics of the human SF3B complex 
To facilitate crystallization, we have delineated a ~254 kDa core complex composed of the HEAT 
domain of SF3B1 (SF3B1HEAT), SF3B3, SF3B5, and PHF5A and a second module composed of 
SF3B2 and SF3B4. We determined the structure of an initial core complex using experimentally 
estimated phases at a resolution of ~3.1 Å (Cretu et al., 2016). More recently, we obtained crystals 
of an optimized core complex (SF3BΔBPB) diffracting X-rays to a resolution of ~2.8 Å (Table S1). 
Kiyoshi Nagai’s lab has recently solved the crystal structure of the yeast SF3B2-SF3B4 core 
module to a resolution of ~2.7 Å (van Roon et al., 2017). Together with the previously reported 
crystal structure of SF3B6/p14 (Schellenberg et al., 2006) and with the recent cryo-EM structures 
of human spliceosomes (Bertram et al., 2017a; Haselbach et al., 2018; Zhang et al., 2018), this 
provides a near-complete view of human SF3B in structural terms (Figure 4.1).  
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4.1.1 The extended SF3B1’s NTD domain is a protein-protein interaction hub  
SF3B1 comprises an N-terminal extended region (NTD) and a conserved C-terminal HEAT 
domain (Figure 2.9). Owing to its dynamic nature, we could not capture the entire SF3B1NTD in a 
crystal structure, and our structural mass spectrometry data indicate that the N-terminal region of 
SF3B1 does indeed sample an ensemble of conformations in the full-length SF3B complex (Cretu 
et al., 2016). However, our crosslinking experiments suggest that, in the isolated SF3B and the 
purified 17S U2 snRNP particle (Cindy L. Will, personal communication), the p14-interacting 
region (pir) of SF3B1NTD adopts a more defined, central location with respect to SF3B1HEAT (Cretu 
et al., 2016). 
Recent cryo-EM snapshots of the human Bact complex (Haselbach et al., 2018; Zhang et al., 2018) 
revealed several additional folded regions in SF3B1NTD. In the human Bact spliceosomes, residues 
75-129 of SF3B1NTD form a helix-loop-helix domain, as in yeast Hsh155p, and interact with the 
RT and Linker domains of Prp8, and with the RES complex (Haselbach et al., 2018; Zhang et al., 
2018). In contrast to the isolated SF3B complex (Cretu et al., 2016), the pir region is positioned in 
the Bact complex more on the outer rim of SF3B1HEAT and further extends towards Prp8’s RT 
domain and SKIP (Zhang et al., 2018). Thus, during spliceosome assembly, SF3B1NTD, likely, 
restructures upon binding to a newly available set of interacting partners.   
Altogether, the available structural data suggest that the elongated topology of SF3B1NTD is 
intimately linked to the functions of SF3B in splicing. By having an extended conformation, 
SF3B1NTD can access concomitantly multiple interactors and thus, in turn, favor a more complex 
and combinatorial regulation of splicing. Hyperphosphorylation of SF3B1NTD provides an 
additional layer of regulation, potentially coupling pre-mRNA splicing to the chromatin landscape 
and Pol II transcription (Girard et al., 2012; Kfir et al., 2015; Hollander et al., 2016). Overall, this 
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is reminiscent of the highly repetitive C-terminal domain (CTD) of Pol II. Similar to SF3B1NTD, 
Pol II CTD has low sequence complexity, adopts an extended conformation, is posttranslationally 
modified, and serves as a docking platform for a large number of RNA processing factors (Bentley, 
2014; Cass and Berglund, 2006; Harlen and Churchman, 2017). 
4.1.2 SF3B1’s HEAT domain has a unique superhelical conformation  
In the crystal structure of the SF3B core complex (Cretu et al., 2016), the C-terminal domain of 
SF3B1 folds as a right-handed superhelix composed of 20 HEAT repeats (Figure 4.1). The 
difference between our crystal structure (Cretu et al., 2016) and the previous assignment (Golas et 
al., 2003; Wang et al., 1998) can be attributed to the relaxed HEAT sequence motif (Cingolani et 
al., 1999; Conti et al., 2006) which complicates structure predictions from amino acid sequences 
alone. Importantly, recent cryo-EM studies of yeast and human spliceosomes (Rauhut et al., 2016; 
Fica and Nagai, 2017; Shi, 2017) reported the same number of repeats for SF3B1HEAT as in the 
crystal structure of the SF3B core (Cretu et al., 2016). Corroborated by consistent chemical 
crosslinking-mass spectrometry data (Cretu et al., 2016), this confirms the overall topology of the 
HEAT domain observed in the SF3B core and rules out potential artifacts resulting from the used 
expression system and constructs, crystallization conditions or packing in a crystal lattice. 
The sequential arrangement of individual HEAT repeats into a spring-like assembly leads to a 
protein fold which is notable for being flexible and elastic (Grinthal et al., 2010; Kappel et al., 
2010; Monecke et al., 2014; Zachariae and Grubmuller, 2008). As the overall conformation of the 
domain can be readily influenced/induced by interaction with other factors, many different 
topological states were observed for karyopherins or other model HEAT domain proteins (Conti 
et al., 2006; Monecke et al., 2014). As in these model systems, the unique superhelical 
conformation of SF3B1HEAT is, likely, a direct consequence of its multiple contacts with the other 
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SF3B subunits (Figure 4.1). That is, SF3B1HEAT appears to fold on a molecular scaffold composed 
of SF3B3 and SF3B5, while the Zn-finger protein PHF5A resides on the concave side of the 
solenoid and interacts along the diameter with its terminal repeats (Cretu et al., 2016). However, 
in contrast to karyopherins, the human SF3B1HEAT domain is not stable on its own and can be 
obtained in a soluble form only by coexpression with SF3B3, SF3B5, and PHF5A (unpublished 
data, see also Teng et al., 2017). 
The large-scale dynamics of certain HEAT-repeat proteins can be explained by differences in the 
relative stability of interfaces between consecutive repeats. Molecular dynamics simulations 
showed the presence of defined “dynamic hotspots” where the HEAT “spring” can bend/break 
more readily (Kappel et al., 2010; Zachariae and Grubmuller, 2008). Intriguingly, the presence of 
such sites is conveniently exploited by various HEAT binding proteins. For example, by direct 
interactions with two such dynamic regions of importin β, RanGTP enforces a particular 
conformation of the “spring” which is incompatible with cargo binding (Cook et al., 2005; Lee et 
al., 2005; Zachariae and Grubmuller, 2008). Subsequent dissociation of RanGDP leads to a more 
relaxed conformation of the HEAT superhelix, to which various importin cargos bind for shuttling 
into the nucleus (Stewart, 2006; Zachariae and Grubmuller, 2008). Similar to Ran, the PHF5A 
subunit is strategically positioned between the two “arms” of the SF3B1HEAT “clamp”, in close 
proximity to a more dynamic region of SF3B1 – the H15-H16 repeats (Cretu et al., 2016; Cretu et 
al., 2018). Such “dynamic hotspots” may support the large-scale reconfiguration of the SF3B1HEAT 
domain observed in the Bact spliceosome (Fica and Nagai, 2017; Shi, 2017), where the protein 
“clamps down” on the branch helix and exhibits a more “closed” conformation (see also 4.2.3). 
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4.1.3 SF3B1’s HEAT domain and recognition of the branch-site region 
In good agreement with earlier experiments (Dybkov et al., 2006; Gozani et al., 1996; Gozani et 
al., 1998), SF3B1HEAT has the required biophysical properties for RNA binding and interacts with 
RNA in isolation (Cretu et al., 2016; Dybkov et al., 2006). Although we could not obtain crystals 
of the SF3B core in complex with single-stranded intron regions or with U2/BS duplexes, recent 
cryo-EM analyses show that upon stable formation of the pre-catalytic spliceosome (Bertram et 
al., 2017a; Plaschka et al., 2017) and of the later Bact complex (Haselbach et al., 2018; Rauhut et 
Figure 4.1. Molecular architecture of the human SF3B complex – a near-
complete picture.  
A near complete, pseudoatomic model of the human SF3B complex (left panel) is shown next to a 
schematic representation (right panel). The model was generated using the crystal structure of the SF3B 
core complex (SF3B1HEAT-PHF5A-SF3B5-SF3B3) (Cretu et al., 2016), the crystal structure of 
p14/SF3B6 in complex with the pir region of SF3B1 (Schellenberg et al., 2006), and the cryo-EM 
structure of the yeast SF3B2-SF3B4 core module from the B complex (Plaschka et al., 2017; van Roon 
et al., 2017). The more flexible p14/SF3B6 subunit was modeled based on chemical crosslinking data 
(crosslinked residues are depicted as blue spheres) (Cretu et al., 2016).  
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al., 2016; Yan et al., 2016) the terminal repeats of SF3B1HEAT act as a “molecular pincer” to 
“embrace” the minor and major grooves of the branch helix. Most importantly, the conserved BS 
adenosine, bulged out from the branch helix, is positioned in a pocket lined by the PHF5A subunit 
and the H15-H17 repeats of SF3B1HEAT, where it is “sequestered” prior to the first step of splicing 
(Rauhut et al., 2016; Warkocki et al., 2009; Yan et al., 2016).  
Our mass spectrometry analyses of crosslinked peptide-RNA conjugates (Cretu et al., 2016) and 
earlier UV crosslinking experiments in nuclear extracts (Gozani et al., 1996; Gozani et al., 1998) 
indicate that SF3B1HEAT interacts with several BS proximal regions as part of a composite RNA 
binding platform. Indeed, in the Bact spliceosomes, the uridine-rich region downstream of the BS 
(i.e., PPT) passes through the center of the HEAT superhelix, contacting both SF3B1 and PHF5A 
residues, and then docks on a conserved basic surface patch defined by the H4-H7 repeats (see 
also 5.1.5). Consistent with reported UV crosslinks in yeast (Schneider et al., 2015), the intron 
regions located upstream of the BS bind to the SF3B2-SF3B4 core module (yeast Cus1 (290-
368)p-Hsh49p) (Plaschka et al., 2017; van Roon et al., 2017). The DUF382 domain of SF3B2, 
which we could not capture in a crystal structure, “folds” on the convex side of SF3B1HEAT 
superhelix in an “extended conformation” (Plaschka et al., 2017) (Figure 4.1). By interacting with 
the H16-H20 repeats of SF3B1HEAT, DUF382 serves as a bridge between the SF3B core complex 
and the SF3B2-SF3B4 core module (Plaschka et al., 2017; Yan et al., 2016), as we recently 
proposed based on chemical-crosslinking experiments (Cretu et al., 2016).   
Overall, our published crystal structure and structural mass spectrometry data (Cretu et al., 2016) 
support the central role of SF3B1HEAT in recognition of the BS and its flanking regions as part of 
a multipartite RNA binding platform. Recent cryo-EM structures of yeast and human spliceosomes 
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provide unprecedented details of this essential molecular recognition event which we failed to 
obtain using a more reductionist approach, typical for X-ray crystallography.  
4.1.4 Is SF3B6/p14 a branch-site interacting protein? 
Biochemical and NMR investigations (Perea et al., 2016; Spadaccini et al., 2006) showed that p14 
alone or in complex with the pir motif of SF3B1NTD lacks the molecular features required for 
specific recognition of the branch helix or the BS-A. This partly explains why in the human Bact 
structures (Haselbach et al., 2018; Zhang et al., 2018), p14 is located on a diametrically opposed 
site (~60 Å) from the BS-A, on the outer rim of the SF3B1HEAT domain, and close to the H1-H2 
repeats. The bulged nucleobase, instead, is recognized by a different ~14 kDa SF3B subunit, 
PHF5A, which frames the BS-A pocket together with SF3B1’s H15-H17 repeats. Importantly, the 
BS-A is recognized in a similar manner in yeast spliceosomes which lack p14 (Rauhut et al., 2016; 
Yan et al., 2016).  
In the isolated SF3B (Cretu et al., 2016) and the 17S U2 snRNP (Cindy L. Will, personal 
communication), despite being somewhat dynamic, p14 samples a more central location within the 
circular perimeter of SF3B1HEAT (Figure 4.1). This suggests that, at the earliest stages of 
spliceosome assembly, p14 might as well participate in the initial docking of the U2 snRNP to the 
BS, for instance, by temporarily replacing SF1 (Figure 2.7). In this case, its recruitment to the BS 
may be facilitated by the established contacts between SF3B1NTD and U2AF2 bound to the PPT 
region of intron (Gozani et al., 1998; Sickmier et al., 2006; Spadaccini et al., 2006) and by a 
possible topological bend of the 3’SS (Gupta et al., 2011; Kent et al., 2003) (Figure 2.7). Although 
p14 was previously crystallized in complex with an adenine base (Schellenberg et al., 2011), it is 
more plausible that the BS-p14 interactions are of electrostatic nature (Perea et al., 2016; 
Spadaccini et al., 2006) and specific contacts between the bulged adenosine and p14 are not present 
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in fully assembled spliceosomes. Instead, the overall surface charge of the SF3B1HEAT-p14 
platform may “guide” the BS region towards the U2 snRNA (Cretu et al., 2016; Perea et al., 2016). 
However, upon the ATP-dependent formation of a stable U2/BS duplex, during pre-spliceosome 
assembly (Query et al., 1996), the BS-A will, likely, be accommodated in the PHF5A-SF3B1 
pocket, as in the EM structures of the later B complex (Bertram et al., 2017a; Plaschka et al., 2017). 
These structural data are in apparent contradiction with previous crosslinking studies, reporting on 
the direct interaction of p14, and not PHF5A, with the BS-A in the A, B, and C complexes 
(MacMillan et al., 1994; Query et al., 1996; Will et al., 2001). It is possible, however, that the ~14 
kDa protein directly crosslinked to the BS-A in spliceosomes was, in fact, PHF5A and that the 
different assignment is due to the comigration of these proteins on denaturing gels (Query et al., 
1996; Will et al., 2001). Future cryo-EM structural studies of earlier human spliceosomes (i.e., E 
and A complexes) may provide a clearer view of the relative contributions of p14 to BS 
recognition. 
4.1.5 SF3B3 – a multipurpose molecular scaffold 
Human SF3B3 structure (Cretu et al., 2016), and of its related orthologs (Cretu et al., 2016; Rauhut 
et al., 2016; Yan et al., 2016), strikingly resembles that of DDB1 (DNA damage-binding protein 
1), a multifunctional protein scaffold involved in the regulation of many cellular processes, such 
as DNA repair, DNA replication and transcription (Jackson and Xiong, 2009; Lee and Zhou, 2007; 
Scrima et al., 2011) (Figure 4.2). As part of the larger Cullin4 RING finger ligase (CRL4) 
complexes, DDB1 serves as an adaptor for specific substrate receptors while recruiting 
concomitantly the E3 ligase module to the substrate (Angers et al., 2006; Fischer et al., 2011). 
DDB1 structure consists of three interspersed WD40-like β-propellers, followed by an all-helical 
domain (Angers et al., 2006; Li et al., 2006). As in the case of DDB1, SF3B3’s BPA and BPC 
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domains frame a deep clam-shaped cavity with the top surfaces of the β-propellers facing each 
other (Cretu et al., 2016). SF3B3’s alpha helical CTD domain folds back and reinforces the double 
β-propeller fold by making extensive contacts with both BPA and BPC (Cretu et al., 2016). 
Overall, this results in a rigid module that stably accommodates the SF3B5 subunit, folded as three 
alpha helices, and the C-terminal region of SF3B1 while interacting, at the same time, with the 
“arms” of SF3B1HEAT (Cretu et al., 2016). 
Similar to DDB1 structures, SF3B3’s BPB domain is more flexible and projects outwards making 
no contacts with the other SF3B subunits (Cretu et al., 2016) (Figure 4.2). The relative mobility 
of SF3B3’s BPB domain indicates that the β-propeller may sample for different splicing factors 
interacting with SF3B and may even contribute to its recruitment to the spliceosome as part of the 
U2 snRNP. Indeed, in the B and Bact complexes, the BPB domain of SF3B3 is rearranged compared 
to the crystal structure (Cretu et al., 2016; Rauhut et al., 2016; Yan et al., 2016) and interacts with 
the Brr2 RNA helicase, a core resident of the U4/U6.U5 tri-snRNP. Thus, the BPB domain may 
serve as an initial docking site for the tri-snRNP upon its association with the pre-spliceosome 
(Bertram et al., 2017a; Plaschka et al., 2017) (Figure 2.6). The structural mobility of SF3B3’s 
BPB domain, which is, likely, of Brownian nature, may increase the capture radius of the complex 
and thus promote the more efficient recruitment of the tri-snRNP. 
The majority of DDB1 substrate receptors, such as DDB2, interact with the BPA-BPC cleft via a 
short alpha-helical motif (i.e., the “DDB-box”) (Fukumoto et al., 2008; Lee and Zhou, 2007). This 
particular motif is not present in SF3B5, and the SF3B subunit interacts tightly with BPA and not 
with BPC as DDB1 ligands do (Li et al., 2006; Scrima et al., 2011). However, the overall fold of 
SF3B5 is reminiscent of the N-terminal helical region of DDB2 and related receptors, whose 
structures also comprise two antiparallel α-helices linked by a short turn (Fischer et al., 2011; 
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Scrima et al., 2011). By analogy, this indicates that SF3B5 acts as a DDB2-like “substrate 
receptor”, whereas SF3B3 is, functionally, the “adaptor” (Figure 4.2). In this respect, SF3B1-
PHF5A can be viewed as the specific splicing “substrate” of the SF3B3-SF3B5 adaptor-receptor 
complex. Intriguingly, SF3B3 is also a stable component of the human transcriptional coactivator 
STAGA (Martinez et al., 2001) and TFTC (Brand et al., 2001) complexes. Recently, SF3B5 was 
observed in the related SAGA complex in Drosophila (Stegeman et al., 2016), suggesting that the 
entire SF3B3-SF3B5 module might be present in these chromatin-modifying complexes. SF3B3 
also interacts directly with several cullins and is, likely, a DDB1-like component of different CRLs 
(Menon et al., 2008). We, therefore, propose that SF3B3 serves as a multipurpose molecular 
scaffold participating in different cellular pathways as part of larger, multi-subunit assemblies. 
Interestingly, in the recent cryo-EM structure of the polymerase module of yeast CPF (cleavage 
and polyadenylation factor), the Cft1 subunit (human CPSF160) adopts a similar fold as SF3B3 
and DDB1, and accommodates in the largely similar BPA-BPC cleft its substrate “receptor” 
subunit Pfs2 (human WDR33) (Casanal et al., 2017). Molecular recognition of Pfs2 by Cft1 also 
involves a small alpha-helical region (Figure 4.2). The Yth1 subunit (human CPSF30) contacts 
the Cft1 BPC domain and Pfs2, and comprises two zinc finger domains assembled in a fold which 
is reminiscent of PHF5A (Casanal et al., 2017). 
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The similar organization of SF3B, CPF polymerase, and CRL4A are indicative of the modular 
architecture of these large assemblies. It also shows how a versatile protein fold, the triple β-
propeller fold of SF3B3/DDB1/Cft1, can be efficiently reused as the central building “brick” of 
more complex molecular “legos”. 
4.1.6 Structural insights into SF3B1’s cancer-related mutations   
The crystal structure of the human SF3B core complex shows that most of the cancer-relevant 
mutations of SF3B1, including the common substitution K700E, map to the H4-H7 repeats of the 
HEAT superhelix in a conserved basic patch (Cretu et al., 2016) (Figure 4.3). Thus, substitution 
of these residues may target an important interaction interface between SF3B1 and pre-mRNA. 
Alternatively, mutations at this site may alter the direct contacts between SF3B1 and other splicing 
factors or trigger a structural reorganization of the entire SF3B complex. We could not detect direct 
UV-crosslinks between these SF3B1 residues and RNA (Cretu et al., 2016) nor we could observe 
a significant change in SF3B1’s RNA crosslinking pattern in the presence of K700E (unpublished 
data). In addition, the affinity of SF3BK700E towards a canonical intron sequence is, apparently, 
unchanged when compared to the wild-type complex (Cretu et al., 2016). Moreover, judging from 
the chemical-crosslinking patterns, the recombinant SF3B complex carrying the K700E hotspot 
mutation (Cretu et al., 2016) has a similar structural organization as the wild-type complex. 
Although the UHM domain of U2AF2 is located close to SF3B1’s hotspot region (Cretu et al., 
2016), the K700E substitution does not affect the direct interaction of SF3B1 with U2AF2. 
Figure 4.2. The similar structural organization of SF3B, CRL4A, and yeast CPF. 
The SF3B core complex (A, this work), the CRL4A E3 ligase (B, PDB 4A0K), and the polymerase module 
of yeast CPF (C, PDB 6EOJ) were structurally aligned using the SF3B3 subunit as a reference (light brown). 
SF3B5, DDB2, and Pfs2 are colored in green. SF3B1 and CUL4A are colored in light blue, while PHF5A 
and Yth1 are shown in light pink. Note that the corresponding BPA and BPC domains of SF3B3, DDB1, 
and Cft1 form a clam-shaped cleft, where SF3B5, DDB2, and Pfs2 bind, respectively.  
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Altogether, these experiments suggest that the etiology of SF3B1-driven cancers is rather complex 
and cannot be fully captured by structural and biochemical analyses of SF3B in isolation.     
Importantly, in the cryo-EM structure of the yeast Bact complex (Rauhut et al., 2016; Yan et al., 
2016), the H4-H7 repeats of SF3B1 are in contact with the uridine-rich region of the intron which 
follows downstream of the BS (Figure 4.3). Structural superposition of human SF3B1 (Cretu et 
al., 2016; Haselbach et al., 2018) onto yeast Hsh155p shows that the K700 hotspot residue does 
interact with the phosphodiester backbone (Figure 4.3). Intriguingly, this contact, likely, induces 
a ~90o “kink” in intron’s structure, while the neighboring Q699 residue stabilizes the flipped-out 
uridine nucleobase via a hydrogen bond (Figure 4.3). It is unclear why such a reorientation of the 
intron is required or whether the equivalent region of the PPT has a similar structure in the human 
spliceosome. Several other SF3B1 residues mutated in cancers (e.g., E622, R625, H662, K666) 
map mainly on the concave side of SF3B1HEAT, facing the uridine-rich region of the intron (Figure 
4.3). These residues bind either directly to the phosphodiester backbone, before the ~90o 
reorientation, or are involved in hydrogen-bonding interactions with neighboring SF3B1 residues 
(Figure 4.3). Altogether, the multiple contacts established by the cancer hotspot residues of 
SF3B1HEAT appear to stabilize the intron structure downstream of the BS. We, therefore, 
hypothesize that SF3B1’s missense substitutions, including the common K700E substitution, may 
interfere with the proper folding of the intron upon binding to the H4-H7 repeats (see also Jenkins 
and Kielkopf, 2017). In turn, this may translate into a weak and/or suboptimal interaction of the 
PPT with SF3B1 and/or U2AF2 (Cretu et al., 2016; Jenkins and Kielkopf, 2017). As the “cryptic” 
BSs can base-pair more efficiently with the U2 snRNA (Alsafadi et al., 2016; Darman et al., 2015), 
their selection under a mutant background may compensate for the altered interaction of the PPT 
(or equivalent sequences) with SF3B1. 
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Interestingly, in the recent cryo-EM structure of the endogenous yeast P complex (Liu et al., 2017), 
the uridine-rich region between the BS and the 3’SS folds into a stem-like structure. As in this late 
stage spliceosome, SF3B1/Hsh155p is no longer present it is possible that, at the earlier stages, the 
HEAT domain of SF3B1 together with U2AF2 may act as “RNA chaperones” to prevent the 
premature formation of this structural element. In the end, it is this plausible function of SF3B1 
that might be comprised in cancer cells (Kesarwani et al., 2017).  
Alternatively, the SF3B1 hotspot mutations may affect the conformation of the HEAT superhelix 
locally and, thus, prevent, indirectly, its interaction with the PPT. In the yeast and human Bact 
structures, the RES complex and the Prp2 RNA helicase are positioned at the 3’ end of the intron, 
close to SF3B1’s HEAT repeats mutated in cancers (Rauhut et al., 2016; Yan et al., 2016). Thus, 
changes in the conformation of SF3B1HEAT could lead to an altered interaction with these splicing 
complexes and, potentially, with earlier factors, such as U2AF2 (Cretu et al., 2016) and/or the 
Prp5/DDX46 RNA helicase (Carrocci et al., 2017; Tang et al., 2016). Finally, all the scenarios 
mentioned above could be valid and, in fact, the alternative BS selection in cancers may result 
from changes in intron’s secondary structure, SF3B1’s conformation, and SF3B1’s interactome.   
SF3B1’s hotspot mutations induce global changes in cell’s transcriptome with the expression 
levels of many genes being reduced/altered due to noncanonical splicing, a phenomenon denoted 
as “spliceosome sickness” (Alsafadi et al., 2016; Darman et al., 2015). However, it is possible that 
the aberrant splicing of certain pre-mRNAs may drive the disease or influence its outcomes. 
Interestingly, SF3B1 hotspot mutations have the highest incidence in RARS (refractory anemia 
with ring sideroblasts, ~80-90%) of all MDS subtypes (Papaemmanuil et al., 2011). A hallmark of 
this disease is the presence of characteristic erythroblasts bearing iron-overloaded mitochondria 
(i.e., ring sideroblasts) (Cazzola et al., 2003). 
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Figure 4.3. SF3B1’s recurrent cancer mutations map to a conserved, intron 
binding site. 
(A) Recurrent mutations in human SF3B1 cluster at the H4-H7 repeats (Cretu et al., 2016). Left, SF3B1 
residues frequently mutated in hematopoietic malignancies and uveal melanoma are shown as spheres and 
colored in orange. SF3B1 and PHF5A are colored in light blue and light pink, respectively. Right, surface 
charge distribution of SF3B1-PHF5A (±7 kT/e, blue: positive, red: negative). SF3B1 hotspot residues from 
the H4-H7 repeats map to a basic surface patch. (B) Left, the structure of human SF3B1 and PHF5A (Cretu 
et al., 2016; Haselbach et al., 2018) bound to the 3’ end of the intron. SF3B1 (light blue) and PHF5A (light 
pink) were modeled based on the structures of the yeast orthologs, Hsh155p and Rds3p, respectively, as 
observed in the Bact complex (PDB 5GM6). The intron is depicted in dark gray, whereas the U2 snRNA is 
colored in teal. SF3B1 residues are shown as orange spheres. The branch-site adenosine (BS-A) is colored 
in green and represented as spheres. Right, SF3B1 residues mutated in cancers, likely, interact with the 
uridine-rich region of the intron (equivalent to the PPT), downstream of the branch-site.  
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Interestingly, the ABCB7 gene, which encodes an iron transporter, is downregulated in RARS due 
to mutant SF3B1-dependent aberrant splicing (Darman et al., 2015; Dolatshad et al., 2016). In this 
example, the disease phenotype correlates well with a more targeted effect of SF3B1 mutations. 
However, further functional studies will be needed to understand better the relationship between 
SF3B1 mutations, aberrant splicing, and the pathophysiology of other related cancers. 
  
4.2 Molecular insights into splicing modulation by antitumor SF3B inhibitors  
Pladienolides, as well as the related spliceostatins, sudemycins, and herboxidiene, target the SF3B 
complex (Hasegawa et al., 2011; Kaida et al., 2007; Kotake et al., 2007) and interfere with the 
stable binding of the U2 snRNP to the BS region of the intron (Corrionero et al., 2011; Folco et 
al., 2011). Here, we determined crystal structures of SF3B in complex with different pladienolides 
and herboxidiene. Our structures show that these small-molecule compounds share a common 
binding site on SF3B. The modulator binding tunnel exists in the “open” conformation of the 
complex and is defined by the H15-H17 repeats of SF3B1 and several invariant residues of 
PHF5A. Our comparative structural analyses suggest that pladienolides and herboxidiene prevent 
a conformational change in SF3B1 which is required for the stable recognition of the branch helix 
and of the BS-A.  
4.2.1 A pipeline for structure-based discovery of next-generation splicing modulators 
Structure determination of large and multimeric complexes by X-ray crystallography is typically 
challenging and requires extensive engineering of the protein constructs, optimization of the 
crystallization conditions and data collection strategies (Bunker, 2016; Hoelz et al., 2016; McGinty 
and Tan, 2015). Generally, a robust high-throughput pipeline for drug discovery relies on the 
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ability to obtain the macromolecule of interest in significant amounts, to grow high-quality crystals 
which diffract routinely X-rays to high resolution, and to trivially solve the phase problem (i.e., by 
molecular replacement) (Blundell et al., 2002; Jubb et al., 2012). 
 In our long-standing efforts to determine structures of SF3B in complex with splicing modulators, 
we have systematically optimized: (i) the heterologous overexpression of the entire complex and 
various core complexes in insect cells (Cretu et al., 2016); (ii) the structural homogeneity of the 
used protein constructs, by removing disordered regions and/or flexible domains, while preserving 
intact the drug binding pocket (Cretu et al., 2018, unpublished data); (iii) the crystallization and 
cryoprotection procedures (Cretu et al., 2016; Cretu et al., 2018; unpublished data). The result is 
a crystal-to-structure pipeline (unpublished data) which we used, as a proof of principle, to solve 
structures of SF3B in complex with pladienolide and herboxidiene modulators at resolutions 
enabling an unambiguous placement of the target ligand. In its current form, our pipeline can be 
further applied to determine crystal structures of SF3B in complex with other families of 
modulators (such as spliceostatins, meayamycin, thailanstatins or sudemycins). Moreover, our 
approach can be adapted for different serial crystallography routines that are becoming 
increasingly popular with the advent of new microfocused beamlines and of free-electron lasers 
(Erlanson et al., 2016; Schlichting, 2015). In addition, we think that our pipeline may support 
ongoing drug discovery efforts of novel compounds targeting SF3B using fragment-based 
methodologies (Erlanson et al., 2016; Murray et al., 2012). 
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4.2.2 Revisiting the common pharmacophore hypothesis 
In our crystal structures, pladienolides (PB, E7107, H3B-8800) and herboxidiene (GEX1A) bind 
to an “hourglass-shaped tunnel” located at the interface between SF3B1’s H15-H17 repeats and 
PHF5A. Importantly, the small-molecules compounds are accommodated in the tunnel as such that 
the ring group (i.e., macrolide or pyran) resides in the top “funnel”, facing SF3B3, while the 
“kinked” aliphatic chain is situated in the bottom “funnel”, projecting towards SF3B1 (Figure 
4.4). The invariant diene moiety is positioned at the “neck” region of the tunnel, where it adopts 
similar poses in all structures, except H3B-8800 (Cretu et al., 2018; unpublished data). Notably, 
the diene group is involved in π-π and, likely, cation-π interactions with PHF5A-Y36 and SF3B1-
R1074 residues, respectively, whose mutations affect binding of modulators to the complex (Cretu 
et al., 2018; Teng et al., 2017) and result in drug resistance in cells (Cretu et al., 2018; Teng et al., 
2017). In good agreement with the proposed pharmacophore model (Lagisetti et al., 2008; Lagisetti 
et al., 2014), this indicates that the diene group represents an essential molecular feature of 
pladienolides and herboxidiene (Figure 4.4). 
Conversely, our co-crystal structures do not confirm the general importance of the other chemical 
groups from the proposed pharmacophore model (Lagisetti et al., 2008; Lagisetti et al., 2014) 
(Figure 4.5). The C7 oxycarbonyl group, attached to the macrolide ring of pladienolides, does 
form a crucial hydrogen bond with the backbone amide of PHF5A-R38 (Cretu et al., 2018) (Figure 
4.5). However, a similar interaction is not observed in the case of herboxidiene. Instead, the 
carboxyl group of the pyran core (C3) is involved in a polar contact with the SF3B1-K1071 
residue, on the opposed side of the SF3B1-PHF5A tunnel (Figure 4.5). Moreover, in all structures, 
the epoxide group is exposed to the solvent and appears to contribute very little to the overall 
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recognition (Cretu et al., 2018; unpublished data), suggesting that its replacement with 
cyclopropane could be well tolerated (Villa et al., 2013).  
When compared to pladienolides and herboxidiene, spliceostatins and the related compounds share 
a common diene group (Figure 2.11). However, the chemistry of the other moieties is significantly 
different as such that structural docking is not reliable. Although spliceostatins/sudemycins share 
a common binding site with pladienolides/herboxidiene (Effenberger et al., 2016; Teng et al., 
2017), these compounds may still adopt distinct poses in the SF3B1-PHF5A tunnel or even use 
different principles of molecular recognition. 
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The overall topology and rich chemistry of the SF3B1-PHF5A tunnel suggest further strategies for 
drug design and optimization. Derivatization of the pladienolide macrocycle at C7 with an N-
cycloheptyl-piperazine (CyPip) group in E7107 is well tolerated by the binding site (Figures 4.4 
and 4.5). Therefore, relatively large groups can be grafted at C7 without significant effects on 
macrolide’s binding to the SF3B1-PHF5A tunnel (see also Kotake et al., 2007).  The bulky moiety 
of E7107 is accommodated by the newly established interactions with PHF5A-R38, SF3B1-
Y1157, and SF3B1-E1121 which form an extended pocket and sandwich the piperazine group 
(Figures 4.4 and 4.5). The cycloheptyl group of CyPip does not appear to interact with SF3B and 
is, likely, flexible (Figures 4.4 and 4.5). Our structure, thus, explains why its removal in H3B-
8800 does not change the orientation and recognition of the piperazine group drastically.  
 Replacement of the entire aliphatic arm of E7107 with a pyridine (Pyr) ring in H3B-8800 results 
in the decrease in the affinity and potency of the compound (Seiler et al., 2018) (Figure 4.4). 
Strikingly, our crystal structure shows that the significant change in the ligand structure affects the 
orientation of the diene moiety, but not of the macrolide group; the macrolide core of H3B-8800 
adopts a largely similar pose as in the case of the parent compound (i.e., E7107). This indicates 
that pladienolides and, possibly, herboxidiene bind SF3B1-PHF5A in a directional manner, 
primarily defined by the shape complementarity between the macrolide/pyran group and the 
tunnel. Therefore, it is likely that swapping the aliphatic chain for a pyridine ring in herboxidiene 
Figure 4.4. Accommodation of splicing modulators by SF3B. 
Side-by-side comparison of different pladienolides and herboxidiene bound to the SF3B1-PHF5A tunnel. 
The structural alignment was carried out using the PB (orange) co-crystal structure as a reference. 
Herboxidiene (HB) is colored in teal and shown in stick representation. The lead pladienolides H3B-8800 
and E7107 are colored in magenta and brown, respectively. SF3B1’s side of the tunnel is depicted as a 
molecular surface (light blue). For the sake of clarity, only the PHF5A residues which contact the splicing 
modulators are depicted (sticks, colored in pink). MePip represents the N-methyl-piperazine group of H3B-
8800, Pyr – the pyridine group of H3B-8800, and CyPip – the N-cycloheptyl-piperazine group of E7107. 
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will not abolish entirely its binding to the SF3B tunnel. With its simplified chemistry, the 
herboxidiene-H3B-8000 hybrid, where the pladienolide macrocycle is replaced by a functionalized 
pyran ring, could be more stable in aqueous solutions and more amenable to industrial scale 
synthesis.   
4.2.3 Splicing modulators binding site reveals a conformational switch in SF3B1 
The discrete conformational transitions of SF3B have been linked to the binding and unloading of 
the branch helix during splicing catalysis (Golas et al., 2005; Hilliker et al., 2007; Rauhut et al., 
2016). Earlier low-resolution EM analyses of the isolated SF3B (Golas et al., 2003) and of the 
U11/U12 di-snRNP particle (Golas et al., 2005) provided the first indications that the HEAT 
superhelix of SF3B1 might undergo a structural rearrangement, by way of a hinge region, during 
spliceosome’s assembly cycle. 
Our crystal structure of the SF3B core complex (Cretu et al., 2016) and recent cryo-EM structures 
of spliceosomal complexes (Fica and Nagai, 2017; Shi, 2017) showed that indeed SF3B1 has at 
least two defined conformational states. In the isolated complex, SF3B1 folds onto the SF3B3-
SF3B5 protein scaffold in an “open” conformation with PHF5A positioned between the N-terminal 
H2-H3 and the C-terminal H15-H18 HEAT repeats (Cretu et al., 2016). However, a more “closed” 
state of SF3B1 was detected in the presence of a stably bound branch helix. In this conformation 
of the protein, the distance between the terminal HEAT repeats is reduced to ~18 Å, and PHF5A 
is repositioned with respect to the N-terminus of SF3B1 (Rauhut et al., 2016; Yan et al., 2016). As 
the branch helix makes extensive contacts with opposed HEAT repeats of SF3B1 (H1 and H15-
H19), the bulged BS adenosine is accommodated in a protein pocket formed by SF3B1’s H15-
H17 repeats and PHF5A (Rauhut et al., 2016; Yan et al., 2016) (Figure 4.3B). 
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Our follow-up structures of SF3B bound to different splicing modulators advance a more detailed 
understanding of the structural dynamics of SF3B1. The co-crystal structures of SF3B in complex 
with different pladienolides and herboxidiene (Cretu et al., 2018, unpublished data) show that the 
small molecules are bound to the “open” state of SF3B1 in a conserved tunnel formed between the 
H15-H17 region and PHF5A (Figure 4.4). In contrast, the BS-A pocket, observed in the presence 
of the branch helix, lacks important structural features required for splicing modulators binding 
(Cretu et al., 2018) (see also 5.2.4). Thus, the BS-A and the SF3B modulators bind to mutually 
exclusive pockets, available in the “closed” and “open” SF3B1 conformation, respectively. 
Importantly, our comparisons between the “open” conformation, observed in the presence of 
modulators, and the “closed” state of SF3B1 indicate that the large conformational difference can 
be explained by the presence of a hinge located in the H15-H16 region of SF3B1, where both 
splicing modulators and the BS-A bind (Cretu et al., 2018). Thus, the transition from the “open” 
to the “closed” conformation of SF3B1, likely, entails a ~23o rotation and ~17o lateral translation 
of the H15 HEAT repeat over the H15-H16 hinge which leads, in the end, to the large-scale 
movement of the entire H1-H15 arch of SF3B1 (Cretu et al., 2018).  
Figure 4.5. Molecular recognition of splicing modulators: differences and 
similarities.  
(A) Schematic depiction of the contacts between the SF3B1-PHF5A tunnel and pladienolide B 
(PB). Polar contacts are colored in green and represented as dashed lines, whereas the 
hydrophobic and weak polar interactions are depicted as semicircles and colored in gray. (B) 
Binding of different pladienolides and herboxidiene to the SF3B1-PHF5A tunnel. SF3B1 (light 
blue) and PHF5A (light pink) residues, framing the binding tunnel, are shown as sticks. PB, H3B-
8800, E7107, and herboxidiene (HB) are depicted as in Fig. 4.4. Representative hydrophobic and 
weak polar interactions between PHF5A-Y36 and the splicing modulators are shown as dashed 
gray lines. For the sake of simplicity, all the other hydrophobic/weak interactions are not 
depicted. The polar contacts between the splicing modulators and the SF3B1-PHF5A tunnel are 
indicated as dashed lines, colored in green. Note that in all pladienolides, the C7 oxycarbonyl 
group of the macrolide core forms a hydrogen bond with the PHF5A-R38 backbone amide. 
However, the C3 carboxyl group of HB establishes a polar contact with SF3B1-K1071. 
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4.2.4 Novel structural insights into spliceosome assembly 
The precise order of events leading to a stable pre-spliceosome (A complex) is not entirely known. 
Accurate biochemical and structural investigations were hampered by the fast assembly kinetics 
and the relative instability of the assembly intermediates (Das et al., 2000). This might explain a 
certain ambiguity in interpreting the relative effects of splicing modulators on spliceosome 
assembly in vitro. Reed lab reported that the pladienolide D derivative E7107 prevents an “ATP-
dependent conformational change in the U2 snRNP” which is required for stable binding of U2 to 
the BS region (Folco et al., 2011). In their assay, the U2 snRNP complexes pre-treated with ATP 
were resistant to E7107 and could stably bind a BS oligonucleotide (Folco et al., 2011). More 
recently, Seiler et al. showed that a similar resistance to E7107 can be artificially induced by 
mutations in the SF3B1-PHF5A tunnel which inhibit splicing modulators binding (Seiler et al., 
2018). Valcarcel lab and Jurica lab, however, showed that spliceostatin A and pladienolide B 
destabilize the A complex assembly by disrupting critical interactions between SF3B1 and the 
intron at the BS, even in nuclear extracts pre-incubated with ATP (Corrionero et al., 2011; 
Effenberger et al., 2016). Importantly, none of these results can be convincingly explained by 
simple binding of the small molecule compounds to SF3B1 (Effenberger et al., 2016). 
In our model (Figure 4.6), derived from structural analyses, we show that pladienolides and related 
splicing modulators interfere/prevent a conformational change in SF3B1, required for branch helix 
binding and stabilization/formation (Cretu et al., 2018). We, therefore, propose that the very same 
“open” conformation of SF3B1 is also present in the A-like complexes stalled with SF3B 
modulators and in the isolated U2 snRNP and U11/U12 di-snRNP. It is tempting to speculate that 
this early A-like spliceosome may, in fact, represent a novel splicing complex which follows 
immediately after the E complex, also known as the E* complex (Champion-Arnaud et al., 1995). 
4 | Discussion and Perspectives 
 
126 
 
In this splicing complex, SF1/mBBP might have already been displaced from the BS, explaining 
the ATP-dependency (Champion-Arnaud et al., 1995; Corrionero et al., 2011; Effenberger et al., 
2016), and, as a result, the U2 snRNP is more stably bound, compared to the E complex (Das et 
al., 2000). In part, this is due to the strong interactions established between SF3B1NTD and U2AF2 
(Cass and Berglund, 2006; Cretu et al., 2016; Thickman et al., 2006). However, as SF3B1 is 
trapped in an “open” state, the branch helix cannot stably anneal, as its formation requires a 
“closed” conformation of SF3B1 (Plaschka et al., 2017; Rauhut et al., 2016; Yan et al., 2016). 
Thus, the overall conformation of the U2 snRNA and the orientation of other BS-interacting 
factors, such as SF3A2, might be altered in the A-like complex versus a stable pre-spliceosome 
(Haselbach et al., 2018; Plaschka et al., 2017). Altogether, this would result in a spliceosome 
complex to which the U4/U6.U5 tri-snRNP cannot be recruited in a productive manner, thus 
explaining the stalled splicing assembly pathway.  
Intriguingly, in the yeast B complex, the primary interfaces between the U2 snRNP and the tri-
snRNP involve SF3B proteins: SF3B1’s (yeast Hsh155p) H11-H13 repeats contact the N-terminal 
region of Prp3, while SF3B3’s BPB domain (yeast Rse1p) and SF3B2 (yeast Cus1p) interact with 
the Brr2 RNA helicase of the tri-snRNP (Plaschka et al., 2017). At the same time, the U2 snRNA 
base-pairs with U6 snRNA to form the U2/U6 helix II (Plaschka et al., 2017). Thus, it is possible 
that the conformational change in SF3B1, upon the stable formation of the branch helix, “opens 
up” the U2 snRNP for the tri-snRNP binding. In this respect, the conformational switch in SF3B1 
may serve as a checkpoint to ensure that the tri-snRNP is only recruited after the branch helix has 
stably formed. Current data from us (Cretu et al., 2018) and from other labs (Effenberger et al., 
2016; Roybal and Jurica, 2010) suggest that this functional checkpoint in the spliceosome 
assembly is targeted by SF3B modulators. 
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 Alternatively, the labile A-like spliceosome formed in the presence of SF3B modulators may 
represent a “dead-end” complex and not a splicing intermediate. However, this scenario is less 
likely to occur, given the reversibility of splicing inhibition in the presence of inactive analogs of 
modulators (Effenberger et al., 2016). Nevertheless, it will be interesting to compare the protein 
and RNA composition of the purified A-like complex with the composition of the human E and A 
complexes (Behzadnia et al., 2006; Das et al., 2000; Hartmuth et al., 2002).  
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The conformational change in SF3B1, which, likely, occurs during pre-spliceosome assembly, 
may be coupled to the Prp5-dependent rearrangements of the U2 stem II region (Figure 2.8), 
required for the BS binding in yeast (Hilliker et al., 2007; Perriman and Ares, 2010; Perriman and 
Ares, 2007). The stem II region of the U2 snRNA is located 3’ from the BS interacting sequence 
(BSiR) and may adopt two mutually exclusive conformations: stem-loop IIa and stem IIc (Hilliker 
et al., 2007; Zavanelli et al., 1994). Genetics studies in yeast showed that the U2 stem-loop IIa 
promotes the stable pre-spliceosome formation (Perriman and Ares, 2007; Zavanelli et al., 1994). 
Conversely, the U2 stem IIc has an inhibitory effect on the assembly of the A complex (Perriman 
and Ares, 2007; Zavanelli et al., 1994), but favors the branching reaction (Hilliker et al., 2007). 
Most recently, the stem-loop IIa configuration of the U2 snRNA was detected in the yeast and 
human B and Bact complexes (Fica and Nagai, 2017; Shi, 2017), whereas the stem IIc was observed 
in the later C and C* spliceosomes (Fica and Nagai, 2017; Galej et al., 2016). Importantly, in the 
B and Bact complexes, where SF3B1 exhibits a “closed” conformation, the stem-loop IIa region of 
the U2 snRNA is stabilized by the SF3B1/Hsh155p H20 repeat, SF3A3/Prp9p, and SF3B2/Cus1p 
(Plaschka et al., 2017; Yan et al., 2016). During the catalytic activation of the spliceosome (i.e., 
the Bact to B* transition), the SF3A and SF3B complexes are destabilized and no longer interact 
with the branch helix (Rauhut et al., 2016; Warkocki et al., 2009; Yan et al., 2016). As the 
branching reaction requires the stem IIc conformation of U2 (Hilliker et al., 2007), it is possible 
Figure 4.6. Splicing modulators may interfere with a conformational switch 
in SF3B1 required for the stable formation of the pre-spliceosome. 
The stable formation of the branch helix requires a “closed” conformation of SF3B1 (left). During 
pre-spliceosome formation, it is likely that SF3B1 undergoes a conformational transition to the 
“closed” state, stabilizing the branch helix. In the close state of SF3B1, the branch site adenosine 
(BS-A) is accommodated in the SF3B1-PHF5A pocket. In the presence of splicing modulators 
(SPMs), SF3B1 is locked in the “open” state (right). This state of SF3B1 is incompatible with the 
BS recognition, thus explaining the stalled splicing assembly (right). Adapted with modifications 
from (Cretu et al., 2018).  
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that the stem IIc state of U2 is linked to a more “open” conformation of SF3B1, likely to be 
observed in the B* and C complexes. Instead, the “closed” state of SF3B1, exhibiting high-affinity 
for the branch helix, is associated with the stem-loop IIa configuration of the U2 snRNA. In this 
respect, the “ATP-stabilization” of the pre-spliceosome (Perriman and Ares, 2000; Perriman et al., 
2003), likely, involves the Prp5-dependent remodeling of the stem-loop IIa region of U2. In turn, 
this might promote the stable BS binding to the U2 snRNA and an induced fit transition of SF3B1 
towards a “closed” conformation.  
A clearer understanding of the relations between Prp5’s actions, U2 and SF3B1 dynamics, and 
splicing modulators binding to SF3B require additional structural, biochemical, and biophysical 
investigations. For example, the spliceosomal A-like complexes formed in the presence of SF3B 
modulators can be purified from the HeLa nuclear extract, frozen in vitreous ice and imaged using 
cryo-EM. The relative dynamics of the U2 snRNA and the correlative changes in the conformation 
of SF3B1 can be accurately traced using single-molecule spectroscopy approaches (i.e., FRET, 
CoSMoS), as it was elegantly shown for the yeast E complex (Larson and Hoskins, 2017). Such 
complementary approaches would provide additional insights into spliceosome’s dynamics at the 
earliest stages of assembly and into the biology of SF3B modulators.  
4.2.5 Splicing modulators as competitive branch-site antagonists 
Splicing modulators from the pladienolide and herboxidiene families bind SF3B in a conserved 
SF3B1-PHF5A tunnel, close to the BS adenosine (BS-A) binding pocket (Rauhut et al., 2016; Yan 
et al., 2016). The BS-A pocket, likely, forms during pre-spliceosome assembly and was observed 
both in the later pre-catalytic and activated spliceosomes (Plaschka et al., 2017; Rauhut et al., 
2016; Yan et al., 2016). Structural comparisons indicate that the two pockets are formed by a 
similar set of residues which have different and, most importantly, mutually exclusive topologies. 
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In the presence of the BS-A, the invariant PHF5A-Y36 contacts and stabilizes the K1071 and the 
R1075 residues of SF3B1, whereas in the presence of modulators the residue interacts with the 
diene group of the compounds. Consistently, the conserved SF3B1-R1074 residue contacts the 
diene moiety of modulators, while facing the intron side of SF3B1 in spliceosomes. Moreover, our 
analyses suggest that the concomitant accommodation of splicing modulators and the BS-A is not 
possible due to steric clashes between the extended aliphatic sidechain of pladienolides/ 
herboxidiene and the BS-A (Cretu et al., 2018, unpublished data). Corroborated by previous 
competition studies between SF3B modulators and their inactive analogs (Effenberger et al., 
2016), this allowed us to propose that splicing modulators act as competitive antagonists (Cretu et 
al., 2018) (Figure 4.7). That is, binding of the BS-A (“agonist”) to the SF3B1-PHF5A tunnel in 
the “open” state of SF3B1 (see also 5.2.3), likely, results in an induced fit conformational transition 
towards the “closed” conformation, where the nucleobase is stable accommodated in the BS-A 
pocket. Conversely, binding of splicing modulators (“antagonists”) to the same site traps SF3B1 
in an “open” state which does not engage in a productive conformational transition.  
Such an “agonist-antagonist” model (Figure 4.7) suggests that the relative inhibition of splicing 
by SF3B modulators would depend on: (i) the relative affinities of the “antagonist” (i.e., splicing 
modulators) and “agonist” (i.e., the BS-A) for the binding site; (ii) the effective concentrations of 
modulators and the BS-A. In metazoans, the BS sequence of the intron is only weakly conserved 
and exhibits different degrees of complementarity to the U2 snRNA (Gao et al., 2008; Taggart et 
al., 2017) (Figure 2.2). “Strong” BSs, compared to “weaker” BS sequences, can engage more 
readily the U2 snRNA to form the U2/BS duplex, where the BS-A is bulged out. Therefore, in this 
context, it is the entire BS region that should be viewed as “substrate” for SF3B, rather than the 
BS-A alone. 
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Accordingly, in an “agonist-antagonist” model, a “strong” splicing substrate may compete more 
efficiently with modulators for SF3B binding, whereas “weaker” substrates may be more sensitive 
to inhibition (Figure 4.7). Indeed, using an in vitro splicing system and a model pool of RNA 
substrates with different “strengths”, we showed that the more potent BS antagonists, such as 
pladienolide B, exhibit an apparent BS independent inhibition profile. In contrast, “weaker” 
antagonists, such PB-OH, were able to inhibit efficiently splicing of pre-mRNA substrates 
harboring weak BSs (Cretu et al., 2018). Altogether, these experiments support our hypothesis that 
splicing modulators may act as competitive BS antagonists (Figure 4.7) and provide an 
explanation for their modulatory effects in cells (see also Effenberger et al., 2017). In addition, our 
model suggests that by tuning the affinity of modulators (“antagonists”) for the SF3B complex one 
could achieve a more targeted effect on splicing in cells, as it was recently reported for the lead 
pladienolide H3B-8800 (Seiler et al., 2018). 
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Figure 4.7. Splicing modulators as competitive branch-site antagonists. 
The “agonist-antagonist” model postulates that splicing modulators (SPMs) and the BS/BS-A compete 
for the same “open” conformation of SF3B1. Stable binding of the branch helix results in an induced 
fit transition to the “closed” state. Conversely, SPM binding locks SF3B1 in an “open” conformation. 
The model also predicts that a “weak” antagonist (SPM*) would compete less efficiently with “strong” 
substrates, for SF3B1 binding, than with “weak” RNA substrates. SF3B1 is depicted as in Figure 4.6 
and the two arches (i.e., H1-H15, H16-H20) of the SF3B1 HEAT superhelix are colored in blue and 
teal, respectively. 
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5 Conclusions and Outlook 
The multimeric SF3B complex is an essential building block of the U2 snRNP and spliceosomes. 
SF3B is key to the selection and accurate recognition of the branch-site (BS) region of the intron 
during pre-mRNA splicing, and mutations in the SF3B1 subunit are connected to cancers. The 
complex is also targeted by different small-molecule compounds, “splicing modulators”, that are 
emerging as potential chemotherapeutic agents.  
In this thesis work, we determined the crystal structures of a minimal SF3B core, comprising the 
HEAT domain of SF3B1, SF3B3, PHF5A, and SF3B5, in the “apo” state (Cretu et al., 2016) and 
in complex with different splicing modulators (Cretu et al., 2018, unpublished data). Our structures 
revealed that the SF3B3 subunit exhibits a DDB1-like triple-propeller fold. SF3B3 together with 
PHF5A and SF3B5 assemble a composite scaffold onto which SF3B1’s HEAT domain stably 
binds. SF3B1’s HEAT domain consists of 20 repeats which form a unique α-α superhelix and 
functions, in spliceosomes, as a “molecular clamp” to accommodate the branch duplex. Cancer-
related mutations of SF3B1 affect residues from the H4-H7 repeats of the HEAT superhelix. These 
residues cluster around a basic surface patch and are essential for intron recognition in 
spliceosomes. 
The crystal structures of different splicing modulators bound to SF3B revealed the general 
principles for their molecular recognition. That is, splicing modulators from the pladienolide and 
herboxidiene families bind to a conserved hourglass-shaped tunnel framed by the SF3B1 and 
PHF5A subunits. The chemical groups from their common pharmacophore make critical contacts 
with both SF3B1 and PHF5A, indicating how the specific recognition is achieved. Structural 
comparisons with recent cryo-EM structures suggest that these compounds bind SF3B1 in the 
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proximity of the BS adenosine (BS-A) binding pocket, close to a tentative hinge region. As SF3B1 
cannot accommodate the modulators and the BS-A at the same time, this raises the possibility that 
these compounds interfere with a conformational transition of SF3B1 required for the stable 
binding of the BS. In this respect, splicing modulators may be viewed as competitive BS 
antagonists. The structures also show that although these BS antagonists target the same site on 
SF3B, they exploit the rich chemistry of the binding tunnel in a unique manner. Overall, our crystal 
structures provide a framework for the future structure-based design of more stable, more soluble, 
and more targeted splicing modulators that could be readily available as novel therapeutic agents 
in cancers and, possibly, in other complex human diseases.  
Even in the “structural era” of the spliceosome (Abelson, 2017), X-ray crystallography of 
individual modules of the complex machinery can complement and even validate the cryo-EM 
structures of the larger assemblies (van Roon et al., 2017). The higher resolution crystal structure 
of the human SF3B core complex was critical to the accurate modeling of the yeast (Rauhut et al., 
2016) and human Bact spliceosomes (Haselbach et al., 2018) as it provided confidence in the 
modeled residue register (i.e., cross-validated using selenium marker sites). Individual snapshots 
obtained by X-ray crystallography may even provide additional context, and unexpected molecular 
insights as our lab recently showed for the Prp19 core complex (de Moura et al., 2018). Despite 
significant technical and methodological improvements (Bai et al., 2015; Nogales, 2016), it is still 
challenging to accurately model small-molecule ligands in the relatively low resolution and 
anisotropic EM density maps of spliceosomal complexes (~3.5-4.0 Å). Thus, crystallography of 
“druggable” spliceosomal subcomplexes, such as SF3B, may represent a better alternative. 
 
References 
 
135 
 
References 
Abelson, J. (2017). A close-up look at the spliceosome, at last. Proc Natl Acad Sci U S A 114, 
4288-4293. 
Abovich, N., and Rosbash, M. (1997). Cross-intron bridging interactions in the yeast commitment 
complex are conserved in mammals. Cell 89, 403-412. 
Agafonov, D.E., Kastner, B., Dybkov, O., Hofele, R.V., Liu, W.T., Urlaub, H., Luhrmann, R., and 
Stark, H. (2016). Molecular architecture of the human U4/U6.U5 tri-snRNP. Science 351, 1416-
1420. 
Alsafadi, S., Houy, A., Battistella, A., Popova, T., Wassef, M., Henry, E., Tirode, F., Constantinou, 
A., Piperno-Neumann, S., Roman-Roman, S., et al. (2016). Cancer-associated SF3B1 mutations 
affect alternative splicing by promoting alternative branchpoint usage. Nat Commun 7, 10615. 
Angers, S., Li, T., Yi, X., MacCoss, M.J., Moon, R.T., and Zheng, N. (2006). Molecular 
architecture and assembly of the DDB1-CUL4A ubiquitin ligase machinery. Nature 443, 590-593. 
Ast, G. (2004). How did alternative splicing evolve? Nat Rev Genet 5, 773-782. 
Bai, R., Yan, C., Wan, R., Lei, J., and Shi, Y. (2017). Structure of the Post-catalytic Spliceosome 
from Saccharomyces cerevisiae. Cell 171, 1589-1598 e1588. 
Bai, X.C., McMullan, G., and Scheres, S.H. (2015). How cryo-EM is revolutionizing structural 
biology. Trends Biochem Sci 40, 49-57. 
Behzadnia, N., Hartmuth, K., Will, C.L., and Luhrmann, R. (2006). Functional spliceosomal A 
complexes can be assembled in vitro in the absence of a penta-snRNP. RNA 12, 1738-1746. 
Bennett, M., Michaud, S., Kingston, J., and Reed, R. (1992). Protein components specifically 
associated with prespliceosome and spliceosome complexes. Genes Dev 6, 1986-2000. 
Bentley, D.L. (2014). Coupling mRNA processing with transcription in time and space. Nat Rev 
Genet 15, 163-175. 
Berget, S.M. (1995). Exon recognition in vertebrate splicing. J Biol Chem 270, 2411-2414. 
Berglund, J.A., Chua, K., Abovich, N., Reed, R., and Rosbash, M. (1997). The splicing factor BBP 
interacts specifically with the pre-mRNA branchpoint sequence UACUAAC. Cell 89, 781-787. 
Berglund, J.A., Fleming, M.L., and Rosbash, M. (1998). The KH domain of the branchpoint 
sequence binding protein determines specificity for the pre-mRNA branchpoint sequence. RNA 4, 
998-1006. 
Bertram, K., Agafonov, D.E., Dybkov, O., Haselbach, D., Leelaram, M.N., Will, C.L., Urlaub, H., 
Kastner, B., Luhrmann, R., and Stark, H. (2017a). Cryo-EM Structure of a Pre-catalytic Human 
Spliceosome Primed for Activation. Cell 170, 701-713 e711. 
Bertram, K., Agafonov, D.E., Liu, W.T., Dybkov, O., Will, C.L., Hartmuth, K., Urlaub, H., 
Kastner, B., Stark, H., and Luhrmann, R. (2017b). Cryo-EM structure of a human spliceosome 
activated for step 2 of splicing. Nature 542, 318-323. 
Bessonov, S., Anokhina, M., Krasauskas, A., Golas, M.M., Sander, B., Will, C.L., Urlaub, H., 
Stark, H., and Luhrmann, R. (2010). Characterization of purified human Bact spliceosomal 
complexes reveals compositional and morphological changes during spliceosome activation and 
first step catalysis. RNA 16, 2384-2403. 
Black, D.L., Chabot, B., and Steitz, J.A. (1985). U2 as well as U1 small nuclear ribonucleoproteins 
are involved in premessenger RNA splicing. Cell 42, 737-750. 
Blundell, T.L., Jhoti, H., and Abell, C. (2002). High-throughput crystallography for lead discovery 
in drug design. Nat Rev Drug Discov 1, 45-54. 
References 
 
136 
 
Boesler, C., Rigo, N., Anokhina, M.M., Tauchert, M.J., Agafonov, D.E., Kastner, B., Urlaub, H., 
Ficner, R., Will, C.L., and Luhrmann, R. (2016). A spliceosome intermediate with loosely 
associated tri-snRNP accumulates in the absence of Prp28 ATPase activity. Nat Commun 7, 
11997. 
Bonnal, S., Vigevani, L., and Valcarcel, J. (2012). The spliceosome as a target of novel antitumour 
drugs. Nat Rev Drug Discov 11, 847-859. 
Brand, M., Moggs, J.G., Oulad-Abdelghani, M., Lejeune, F., Dilworth, F.J., Stevenin, J., 
Almouzni, G., and Tora, L. (2001). UV-damaged DNA-binding protein in the TFTC complex links 
DNA damage recognition to nucleosome acetylation. EMBO J 20, 3187-3196. 
Bunker, R.D. (2016). Tackling the crystallographic structure determination of the COP9 
signalosome. Acta Crystallogr D Struct Biol 72, 326-335. 
Carrocci, T.J., Zoerner, D.M., Paulson, J.C., and Hoskins, A.A. (2017). SF3b1 mutations 
associated with myelodysplastic syndromes alter the fidelity of branchsite selection in yeast. 
Nucleic acids research 45, 4837-4852. 
Casanal, A., Kumar, A., Hill, C.H., Easter, A.D., Emsley, P., Degliesposti, G., Gordiyenko, Y., 
Santhanam, B., Wolf, J., Wiederhold, K., et al. (2017). Architecture of eukaryotic mRNA 3'-end 
processing machinery. Science 358, 1056-1059. 
Cass, D.M., and Berglund, J.A. (2006). The SF3b155 N-terminal domain is a scaffold important 
for splicing. Biochemistry 45, 10092-10101. 
Cazzola, M., Invernizzi, R., Bergamaschi, G., Levi, S., Corsi, B., Travaglino, E., Rolandi, V., 
Biasiotto, G., Drysdale, J., and Arosio, P. (2003). Mitochondrial ferritin expression in erythroid 
cells from patients with sideroblastic anemia. Blood 101, 1996-2000. 
Chabot, B., Black, D.L., LeMaster, D.M., and Steitz, J.A. (1985). The 3' splice site of pre-
messenger RNA is recognized by a small nuclear ribonucleoprotein. Science 230, 1344-1349. 
Champion-Arnaud, P., Gozani, O., Palandjian, L., and Reed, R. (1995). Accumulation of a novel 
spliceosomal complex on pre-mRNAs containing branch site mutations. Mol Cell Biol 15, 5750-
5756. 
Champion-Arnaud, P., and Reed, R. (1994). The prespliceosome components SAP 49 and SAP 
145 interact in a complex implicated in tethering U2 snRNP to the branch site. Genes Dev 8, 1974-
1983. 
Cingolani, G., Petosa, C., Weis, K., and Muller, C.W. (1999). Structure of importin-beta bound to 
the IBB domain of importin-alpha. Nature 399, 221-229. 
Conte, M.R., Grune, T., Ghuman, J., Kelly, G., Ladas, A., Matthews, S., and Curry, S. (2000). 
Structure of tandem RNA recognition motifs from polypyrimidine tract binding protein reveals 
novel features of the RRM fold. EMBO J 19, 3132-3141. 
Conti, E., Muller, C.W., and Stewart, M. (2006). Karyopherin flexibility in nucleocytoplasmic 
transport. Curr Opin Struct Biol 16, 237-244. 
Cook, A., Fernandez, E., Lindner, D., Ebert, J., Schlenstedt, G., and Conti, E. (2005). The structure 
of the nuclear export receptor Cse1 in its cytosolic state reveals a closed conformation 
incompatible with cargo binding. Mol Cell 18, 355-367. 
Cordin, O., Hahn, D., and Beggs, J.D. (2012). Structure, function and regulation of spliceosomal 
RNA helicases. Curr Opin Cell Biol 24, 431-438. 
Corrionero, A., Minana, B., and Valcarcel, J. (2011). Reduced fidelity of branch point recognition 
and alternative splicing induced by the anti-tumor drug spliceostatin A. Genes Dev 25, 445-459. 
References 
 
137 
 
Corsini, L., Bonnal, S., Basquin, J., Hothorn, M., Scheffzek, K., Valcarcel, J., and Sattler, M. 
(2007). U2AF-homology motif interactions are required for alternative splicing regulation by 
SPF45. Nat Struct Mol Biol 14, 620-629. 
Corvelo, A., Hallegger, M., Smith, C.W., and Eyras, E. (2010). Genome-wide association between 
branch point properties and alternative splicing. PLoS Comput Biol 6, e1001016. 
Cretu, C., Schmitzova, J., Ponce-Salvatierra, A., Dybkov, O., De Laurentiis, E.I., Sharma, K., Will, 
C.L., Urlaub, H., Luhrmann, R., and Pena, V. (2016). Molecular Architecture of SF3b and 
Structural Consequences of Its Cancer-Related Mutations. Mol Cell 64, 307-319. 
Cretu, C., Agrawal, A.A., Cook, A., Will, C.L, Fekkes, P., Smith, P.G., Luhrmann, R., Larsen, N., 
Buonamici, S., Pena, V. (2018). Structural basis of splicing modulation by antitumor macrolide 
compounds. Mol Cell, in press, DOI: 10.1016/j.molcel.2018.03.011. 
Darman, R.B., Seiler, M., Agrawal, A.A., Lim, K.H., Peng, S., Aird, D., Bailey, S.L., Bhavsar, 
E.B., Chan, B., Colla, S., et al. (2015). Cancer-Associated SF3B1 Hotspot Mutations Induce 
Cryptic 3’ Splice Site Selection through Use of a Different Branch Point. Cell Rep 13, 1033-1045. 
Das, R., Zhou, Z., and Reed, R. (2000). Functional association of U2 snRNP with the ATP-
independent spliceosomal complex E. Mol Cell 5, 779-787. 
Daubner, G.M., Clery, A., Jayne, S., Stevenin, J., and Allain, F.H. (2012). A syn-anti 
conformational difference allows SRSF2 to recognize guanines and cytosines equally well. EMBO 
J 31, 162-174. 
De, I., Bessonov, S., Hofele, R., dos Santos, K., Will, C.L., Urlaub, H., Luhrmann, R., and Pena, 
V. (2015). The RNA helicase Aquarius exhibits structural adaptations mediating its recruitment to 
spliceosomes. Nat Struct Mol Biol 22, 138-144. 
de Moura, T.R., Mozaffari-Jovin, S., Szabo, C.Z.K., Schmitzova, J., Dybkov, O., Cretu, C., 
Kachala, M., Svergun, D., Urlaub, H., Luhrmann, R., and Pena, V. (2018). Prp19/Pso4 Is an 
Autoinhibited Ubiquitin Ligase Activated by Stepwise Assembly of Three Splicing Factors. Mol 
Cell 69, 979-992 e976. 
DeBoever, C., Ghia, E.M., Shepard, P.J., Rassenti, L., Barrett, C.L., Jepsen, K., Jamieson, C.H., 
Carson, D., Kipps, T.J., and Frazer, K.A. (2015). Transcriptome sequencing reveals potential 
mechanism of cryptic 3' splice site selection in SF3B1-mutated cancers. PLoS Comput Biol 11, 
e1004105. 
Deutsch, M., and Long, M. (1999). Intron-exon structures of eukaryotic model organisms. Nucleic 
acids research 27, 3219-3228. 
Didychuk, A.L., Butcher, S.E., and Brow, D.A. (2018). The life of U6 small nuclear RNA, from 
cradle to grave. RNA 24, 437-460. 
Dolatshad, H., Pellagatti, A., Liberante, F.G., Llorian, M., Repapi, E., Steeples, V., Roy, S., Scifo, 
L., Armstrong, R.N., Shaw, J., et al. (2016). Cryptic splicing events in the iron transporter ABCB7 
and other key target genes in SF3B1-mutant myelodysplastic syndromes. Leukemia 30, 2322-
2331. 
Dvinge, H., and Bradley, R.K. (2015). Widespread intron retention diversifies most cancer 
transcriptomes. Genome medicine 7, 45. 
Dvinge, H., Kim, E., Abdel-Wahab, O., and Bradley, R.K. (2016). RNA splicing factors as 
oncoproteins and tumour suppressors. Nat Rev Cancer 16, 413-430. 
Dybkov, O., Will, C.L., Deckert, J., Behzadnia, N., Hartmuth, K., and Luhrmann, R. (2006). U2 
snRNA-protein contacts in purified human 17S U2 snRNPs and in spliceosomal A and B 
complexes. Mol Cell Biol 26, 2803-2816. 
References 
 
138 
 
Effenberger, K.A., Urabe, V.K., and Jurica, M.S. (2017). Modulating splicing with small 
molecular inhibitors of the spliceosome. Wiley Interdiscip Rev RNA 8. 
Effenberger, K.A., Urabe, V.K., Prichard, B.E., Ghosh, A.K., and Jurica, M.S. (2016). 
Interchangeable SF3B1 inhibitors interfere with pre-mRNA splicing at multiple stages. RNA 22, 
350-359. 
Erlanson, D.A., Fesik, S.W., Hubbard, R.E., Jahnke, W., and Jhoti, H. (2016). Twenty years on: 
the impact of fragments on drug discovery. Nat Rev Drug Discov 15, 605-619. 
Eskens, F.A., Ramos, F.J., Burger, H., O'Brien, J.P., Piera, A., de Jonge, M.J., Mizui, Y., Wiemer, 
E.A., Carreras, M.J., Baselga, J., et al. (2013). Phase I pharmacokinetic and pharmacodynamic 
study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumors. 
Clinical cancer research : an official journal of the American Association for Cancer Research 19, 
6296-6304. 
Fabrizio, P., Dannenberg, J., Dube, P., Kastner, B., Stark, H., Urlaub, H., and Luhrmann, R. 
(2009). The evolutionarily conserved core design of the catalytic activation step of the yeast 
spliceosome. Mol Cell 36, 593-608. 
Fedor, M.J., and Williamson, J.R. (2005). The catalytic diversity of RNAs. Nat Rev Mol Cell Biol 
6, 399-412. 
Fica, S.M., and Nagai, K. (2017). Cryo-electron microscopy snapshots of the spliceosome: 
structural insights into a dynamic ribonucleoprotein machine. Nat Struct Mol Biol 24, 791-799. 
Fischer, E.S., Scrima, A., Bohm, K., Matsumoto, S., Lingaraju, G.M., Faty, M., Yasuda, T., 
Cavadini, S., Wakasugi, M., Hanaoka, F., et al. (2011). The molecular basis of CRL4DDB2/CSA 
ubiquitin ligase architecture, targeting, and activation. Cell 147, 1024-1039. 
Folco, E.G., Coil, K.E., and Reed, R. (2011). The anti-tumor drug E7107 reveals an essential role 
for SF3b in remodeling U2 snRNP to expose the branch point-binding region. Genes Dev 25, 440-
444. 
Fox-Walsh, K.L., Dou, Y., Lam, B.J., Hung, S.P., Baldi, P.F., and Hertel, K.J. (2005). The 
architecture of pre-mRNAs affects mechanisms of splice-site pairing. Proc Natl Acad Sci U S A 
102, 16176-16181. 
Frilander, M.J., and Steitz, J.A. (1999). Initial recognition of U12-dependent introns requires both 
U11/5' splice-site and U12/branchpoint interactions. Genes Dev 13, 851-863. 
Fukumoto, Y., Dohmae, N., and Hanaoka, F. (2008). Schizosaccharomyces pombe Ddb1 recruits 
substrate-specific adaptor proteins through a novel protein motif, the DDB-box. Mol Cell Biol 28, 
6746-6756. 
Galej, W.P., Oubridge, C., Newman, A.J., and Nagai, K. (2013). Crystal structure of Prp8 reveals 
active site cavity of the spliceosome. Nature 493, 638-643. 
Galej, W.P., Wilkinson, M.E., Fica, S.M., Oubridge, C., Newman, A.J., and Nagai, K. (2016). 
Cryo-EM structure of the spliceosome immediately after branching. Nature 537, 197-201. 
Gao, K., Masuda, A., Matsuura, T., and Ohno, K. (2008). Human branch point consensus sequence 
is yUnAy. Nucleic acids research 36, 2257-2267. 
Garcia-Blanco, M.A., Jamison, S.F., and Sharp, P.A. (1989). Identification and purification of a 
62,000-dalton protein that binds specifically to the polypyrimidine tract of introns. Genes Dev 3, 
1874-1886. 
Girard, C., Will, C.L., Peng, J., Makarov, E.M., Kastner, B., Lemm, I., Urlaub, H., Hartmuth, K., 
and Luhrmann, R. (2012). Post-transcriptional spliceosomes are retained in nuclear speckles until 
splicing completion. Nat Commun 3, 994. 
References 
 
139 
 
Golas, M.M., Sander, B., Will, C.L., Luhrmann, R., and Stark, H. (2003). Molecular architecture 
of the multiprotein splicing factor SF3b. Science 300, 980-984. 
Golas, M.M., Sander, B., Will, C.L., Luhrmann, R., and Stark, H. (2005). Major conformational 
change in the complex SF3b upon integration into the spliceosomal U11/U12 di-snRNP as 
revealed by electron cryomicroscopy. Mol Cell 17, 869-883. 
Gozani, O., Feld, R., and Reed, R. (1996). Evidence that sequence-independent binding of highly 
conserved U2 snRNP proteins upstream of the branch site is required for assembly of spliceosomal 
complex A. Genes Dev 10, 233-243. 
Gozani, O., Potashkin, J., and Reed, R. (1998). A potential role for U2AF-SAP 155 interactions in 
recruiting U2 snRNP to the branch site. Molecular and cellular biology 18, 4752-4760. 
Grinthal, A., Adamovic, I., Weiner, B., Karplus, M., and Kleckner, N. (2010). PR65, the HEAT-
repeat scaffold of phosphatase PP2A, is an elastic connector that links force and catalysis. Proc 
Natl Acad Sci U S A 107, 2467-2472. 
Gupta, A., Jenkins, J.L., and Kielkopf, C.L. (2011). RNA induces conformational changes in the 
SF1/U2AF65 splicing factor complex. J Mol Biol 405, 1128-1138. 
Handa, N., Nureki, O., Kurimoto, K., Kim, I., Sakamoto, H., Shimura, Y., Muto, Y., and 
Yokoyama, S. (1999). Structural basis for recognition of the tra mRNA precursor by the Sex-lethal 
protein. Nature 398, 579-585. 
Harlen, K.M., and Churchman, L.S. (2017). The code and beyond: transcription regulation by the 
RNA polymerase II carboxy-terminal domain. Nat Rev Mol Cell Biol 18, 263-273. 
Hartmuth, K., Urlaub, H., Vornlocher, H.P., Will, C.L., Gentzel, M., Wilm, M., and Luhrmann, R. 
(2002). Protein composition of human prespliceosomes isolated by a tobramycin affinity-selection 
method. Proc Natl Acad Sci U S A 99, 16719-16724. 
Hasegawa, M., Miura, T., Kuzuya, K., Inoue, A., Won Ki, S., Horinouchi, S., Yoshida, T., Kunoh, 
T., Koseki, K., Mino, K., et al. (2011). Identification of SAP155 as the target of GEX1A 
(Herboxidiene), an antitumor natural product. ACS Chem Biol 6, 229-233. 
Haselbach, D., Komarov, I., Agafonov, D.E., Hartmuth, K., Graf, B., Dybkov, O., Urlaub, H., 
Kastner, B., Luhrmann, R., and Stark, H. (2018). Structure and Conformational Dynamics of the 
Human Spliceosomal B(act) Complex. Cell 172, 454-464 e411. 
Hilliker, A.K., Mefford, M.A., and Staley, J.P. (2007). U2 toggles iteratively between the stem IIa 
and stem IIc conformations to promote pre-mRNA splicing. Genes Dev 21, 821-834. 
Hirose, Y., and Manley, J.L. (2000). RNA polymerase II and the integration of nuclear events. 
Genes Dev 14, 1415-1429. 
Hoelz, A., Glavy, J.S., and Beck, M. (2016). Toward the atomic structure of the nuclear pore 
complex: when top down meets bottom up. Nat Struct Mol Biol 23, 624-630. 
Hollander, D., Naftelberg, S., Lev-Maor, G., Kornblihtt, A.R., and Ast, G. (2016). How Are Short 
Exons Flanked by Long Introns Defined and Committed to Splicing? Trends Genet 32, 596-606. 
Hong, W., Bennett, M., Xiao, Y., Feld Kramer, R., Wang, C., and Reed, R. (1997). Association of 
U2 snRNP with the spliceosomal complex E. Nucleic acids research 25, 354-361. 
Igel, H., Wells, S., Perriman, R., and Ares, M., Jr. (1998). Conservation of structure and subunit 
interactions in yeast homologues of splicing factor 3b (SF3b) subunits. RNA 4, 1-10. 
Ilagan, J.O., Ramakrishnan, A., Hayes, B., Murphy, M.E., Zebari, A.S., Bradley, P., and Bradley, 
R.K. (2015). U2AF1 mutations alter splice site recognition in hematological malignancies. 
Genome Res 25, 14-26. 
International Human Genome Sequencing, C. (2004). Finishing the euchromatic sequence of the 
human genome. Nature 431, 931-945. 
References 
 
140 
 
Irimia, M., and Roy, S.W. (2014). Origin of spliceosomal introns and alternative splicing. Cold 
Spring Harb Perspect Biol 6. 
Jackson, S., and Xiong, Y. (2009). CRL4s: the CUL4-RING E3 ubiquitin ligases. Trends Biochem 
Sci 34, 562-570. 
Jenkins, J.L., and Kielkopf, C.L. (2017). Splicing Factor Mutations in Myelodysplasias: Insights 
from Spliceosome Structures. Trends Genet 33, 336-348. 
Jubb, H., Higueruelo, A.P., Winter, A., and Blundell, T.L. (2012). Structural biology and drug 
discovery for protein-protein interactions. Trends Pharmacol Sci 33, 241-248. 
Kaida, D., Motoyoshi, H., Tashiro, E., Nojima, T., Hagiwara, M., Ishigami, K., Watanabe, H., 
Kitahara, T., Yoshida, T., Nakajima, H., et al. (2007). Spliceostatin A targets SF3b and inhibits 
both splicing and nuclear retention of pre-mRNA. Nat Chem Biol 3, 576-583. 
Kappel, C., Zachariae, U., Dolker, N., and Grubmuller, H. (2010). An unusual hydrophobic core 
confers extreme flexibility to HEAT repeat proteins. Biophys J 99, 1596-1603. 
Kent, O.A., Reayi, A., Foong, L., Chilibeck, K.A., and MacMillan, A.M. (2003). Structuring of 
the 3' splice site by U2AF65. J Biol Chem 278, 50572-50577. 
Kesarwani, A.K., Ramirez, O., Gupta, A.K., Yang, X., Murthy, T., Minella, A.C., and Pillai, M.M. 
(2017). Cancer-associated SF3B1 mutants recognize otherwise inaccessible cryptic 3' splice sites 
within RNA secondary structures. Oncogene 36, 1123-1133. 
Kfir, N., Lev-Maor, G., Glaich, O., Alajem, A., Datta, A., Sze, S.K., Meshorer, E., and Ast, G. 
(2015). SF3B1 association with chromatin determines splicing outcomes. Cell Rep 11, 618-629. 
Khatter, H., Vorlander, M.K., and Muller, C.W. (2017). RNA polymerase I and III: similar yet 
unique. Curr Opin Struct Biol 47, 88-94. 
Kielkopf, C.L., Rodionova, N.A., Green, M.R., and Burley, S.K. (2001). A novel peptide 
recognition mode revealed by the X-ray structure of a core U2AF35/U2AF65 heterodimer. Cell 
106, 595-605. 
Kim, E., Ilagan, J.O., Liang, Y., Daubner, G.M., Lee, S.C., Ramakrishnan, A., Li, Y., Chung, Y.R., 
Micol, J.B., Murphy, M.E., et al. (2015). SRSF2 Mutations Contribute to Myelodysplasia by 
Mutant-Specific Effects on Exon Recognition. Cancer Cell 27, 617-630. 
Kondo, Y., Oubridge, C., van Roon, A.M., and Nagai, K. (2015). Crystal structure of human U1 
snRNP, a small nuclear ribonucleoprotein particle, reveals the mechanism of 5' splice site 
recognition. Elife 4. 
Kotake, Y., Sagane, K., Owa, T., Mimori-Kiyosue, Y., Shimizu, H., Uesugi, M., Ishihama, Y., 
Iwata, M., and Mizui, Y. (2007). Splicing factor SF3b as a target of the antitumor natural product 
pladienolide. Nat Chem Biol 3, 570-575. 
Kramer, A., Gruter, P., Groning, K., and Kastner, B. (1999). Combined biochemical and electron 
microscopic analyses reveal the architecture of the mammalian U2 snRNP. J Cell Biol 145, 1355-
1368. 
Lagisetti, C., Palacios, G., Goronga, T., Freeman, B., Caufield, W., and Webb, T.R. (2013). 
Optimization of antitumor modulators of pre-mRNA splicing. J Med Chem 56, 10033-10044. 
Lagisetti, C., Pourpak, A., Jiang, Q., Cui, X., Goronga, T., Morris, S.W., and Webb, T.R. (2008). 
Antitumor compounds based on a natural product consensus pharmacophore. J Med Chem 51, 
6220-6224. 
Lagisetti, C., Yermolina, M.V., Sharma, L.K., Palacios, G., Prigaro, B.J., and Webb, T.R. (2014). 
Pre-mRNA splicing-modulatory pharmacophores: the total synthesis of herboxidiene, a 
pladienolide-herboxidiene hybrid analog and related derivatives. ACS Chem Biol 9, 643-648. 
References 
 
141 
 
Larson, J.D., and Hoskins, A.A. (2017). Dynamics and consequences of spliceosome E complex 
formation. Elife 6. 
Lee, J., and Zhou, P. (2007). DCAFs, the missing link of the CUL4-DDB1 ubiquitin ligase. Mol 
Cell 26, 775-780. 
Lee, S.C., Dvinge, H., Kim, E., Cho, H., Micol, J.B., Chung, Y.R., Durham, B.H., Yoshimi, A., 
Kim, Y.J., Thomas, M., et al. (2016). Modulation of splicing catalysis for therapeutic targeting of 
leukemia with mutations in genes encoding spliceosomal proteins. Nat Med 22, 672-678. 
Lee, S.J., Matsuura, Y., Liu, S.M., and Stewart, M. (2005). Structural basis for nuclear import 
complex dissociation by RanGTP. Nature 435, 693-696. 
Lee, Y., and Rio, D.C. (2015). Mechanisms and Regulation of Alternative Pre-mRNA Splicing. 
Annu Rev Biochem 84, 291-323. 
Li, J., Leung, A.K., Kondo, Y., Oubridge, C., and Nagai, K. (2016). Re-refinement of the 
spliceosomal U4 snRNP core-domain structure. Acta Crystallogr D Struct Biol 72, 131-146. 
Li, T., Chen, X., Garbutt, K.C., Zhou, P., and Zheng, N. (2006). Structure of DDB1 in complex 
with a paramyxovirus V protein: viral hijack of a propeller cluster in ubiquitin ligase. Cell 124, 
105-117. 
Liao, X.L., Kretzner, L., Seraphin, B., and Rosbash, M. (1990). Universally conserved and yeast-
specific U1 snRNA sequences are important but not essential for U1 snRNP function. Genes Dev 
4, 1766-1774. 
Libri, D., Graziani, N., Saguez, C., and Boulay, J. (2001). Multiple roles for the yeast 
SUB2/yUAP56 gene in splicing. Genes Dev 15, 36-41. 
Liu, S., Li, X., Zhang, L., Jiang, J., Hill, R.C., Cui, Y., Hansen, K.C., Zhou, Z.H., and Zhao, R. 
(2017). Structure of the yeast spliceosomal postcatalytic P complex. Science 358, 1278-1283. 
Liu, Z., Luyten, I., Bottomley, M.J., Messias, A.C., Houngninou-Molango, S., Sprangers, R., 
Zanier, K., Kramer, A., and Sattler, M. (2001). Structural basis for recognition of the intron branch 
site RNA by splicing factor 1. Science 294, 1098-1102. 
Loerch, S., and Kielkopf, C.L. (2016). Unmasking the U2AF homology motif family: a bona fide 
protein-protein interaction motif in disguise. RNA 22, 1795-1807. 
Loerch, S., Maucuer, A., Manceau, V., Green, M.R., and Kielkopf, C.L. (2014). Cancer-relevant 
splicing factor CAPERalpha engages the essential splicing factor SF3b155 in a specific ternary 
complex. J Biol Chem 289, 17325-17337. 
Mackereth, C.D., Simon, B., and Sattler, M. (2005). Extending the size of protein-RNA complexes 
studied by nuclear magnetic resonance spectroscopy. Chembiochem 6, 1578-1584. 
MacMillan, A.M., Query, C.C., Allerson, C.R., Chen, S., Verdine, G.L., and Sharp, P.A. (1994). 
Dynamic association of proteins with the pre-mRNA branch region. Genes Dev 8, 3008-3020. 
Madan, V., Kanojia, D., Li, J., Okamoto, R., Sato-Otsubo, A., Kohlmann, A., Sanada, M., 
Grossmann, V., Sundaresan, J., Shiraishi, Y., et al. (2015). Aberrant splicing of U12-type introns 
is the hallmark of ZRSR2 mutant myelodysplastic syndrome. Nat Commun 6, 6042. 
Makowski, K., Vigevani, L., Albericio, F., Valcarcel, J., and Alvarez, M. (2017). Sudemycin K: 
A Synthetic Antitumor Splicing Inhibitor Variant with Improved Activity and Versatile Chemistry. 
ACS Chem Biol 12, 163-173. 
Martinez, E., Palhan, V.B., Tjernberg, A., Lymar, E.S., Gamper, A.M., Kundu, T.K., Chait, B.T., 
and Roeder, R.G. (2001). Human STAGA complex is a chromatin-acetylating transcription 
coactivator that interacts with pre-mRNA splicing and DNA damage-binding factors in vivo. Mol 
Cell Biol 21, 6782-6795. 
References 
 
142 
 
Matera, A.G., and Wang, Z. (2014). A day in the life of the spliceosome. Nat Rev Mol Cell Biol 
15, 108-121. 
McGinty, R.K., and Tan, S. (2015). Nucleosome structure and function. Chem Rev 115, 2255-
2273. 
Menon, S., Tsuge, T., Dohmae, N., Takio, K., and Wei, N. (2008). Association of SAP130/SF3b-
3 with Cullin-RING ubiquitin ligase complexes and its regulation by the COP9 signalosome. BMC 
Biochem 9, 1. 
Michaud, S., and Reed, R. (1991). An ATP-independent complex commits pre-mRNA to the 
mammalian spliceosome assembly pathway. Genes Dev 5, 2534-2546. 
Monecke, T., Dickmanns, A., and Ficner, R. (2014). Allosteric control of the exportin CRM1 
unraveled by crystal structure analysis. FEBS J 281, 4179-4194. 
Murray, C.W., Verdonk, M.L., and Rees, D.C. (2012). Experiences in fragment-based drug 
discovery. Trends Pharmacol Sci 33, 224-232. 
Neuenkirchen, N., Chari, A., and Fischer, U. (2008). Deciphering the assembly pathway of Sm-
class U snRNPs. FEBS Lett 582, 1997-2003. 
Nguyen, T.H.D., Galej, W.P., Bai, X.C., Oubridge, C., Newman, A.J., Scheres, S.H.W., and Nagai, 
K. (2016). Cryo-EM structure of the yeast U4/U6.U5 tri-snRNP at 3.7 A resolution. Nature 530, 
298-302. 
Nogales, E. (2016). The development of cryo-EM into a mainstream structural biology technique. 
Nat Methods 13, 24-27. 
Norton, P.A. (1994). Polypyrimidine tract sequences direct selection of alternative branch sites 
and influence protein binding. Nucleic acids research 22, 3854-3860. 
Obeng, E.A., Chappell, R.J., Seiler, M., Chen, M.C., Campagna, D.R., Schmidt, P.J., Schneider, 
R.K., Lord, A.M., Wang, L., Gambe, R.G., et al. (2016). Physiologic Expression of Sf3b1(K700E) 
Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome 
Modulation. Cancer Cell 30, 404-417. 
Oberstrass, F.C., Auweter, S.D., Erat, M., Hargous, Y., Henning, A., Wenter, P., Reymond, L., 
Amir-Ahmady, B., Pitsch, S., Black, D.L., et al. (2005). Structure of PTB bound to RNA: specific 
binding and implications for splicing regulation. Science 309, 2054-2057. 
Papaemmanuil, E., Cazzola, M., Boultwood, J., Malcovati, L., Vyas, P., Bowen, D., Pellagatti, A., 
Wainscoat, J.S., Hellstrom-Lindberg, E., Gambacorti-Passerini, C., et al. (2011). Somatic SF3B1 
mutation in myelodysplasia with ring sideroblasts. The New England journal of medicine 365, 
1384-1395. 
Patel, A.A., and Steitz, J.A. (2003). Splicing double: insights from the second spliceosome. Nat 
Rev Mol Cell Biol 4, 960-970. 
Pauling, M.H., McPheeters, D.S., and Ares, M., Jr. (2000). Functional Cus1p is found with 
Hsh155p in a multiprotein splicing factor associated with U2 snRNA. Mol Cell Biol 20, 2176-
2185. 
Peled-Zehavi, H., Berglund, J.A., Rosbash, M., and Frankel, A.D. (2001). Recognition of RNA 
branch point sequences by the KH domain of splicing factor 1 (mammalian branch point binding 
protein) in a splicing factor complex. Mol Cell Biol 21, 5232-5241. 
Perea, W., Schroeder, K.T., Bryant, A.N., and Greenbaum, N.L. (2016). Interaction between the 
Spliceosomal Pre-mRNA Branch Site and U2 snRNP Protein p14. Biochemistry 55, 629-632. 
Perriman, R., and Ares, M., Jr. (2000). ATP can be dispensable for prespliceosome formation in 
yeast. Genes Dev 14, 97-107. 
References 
 
143 
 
Perriman, R., and Ares, M., Jr. (2010). Invariant U2 snRNA nucleotides form a stem loop to 
recognize the intron early in splicing. Mol Cell 38, 416-427. 
Perriman, R., Barta, I., Voeltz, G.K., Abelson, J., and Ares, M., Jr. (2003). ATP requirement for 
Prp5p function is determined by Cus2p and the structure of U2 small nuclear RNA. Proc Natl Acad 
Sci U S A 100, 13857-13862. 
Perriman, R.J., and Ares, M., Jr. (2007). Rearrangement of competing U2 RNA helices within the 
spliceosome promotes multiple steps in splicing. Genes Dev 21, 811-820. 
Plaschka, C., Lin, P.C., and Nagai, K. (2017). Structure of a pre-catalytic spliceosome. Nature 546, 
617-621. 
Pyle, A.M. (2016). Group II Intron Self-Splicing. Annu Rev Biophys 45, 183-205. 
Query, C.C., Moore, M.J., and Sharp, P.A. (1994). Branch nucleophile selection in pre-mRNA 
splicing: evidence for the bulged duplex model. Genes Dev 8, 587-597. 
Query, C.C., Strobel, S.A., and Sharp, P.A. (1996). Three recognition events at the branch-site 
adenine. EMBO J 15, 1392-1402. 
Quesada, V., Conde, L., Villamor, N., Ordonez, G.R., Jares, P., Bassaganyas, L., Ramsay, A.J., 
Bea, S., Pinyol, M., Martinez-Trillos, A., et al. (2011). Exome sequencing identifies recurrent 
mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nature genetics 44, 
47-52. 
Rauhut, R., Fabrizio, P., Dybkov, O., Hartmuth, K., Pena, V., Chari, A., Kumar, V., Lee, C.T., 
Urlaub, H., Kastner, B., et al. (2016). Molecular architecture of the Saccharomyces cerevisiae 
activated spliceosome. Science 353, 1399-1405. 
Reed, R. (1989). The organization of 3' splice-site sequences in mammalian introns. Genes Dev 3, 
2113-2123. 
Roscigno, R.F., Weiner, M., and Garcia-Blanco, M.A. (1993). A mutational analysis of the 
polypyrimidine tract of introns. Effects of sequence differences in pyrimidine tracts on splicing. J 
Biol Chem 268, 11222-11229. 
Roy, S.W., and Gilbert, W. (2006). The evolution of spliceosomal introns: patterns, puzzles and 
progress. Nat Rev Genet 7, 211-221. 
Roybal, G.A., and Jurica, M.S. (2010). Spliceostatin A inhibits spliceosome assembly subsequent 
to prespliceosome formation. Nucleic acids research 38, 6664-6672. 
Sainsbury, S., Bernecky, C., and Cramer, P. (2015). Structural basis of transcription initiation by 
RNA polymerase II. Nat Rev Mol Cell Biol 16, 129-143. 
Saldi, T., Cortazar, M.A., Sheridan, R.M., and Bentley, D.L. (2016). Coupling of RNA Polymerase 
II Transcription Elongation with Pre-mRNA Splicing. J Mol Biol 428, 2623-2635. 
Salton, M., and Misteli, T. (2016). Small Molecule Modulators of Pre-mRNA Splicing in Cancer 
Therapy. Trends Mol Med 22, 28-37. 
Schellenberg, M.J., Dul, E.L., and MacMillan, A.M. (2011). Structural model of the p14/SF3b155 
. branch duplex complex. RNA 17, 155-165. 
Schellenberg, M.J., Edwards, R.A., Ritchie, D.B., Kent, O.A., Golas, M.M., Stark, H., Luhrmann, 
R., Glover, J.N., and MacMillan, A.M. (2006). Crystal structure of a core spliceosomal protein 
interface. Proc Natl Acad Sci U S A 103, 1266-1271. 
Schlichting, I. (2015). Serial femtosecond crystallography: the first five years. IUCrJ 2, 246-255. 
Schneider, C., Agafonov, D.E., Schmitzova, J., Hartmuth, K., Fabrizio, P., and Luhrmann, R. 
(2015). Dynamic Contacts of U2, RES, Cwc25, Prp8 and Prp45 Proteins with the Pre-mRNA 
Branch-Site and 3' Splice Site during Catalytic Activation and Step 1 Catalysis in Yeast 
Spliceosomes. PLoS Genet 11, e1005539. 
References 
 
144 
 
Scotti, M.M., and Swanson, M.S. (2016). RNA mis-splicing in disease. Nat Rev Genet 17, 19-32. 
Scrima, A., Fischer, E.S., Lingaraju, G.M., Bohm, K., Cavadini, S., and Thoma, N.H. (2011). 
Detecting UV-lesions in the genome: The modular CRL4 ubiquitin ligase does it best! FEBS Lett 
585, 2818-2825. 
Seiler, M., Yoshimi, A., Darman, R., Chan, B., Keaney, G., Thomas, M., Agrawal, A.A., Caleb, 
B., Csibi, A., Sean, E., et al. (2018). H3B-8800, an orally available small-molecule splicing 
modulator, induces lethality in spliceosome-mutant cancers. Nat Med. 
Selenko, P., Gregorovic, G., Sprangers, R., Stier, G., Rhani, Z., Kramer, A., and Sattler, M. (2003). 
Structural basis for the molecular recognition between human splicing factors U2AF65 and 
SF1/mBBP. Mol Cell 11, 965-976. 
Seraphin, B., Kretzner, L., and Rosbash, M. (1988). A U1 snRNA:pre-mRNA base pairing 
interaction is required early in yeast spliceosome assembly but does not uniquely define the 5' 
cleavage site. EMBO J 7, 2533-2538. 
Shao, W., Kim, H.S., Cao, Y., Xu, Y.Z., and Query, C.C. (2012). A U1-U2 snRNP interaction 
network during intron definition. Mol Cell Biol 32, 470-478. 
Shen, H., Kan, J.L., and Green, M.R. (2004). Arginine-serine-rich domains bound at splicing 
enhancers contact the branchpoint to promote prespliceosome assembly. Mol Cell 13, 367-376. 
Shi, Y. (2017). Mechanistic insights into precursor messenger RNA splicing by the spliceosome. 
Nat Rev Mol Cell Biol 18, 655-670. 
Shi, Y., Reddy, B., and Manley, J.L. (2006). PP1/PP2A phosphatases are required for the second 
step of Pre-mRNA splicing and target specific snRNP proteins. Mol Cell 23, 819-829. 
Shirai, C.L., Ley, J.N., White, B.S., Kim, S., Tibbitts, J., Shao, J., Ndonwi, M., Wadugu, B., 
Duncavage, E.J., Okeyo-Owuor, T., et al. (2015). Mutant U2AF1 Expression Alters 
Hematopoiesis and Pre-mRNA Splicing In Vivo. Cancer Cell 27, 631-643. 
Shirai, C.L., White, B.S., Tripathi, M., Tapia, R., Ley, J.N., Ndonwi, M., Kim, S., Shao, J., Carver, 
A., Saez, B., et al. (2017). Mutant U2AF1-expressing cells are sensitive to pharmacological 
modulation of the spliceosome. Nat Commun 8, 14060. 
Sickmier, E.A., Frato, K.E., Shen, H., Paranawithana, S.R., Green, M.R., and Kielkopf, C.L. 
(2006). Structural basis for polypyrimidine tract recognition by the essential pre-mRNA splicing 
factor U2AF65. Mol Cell 23, 49-59. 
Spadaccini, R., Reidt, U., Dybkov, O., Will, C., Frank, R., Stier, G., Corsini, L., Wahl, M.C., 
Luhrmann, R., and Sattler, M. (2006). Biochemical and NMR analyses of an SF3b155-p14-U2AF-
RNA interaction network involved in branch point definition during pre-mRNA splicing. RNA 12, 
410-425. 
Staley, J.P., and Guthrie, C. (1998). Mechanical devices of the spliceosome: motors, clocks, 
springs, and things. Cell 92, 315-326. 
Stegeman, R., Spreacker, P.J., Swanson, S.K., Stephenson, R., Florens, L., Washburn, M.P., and 
Weake, V.M. (2016). The Spliceosomal Protein SF3B5 is a Novel Component of Drosophila 
SAGA that Functions in Gene Expression Independent of Splicing. J Mol Biol 428, 3632-3649. 
Stewart, M. (2006). Structural basis for the nuclear protein import cycle. Biochem Soc Trans 34, 
701-704. 
Taggart, A.J., Lin, C.L., Shrestha, B., Heintzelman, C., Kim, S., and Fairbrother, W.G. (2017). 
Large-scale analysis of branchpoint usage across species and cell lines. Genome Res 27, 639-649. 
Tang, Q., Rodriguez-Santiago, S., Wang, J., Pu, J., Yuste, A., Gupta, V., Moldon, A., Xu, Y.Z., 
and Query, C.C. (2016). SF3B1/Hsh155 HEAT motif mutations affect interaction with the 
References 
 
145 
 
spliceosomal ATPase Prp5, resulting in altered branch site selectivity in pre-mRNA splicing. 
Genes Dev 30, 2710-2723. 
Teigelkamp, S., Mundt, C., Achsel, T., Will, C.L., and Luhrmann, R. (1997). The human U5 
snRNP-specific 100-kD protein is an RS domain-containing, putative RNA helicase with 
significant homology to the yeast splicing factor Prp28p. RNA 3, 1313-1326. 
Teng, T., Tsai, J.H., Puyang, X., Seiler, M., Peng, S., Prajapati, S., Aird, D., Buonamici, S., Caleb, 
B., Chan, B., et al. (2017). Splicing modulators act at the branch point adenosine binding pocket 
defined by the PHF5A-SF3b complex. Nat Commun 8, 15522. 
Thickman, K.R., Swenson, M.C., Kabogo, J.M., Gryczynski, Z., and Kielkopf, C.L. (2006). 
Multiple U2AF65 binding sites within SF3b155: thermodynamic and spectroscopic 
characterization of protein-protein interactions among pre-mRNA splicing factors. J Mol Biol 356, 
664-683. 
Uhlmann-Schiffler, H., Jalal, C., and Stahl, H. (2006). Ddx42p--a human DEAD box protein with 
RNA chaperone activities. Nucleic acids research 34, 10-22. 
Valcarcel, J., Gaur, R.K., Singh, R., and Green, M.R. (1996). Interaction of U2AF65 RS region 
with pre-mRNA branch point and promotion of base pairing with U2 snRNA [corrected]. Science 
273, 1706-1709. 
van Roon, A.M., Loening, N.M., Obayashi, E., Yang, J.C., Newman, A.J., Hernandez, H., Nagai, 
K., and Neuhaus, D. (2008). Solution structure of the U2 snRNP protein Rds3p reveals a knotted 
zinc-finger motif. Proc Natl Acad Sci U S A 105, 9621-9626. 
van Roon, A.M., Oubridge, C., Obayashi, E., Sposito, B., Newman, A.J., Seraphin, B., and Nagai, 
K. (2017). Crystal structure of U2 snRNP SF3b components: Hsh49p in complex with Cus1p-
binding domain. RNA 23, 968-981. 
Vannini, A., and Cramer, P. (2012). Conservation between the RNA polymerase I, II, and III 
transcription initiation machineries. Mol Cell 45, 439-446. 
Venter, J.C., Adams, M.D., Myers, E.W., Li, P.W., Mural, R.J., Sutton, G.G., Smith, H.O., 
Yandell, M., Evans, C.A., Holt, R.A., et al. (2001). The sequence of the human genome. Science 
291, 1304-1351. 
Vigevani, L., Gohr, A., Webb, T., Irimia, M., and Valcarcel, J. (2017). Molecular basis of 
differential 3' splice site sensitivity to anti-tumor drugs targeting U2 snRNP. Nat Commun 8, 2100. 
Villa, R., Kashyap, M.K., Kumar, D., Kipps, T.J., Castro, J.E., La Clair, J.J., and Burkart, M.D. 
(2013). Stabilized cyclopropane analogs of the splicing inhibitor FD-895. J Med Chem 56, 6576-
6582. 
Wahl, M.C., Will, C.L., and Luhrmann, R. (2009). The spliceosome: design principles of a 
dynamic RNP machine. Cell 136, 701-718. 
Wan, R., Yan, C., Bai, R., Huang, G., and Shi, Y. (2016a). Structure of a yeast catalytic step I 
spliceosome at 3.4 A resolution. Science 353, 895-904. 
Wan, R., Yan, C., Bai, R., Lei, J., and Shi, Y. (2017). Structure of an Intron Lariat Spliceosome 
from Saccharomyces cerevisiae. Cell 171, 120-132 e112. 
Wan, R., Yan, C., Bai, R., Wang, L., Huang, M., Wong, C.C., and Shi, Y. (2016b). The 3.8 A 
structure of the U4/U6.U5 tri-snRNP: Insights into spliceosome assembly and catalysis. Science 
351, 466-475. 
Wang, C., Chua, K., Seghezzi, W., Lees, E., Gozani, O., and Reed, R. (1998). Phosphorylation of 
spliceosomal protein SAP 155 coupled with splicing catalysis. Genes Dev 12, 1409-1414. 
Wang, G.S., and Cooper, T.A. (2007). Splicing in disease: disruption of the splicing code and the 
decoding machinery. Nat Rev Genet 8, 749-761. 
References 
 
146 
 
Wang, Q., He, J., Lynn, B., and Rymond, B.C. (2005). Interactions of the yeast SF3b splicing 
factor. Molecular and cellular biology 25, 10745-10754. 
Wang, Q., and Rymond, B.C. (2003). Rds3p is required for stable U2 snRNP recruitment to the 
splicing apparatus. Molecular and cellular biology 23, 7339-7349. 
Wang, W., Maucuer, A., Gupta, A., Manceau, V., Thickman, K.R., Bauer, W.J., Kennedy, S.D., 
Wedekind, J.E., Green, M.R., and Kielkopf, C.L. (2013). Structure of phosphorylated SF1 bound 
to U2AF(6)(5) in an essential splicing factor complex. Structure 21, 197-208. 
Warkocki, Z., Odenwalder, P., Schmitzova, J., Platzmann, F., Stark, H., Urlaub, H., Ficner, R., 
Fabrizio, P., and Luhrmann, R. (2009). Reconstitution of both steps of Saccharomyces cerevisiae 
splicing with purified spliceosomal components. Nat Struct Mol Biol 16, 1237-1243. 
Warkocki, Z., Schneider, C., Mozaffari-Jovin, S., Schmitzova, J., Hobartner, C., Fabrizio, P., and 
Luhrmann, R. (2015). The G-patch protein Spp2 couples the spliceosome-stimulated ATPase 
activity of the DEAH-box protein Prp2 to catalytic activation of the spliceosome. Genes Dev 29, 
94-107. 
Warner, J.R. (1999). The economics of ribosome biosynthesis in yeast. Trends Biochem Sci 24, 
437-440. 
Watson, J.D., Berry, A.J., and Davies, K. (2017). DNA : the story of the genetic revolution, 
Revised and updated.Second edition. edn (New York: Alfred A. Knopf). 
Wilkinson, M.E., Fica, S.M., Galej, W.P., Norman, C.M., Newman, A.J., and Nagai, K. (2017). 
Postcatalytic spliceosome structure reveals mechanism of 3'-splice site selection. Science 358, 
1283-1288. 
Will, C.L., and Luhrmann, R. (2011). Spliceosome structure and function. Cold Spring Harb 
Perspect Biol 3. 
Will, C.L., Schneider, C., MacMillan, A.M., Katopodis, N.F., Neubauer, G., Wilm, M., Luhrmann, 
R., and Query, C.C. (2001). A novel U2 and U11/U12 snRNP protein that associates with the pre-
mRNA branch site. Embo J 20, 4536-4546. 
Will, C.L., Urlaub, H., Achsel, T., Gentzel, M., Wilm, M., and Luhrmann, R. (2002). 
Characterization of novel SF3b and 17S U2 snRNP proteins, including a human Prp5p homologue 
and an SF3b DEAD-box protein. Embo J 21, 4978-4988. 
Wu, J., and Manley, J.L. (1989). Mammalian pre-mRNA branch site selection by U2 snRNP 
involves base pairing. Genes Dev 3, 1553-1561. 
Wu, J.Y., and Maniatis, T. (1993). Specific interactions between proteins implicated in splice site 
selection and regulated alternative splicing. Cell 75, 1061-1070. 
Xu, Y.Z., Newnham, C.M., Kameoka, S., Huang, T., Konarska, M.M., and Query, C.C. (2004). 
Prp5 bridges U1 and U2 snRNPs and enables stable U2 snRNP association with intron RNA. 
EMBO J 23, 376-385. 
Yan, C., Hang, J., Wan, R., Huang, M., Wong, C.C., and Shi, Y. (2015). Structure of a yeast 
spliceosome at 3.6-angstrom resolution. Science 349, 1182-1191. 
Yan, C., Wan, R., Bai, R., Huang, G., and Shi, Y. (2016). Structure of a yeast activated spliceosome 
at 3.5 A resolution. Science 353, 904-911. 
Yan, D., Perriman, R., Igel, H., Howe, K.J., Neville, M., and Ares, M., Jr. (1998). CUS2, a yeast 
homolog of human Tat-SF1, rescues function of misfolded U2 through an unusual RNA 
recognition motif. Mol Cell Biol 18, 5000-5009. 
Yoshida, H., Park, S.Y., Oda, T., Akiyoshi, T., Sato, M., Shirouzu, M., Tsuda, K., Kuwasako, K., 
Unzai, S., Muto, Y., et al. (2015). A novel 3' splice site recognition by the two zinc fingers in the 
U2AF small subunit. Genes Dev 29, 1649-1660. 
References 
 
147 
 
Yoshida, K., and Ogawa, S. (2014). Splicing factor mutations and cancer. Wiley Interdiscip Rev 
RNA 5, 445-459. 
Yoshida, K., Sanada, M., Shiraishi, Y., Nowak, D., Nagata, Y., Yamamoto, R., Sato, Y., Sato-
Otsubo, A., Kon, A., Nagasaki, M., et al. (2011). Frequent pathway mutations of splicing 
machinery in myelodysplasia. Nature 478, 64-69. 
Yoshimura, S.H., and Hirano, T. (2016). HEAT repeats - versatile arrays of amphiphilic helices 
working in crowded environments? J Cell Sci 129, 3963-3970. 
Zachariae, U., and Grubmuller, H. (2008). Importin-beta: structural and dynamic determinants of 
a molecular spring. Structure 16, 906-915. 
Zavanelli, M.I., Britton, J.S., Igel, A.H., and Ares, M., Jr. (1994). Mutations in an essential U2 
small nuclear RNA structure cause cold-sensitive U2 small nuclear ribonucleoprotein function by 
favoring competing alternative U2 RNA structures. Mol Cell Biol 14, 1689-1697. 
Zhang, X., Yan, C., Zhan, X., Li, L., Lei, J., and Shi, Y. (2018). Structure of the human activated 
spliceosome in three conformational states. Cell Res 28, 307-322. 
Zhao, C., and Pyle, A.M. (2017). Structural Insights into the Mechanism of Group II Intron 
Splicing. Trends Biochem Sci 42, 470-482. 
Zhou, L., Hang, J., Zhou, Y., Wan, R., Lu, G., Yin, P., Yan, C., and Shi, Y. (2014). Crystal 
structures of the Lsm complex bound to the 3' end sequence of U6 small nuclear RNA. Nature 
506, 116-120. 
Zhuang, Y., and Weiner, A.M. (1989). A compensatory base change in human U2 snRNA can 
suppress a branch site mutation. Genes Dev 3, 1545-1552. 
 
Appendix 
 
148 
 
Appendix 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
Figure S1. SF3B1 adopts the same “open” conformation in two different crystal 
forms. 
(A) Crystal packing of SF3B1 in the P3221 crystal form. An alternative crystal form for a SF3B core complex 
was obtained using the very same fragments of SF3B1 (453-1304) and PHF5A (1-98), but lacking the SF3B3 
BPB domain (443-767). These crystals formed under different conditions (Cretu C., Pena V., unpublished 
data) and belonged to a higher-symmetry space group (P3221). SF3B1 is colored purple and the symmetry-
related SF3B1 and PHF5A are colored light blue and gray, respectively. (B) Structural superposition of the 
SF3B1-PHF5A module crystallized in two different space groups. SF3B1 (purple) exhibits the same “open” 
conformation in P3221 as in the P212121 crystal form (green), complexed with pladienolide B (PB, orange).    
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Table S1. Data collection and refinement statistics for the unpublished crystal structures. 
 SF3BΔBPB SF3BΔBPB-HB SF3BΔBPB-H3B-8800 SF3Bcore-E7107 
Data collection    
Space group P3221 P3221 C121 P212121 
a, b, c (Å) 108.05, 108.05, 
359.48 
107.85, 107.85, 
359.17  
184.93, 110.43, 
354.45    
105.11, 154.46, 210.35 
α, β, γ (o) 90.00, 90.00, 120.00 90.00, 90.00, 120.00 90.00, 92.23, 90.00 90.00, 90.00, 90.00 
Wavelength 1.0 1.0 1.0 1.0 
Resolution 49.25-2.8 (2.87-2.8)* 49.17-3.1 (3.21-3.1)* 49.66-3.1 (3.15-3.10)* 48.42-3.0 (3.07- 3.00)* 
Rmerge (%) 9.1 (>100) 14.7 (>100) 21.5 (>100)# 11.5 (>100) 
Rmeas (%) 9.3 (>100) 15.1 (>100) 22.4 (>100) 12.7 (>100) 
Rpim (%) 2.1 (>100) 3.4 (69.3) 6.5 (>100) 5.3 (66.4) 
I/σI 21.4 (0.8) 15.4 (1.1) 9.6 (0.7) 12.3 (1.3) 
CC1/2 1.0 (0.438) 0.999 (0.619) 0.998 (0.289) 0.998 (0.522) 
Completeness (%) 100.0 (99.9) 100.0 (100.0) 99.9 (98.9) 99.9 (100.0) 
Redundancy 19.9 (19.6) 19.9 (20.4) 11.9 (10.7) 5.6 (5.9) 
   
Refinement    
Resolution 49.25-2.8 49.17-3.1 49.66-3.1  48.42-3.1 
No. reflections 60935 45076 129732 62779 
Rwork/Rfree 0.23/0.26 0.22/0.26 0.24/0.26 0.24/0.26 
No. atoms        
Protein 14756 14746 44268 17205 
Ligand/ion 4 34 89 54 
Water -  -  -  - 
B-factors (Å2)        
Macromolecules 109.09 101.62 90.44 83.24 
Ligand/ion 96.58 81.78 70.21 83.54 
Water -  -  -  - 
R.m.s. deviations        
Bond lengths (Å) 0.002 0.004 0.004 0.004 
Bond angles (o) 0.55 0.98 0.95 0.95 
Ramachandran        
favored (%) 95.03 95.19 94.71 94.27 
allowed (%) 4.65 4.54 5.04 5.31 
outliers (%) 0.32 0.27 0.25 0.42 
*Statistics for the highest-resolution shell are shown in parentheses; #Two datasets were merged.  
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Abbreviation Expansion 
ATP adenosine triphosphate 
bp base pair 
ca. circa 
cryo-EM cryo-electron microscopy 
DNA deoxyribonucleic acid 
e.g. exempli gratia 
EM electron microscopy 
HEAT Huntingtin, Elongation Factor 3, Protein phosphatase 
2A, Target of rapamycin 1 
i.e. id est 
kDa kilodalton  
mRNA messenger RNA 
NMR nuclear magnetic resonance 
NTP nucleotide triphosphate 
nts nucleotides 
pre-mRNA precursor mRNA 
RNA ribonucleic acid 
RRM RNA recognition motif 
SDS-PAGE SDS-polyacrylamide gel electrophoresis 
snRNPs small nuclear ribonucleoproteins 
SR serine/arginine-rich  
SS splice site 
U snRNA uridine-rich small nuclear RNA 
U snRNPs uridine-rich small nuclear ribonucleoproteins 
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